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Abstract 
 
Increasingly prevalent are strains of bacteria that have a reduced susceptibility to 
multiple antibiotics, often leaving few therapeutic treatment options for bacterial 
infections. Extended spectrum β-lactamases confer resistance to β-lactam antibiotics 
and have been observed in a wide range of bacterial species.  
Synthetic antisense oligonucleotide analogues have been shown to specifically inhibit 
the translation of targeted bacterial genes and enable the possibility of the restoration of 
antibiotic sensitivity of resistant bacteria by the targeted inhibition of proteins 
responsible for reduced susceptibility, such as β-lactamases, thereby restoring 
antimicrobial efficacy. 
The current study designed and developed antisense oligomers to target 
CTX-M-group 1 extended-spectrum β-lactamase mRNA and inhibit enzyme expression 
via ribosomal hindrance. Expression plasmids harbouring blaCTX-M-15 cloned from field 
isolates were constructed for gene expression inhibition studies. Two assays for the 
quantification of β-lactamase activity were developed. Antisense oligomers significantly 
inhibited CTX-M-15 β-lactamase activity by 92 - 100% (P < 0.001) in a cell-free 
translation-transcription coupled system. An atypically permeable cell-wall mutant 
E. coli strain was transformed with expression plasmids harbouring blaCTX-M-15 to yield a 
resistant phenotype, and in cell growth inhibition assays sensitivity to cefotaxime was 
significantly increased. Antisense oligomers covalently attached to a cell-penetrating 
peptide significantly (P < 0.05) increased sensitivity to cefotaxime in clinical isolates in 
a dose dependent manner.  
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A novel synthetic antisense oligomer delivery vehicle based on a 3D tetrahedral DNA 
structure was also developed and evaluated - a significant increase (P < 0.001) in the 
sensitivity of field and clinical isolates to cefotaxime was observed in a dose dependent 
manner. 
The current study has demonstrated the efficacy of targeted synthetic antisense 
oligomers in partially restoring cefotaxime sensitivity in previously resistant clinical 
E. coli isolates, and demonstrated the efficacy of a novel vector able to deliver antisense 
oligomers into bacteria. 
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Chapter 1.  Introduction 
1.1.  Bacteria 
Bacteria are among the earliest forms of life known to have evolved, with evidence 
having been found to support the possibility of bacteria-like prokaryotic life existing up 
to 3.2 - 3.4 billion years ago [1, 2]. Prokaryotes are highly diverse with an unknown 
number of species, and by many measurable criteria – biomass, population size, 
ecological diversity, age – could be considered the most successful organisms that have 
ever evolved. They are highly adaptable and able to rapidly evolve to survive in 
changing or hostile environments. One of the most important reasons for their success 
would appear to be this adaptability – being a single celled organism with a rapid 
replication time of as little as 20 minutes between generations, evolution and adaptation 
to a new or changing environment can occur much faster than more complex 
multicellular life forms.  
Bacteria are ubiquitous in every known environment on earth, and can survive in the 
harshest of environments. They also live in, and on, other organisms, sometimes 
forming a symbiotic relationship for mutual benefit –  bacterial cells in and on the 
human body outnumber host cells by up to 10:1 [3]. The majority of bacterial species 
inhabiting the human body are commensal, or beneficial to the host, however, those that 
have a negative impact on the health of the host can cause serious life threatening 
infections.  
1.1.1.  Bacterial infections  
Pathogenic bacteria are the causes of some of the most virulent infections and 
conditions that afflict humans. The severity of human bacterial infections range from 
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minor non life-threatening infections such as, for example, a campylobacter 
gastrointestinal infection, to life threatening infections such as tuberculosis or anthrax. 
1.1.2.  Escherichia coli 
Escherichia coli (E. coli) is a non-sporulating rod-shaped gram-negative bacterium 
whose principle environmental habitat is the bowels of endothermic organisms (humans 
for example) as part of their typical gut flora [4, 5]. It is an archetypal member of the 
family Enterobacteriaceae, with a diverse range of genetically variable species [6]. In 
most cases, E. coli is neutral or beneficial to its host organism, for example by the 
inhibition of colonisation by other, potentially pathogenic, bacteria [7]. Pathogenic 
E. coli strains however, can cause conditions from the relatively mild, such as 
gastroenteritis or urinary tract infections, to more severe such as haemolytic-uremic 
syndrome [8]. E. coli is a well-characterised organism; its reproduction rate of as little 
as 20 minutes between generations, the ability to grow in a diverse range of pressure, 
temperature [9] and culture media, and an abundance of non-pathogenic strains, have 
made it an ideal model organism for biological research. 
1.2.  Antibiotics 
Antibiotics are therapeutic antimicrobial agents which are able either to kill or inhibit 
growth of bacteria, and are often the first line of defence against bacterial infection. 
Although the antibiotic era is generally regarded as having begun in the early 20th 
century with the discovery and subsequent synthesis and commercialisation of active 
antimicrobial compounds, there is evidence of human exposure to, or use of, antibiotics 
from much earlier times. Tetracycline traces, for example, have been identified in 
human remains dating to 350 – 500 CE from ancient Sudanese Nubia [10] and from 
Roman period human skeletons [11].  
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The sulphonamides were the first chemotherapeutic agents to be used systemically 
against bacterial infections. Synthesised in 1932, the drug named Prontosil, showed no 
in vitro activity against streptococci, but had a strong effect in streptococcus infections 
in mice [12]. Prontosil was later discovered to be a pro-drug which broke down to 
release the active compound sulphanilamide [13]. This discovery led to the later 
development of many sulphonamide derivatives. 
Alexander Fleming is credited with the accidental discovery of penicillin in 1928 when 
observing the antimicrobial properties of the fungus Penicillium rubens [14]. Whilst 
earlier  researchers such as Sir John Scott Burdon-Sanderson (1870) [15], Joseph Lister 
(1871), William Roberts (1874), Louis Pasteur (1877), Vincenzo Tiberio (1895) [16], 
Ernest Duchesne (1897), and Andre Gratia [17] and Sara Dath (1920s) had all 
previously reported antibiotic activity associated with Penicillium and other fungi, they 
were unable to isolate or describe the active antimicrobial agent. The advent of 
antibiotics heralded a new era in medication and were regarded, and referred to, as 
miracle drugs. 
In the years immediately following the introduction of the first antibiotics, there was a 
period of rapid discovery and development of new classes of antibiotics including: the 
aminoglycosides discovered in 1943, tetracyclines in 1944, the chloramphenicols in 
1946, macrolides in 1948, rifamycins in 1957 and quinolones in 1961 [18]. These 
classes of antibiotics all had different spectra of activity and mechanisms of action, 
some, for example, acting to inhibit cell wall synthesis and others that were ribosomal 
inhibitors. With this rapidly expanding range of antibiotics, bacterial infections were no 
longer regarded as a serious threat and research was prioritised towards the perceived 
greater, and more profitable, threats of such conditions as cancer, viral infections and 
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heart disease. The risk of resistance arising to antibiotics appeared remote, despite 
resistance to each new antibiotic being observed to emerge around the same time, or in 
some cases before, their introduction into therapeutic usage. Partly due to research 
priority focussed elsewhere, especially on more profitable conditions requiring long 
term drug administration, such as cancer, the discovery and introduction of new 
antibiotics slowed to a near standstill after 1986 [18]. As resistance continued to 
increase and evolve, previously effective antibiotics became obsolete and their use 
discontinued. The streptogramins (1998) and oxazolidinones (2000) were the first new 
classes of antibiotics approved for use since 1968 [18].  
New effective antimicrobial agents have become urgently needed - since 2000 only 2 
first-in-class antibiotics have been introduced; fidaxomicin and bedaquiline [19]. With a 
renewed sense of urgency and funding, new approaches to discovering and developing 
antimicrobial agents have shown promise. In 2015, Ling et al. developed methods to 
enable the culturing of soil-dwelling bacteria that were previously considered 
unculturable. This has directly led to the discovery and characterisation of a lipid-
binding antibiotic (teixobactin) active against gram-positive bacteria [20]. An estimated 
99% of soil-dwelling bacteria cannot be lab-cultured. With the new methods now 
available to culture these bacteria, the possibility of the discovery of many more new 
antibiotics now exists. 
1.1.3.  β-Lactam antibiotics 
β-Lactam antibiotics are the most widespread and commonly prescribed class of 
antibiotics worldwide – measured by sales they represented approximately 65% of the 
global antibiotic market in 2003 [21]. They are a broad class of antibiotics characterised 
by the presence of a four-membered cyclic amide (lactam) ring (Figure 1-1). 
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Figure 1-1. Structures of example β-lactam antibiotics.  
The β-lactam ring is shown in red [22]. 
An essential component for bacterial structural integrity (with a few exceptions, such as 
members of the order of Mycoplasmatales, which lack a cell wall [23]) is the 
peptidoglycan layer. This layer consists of glycan strands cross linked by short peptides 
forming a rigid structural layer, either surrounding the lipid membrane in the case of 
gram-positive bacteria, or sandwiched between the inner and outer lipid membranes in 
the case of gram-negative bacteria [24]. This is an essential component without which 
the bacterium would be unable to withstand internal osmotic pressure. β-Lactam 
antibiotics inhibit transpeptidases, the enzymes responsible for catalysing the reaction 
that forms the bonds between peptidoglycan sugar-amino acid molecules. These 
enzymes are also known as penicillin binding proteins because of their high affinity for 
penicillin. β-Lactam antibiotics bind irreversibly to the active site in the transpeptidases, 
resulting in their irreversible inactivation and the inability to form the cross-links in the 
peptidoglycan layer [25].  Inhibition of the synthesis of this layer ultimately leads to the 
lysis of the bacterial cell, and its death. 
The earliest β-lactam antibiotics, the penicillins, were mainly effective against gram-
positive bacteria, but later generations have shown increased activity against gram-
negative bacteria [26]. 
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1.1.3.1.  Cephalosporins 
Originally isolated from the fungus Acremonium, formerly known as Cephalosporium 
[27], cephalosporins are a sub-class of β-lactam antibiotics. They are grouped into 
chronological generations defined by their spectrums of activity, although this is a loose 
grouping which can vary between countries. Generally, each newer generation of 
cephalosporin exhibits greater activity against gram-negative bacteria. First generation 
cephalosporins showed activity against both gram-negative and gram-positive bacteria. 
Second generation cephalosporins exhibited less activity against gram-positive bacteria 
than first generation cephalosporins, but a greater activity against gram-negative 
bacteria. Members of the group of third generation cephalosporins showed decreased 
activity against gram-positive, but an increased broad spectrum of activity against gram-
negative bacteria.  
1.2.  Bacterial antibiotic resistance 
“The first rule of antibiotics is try not to use them, and the second rule is try not to use 
too many of them.” - Paul Marino, The ICU Book 2007 [28]  
Resistance to antibiotics is of global concern to the health of many animal species, 
including human. The evolution and dissemination of antibiotic resistance mechanisms 
in bacteria, which renders certain antibiotics ineffective, is currently proceeding at a 
pace that outstrips the speed of development of new antimicrobial agents. This has the 
potential to result in a situation where there are few treatment options for bacterial 
infections. Margaret Chan, director-general of the World Health Organisation, stated in 
2012: “A post-antibiotic era means, in effect, an end to modern medicine as we know it. 
Things as common as strep throat or a child’s scratched knee could once again kill” 
[29]. 
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In 2014 an estimated 50,000 people died from antimicrobial resistant infections in 
Europe and the US, and 700,000 worldwide [30]. The Centres for Disease Control and 
Prevention (CDC) estimated that in 2013 at least 2 million people in the US were 
infected with resistant bacteria and fungi, responsible for at least 23,000 deaths [31].   
In 2013 Professor Dame Sally Davies, Chief Medical Officer for England, warned of a 
post antibiotic era within 20 years that could lead to deaths from routine infections that 
are currently treated with antibiotics [32]. The journal Nature also drew attention to the 
major causative factors of over prescription of antibiotics to humans and to the 
widespread use in livestock [33]. The European Society of Clinical Microbiology and 
Infectious Disease (ESCMID) warned that without additional spending on drug 
development, more than 1 million human deaths in Europe could be attributable to drug 
resistant bacteria by 2025 [34]. UK Prime Minister David Cameron in 2014 further 
elevated the concern highlighting the “market failure” of a period of 25 years with no 
new classes of antibiotics being developed, and the concern regarding the overuse of 
antibiotics worldwide. In late 2015 the first observation of a plasmid-mediated 
resistance mechanism to polymixin, one of the ‘drugs of last resort’, was reported in 
Enterobacteriaceae in China [35]. After the observation in China, this mechanism of 
resistance was detected in the UK by the Animal and Plant Health Agency in bacteria 
found on three pig farms [36]. 
In addition to the global threat to health arising from antimicrobial resistance, there is 
inevitably an economic impact and financial burden of antimicrobial resistant bacteria – 
more expensive therapies are required and the duration of illnesses and hospital stays 
are usually increased. Difficult to assess, one review, by Smith and Coast in 2013 [37], 
of the available research into the economics of bacterial resistance found that the 
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highest estimate of the cost of bacterial resistance in the US was an annual additional 
$55 billion, which included additional healthcare costs and estimated costs of lost 
productivity [38]. In 2014 a study on the global economic effects of antimicrobial 
resistance estimated that the current rate of growth of resistance would lead to a 
reduction of world gross domestic product, resulting in a cumulative loss by 2050 of 
between $2.1 trillion (low rate of spread of resistance) to $124.5 trillion (worst case 
scenario of no effective antibiotics) [39]. 
A review panel to analyse the key areas of the antimicrobial resistance problem was 
commissioned in 2014 [40]. The implication of the appointment of an economist to 
chair this review could suggest the perception of the antibiotic resistance problem is 
more related to market forces than an understanding of the biology and complexity of 
evolutionary resistance mechanisms. Indeed, there is a prevalent attitude, an 
overconfidence that science can deal with any problem, if given enough financial 
incentive, and perhaps this overconfidence has led to a seeming lack of urgency in 
addressing this situation. 
Antibiotic resistance in previously sensitive bacteria can arise through mutation, and/or 
through the acquisition of pre-existing resistance gene(s). Often borne on plasmids and 
closely associated with transposable elements, resistance genes spread rapidly in the 
presence of sub-lethal antibiotic concentrations [41]. The CDC estimates that up to 50% 
of antibiotics prescribed for people are 'not needed or are not optimally effective' and 
'much of antibiotic use in animals is unnecessary and inappropriate' [31]. For example, 
Yezli and Li (2012) found that in China the overuse of antibiotics was widespread and 
endemic due, in part, to financial incentives for health care professionals to prescribe 
drugs [42]. One study found that greater than 98% of patients from one Chinese hospital 
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were prescribed antibiotics for the common cold [43]. The same study also noted that 
the problem of bacterial resistance was not widely recognised, with many health 
practitioners suggesting the cause of antibiotic ineffectiveness was due to resistance 
within the patient rather than the bacterium. A study of antimicrobial medicines in 
emerging countries, such as India, found a proportion (6%) were of substandard and 
sub-therapeutic quality, contributing to the spread of antimicrobial resistance [44]. 
A commonly criticised example of inappropriate, non-therapeutic use of antibiotics in 
food animals is the routine administering of antibiotics solely to promote growth. This 
practice originated in the 1950s when the effect of non-medicinal low dose antibiotics 
on growth was noted, although the cause or mechanism for this effect still remains 
unclear. This practice was restricted in the European Union from 2006 [45].  
This situation of the exposure of bacteria to antibiotics, often in insufficient doses, is the 
ideal environment for resistance to evolve, develop and spread. Systems of antibiotic 
stewardship are regularly recommended by overseeing bodies to curtail excessive 
practices and slow the advance of resistance [31, 32, 46]. 
When antibiotics were first introduced and widely used in the 1950s, the prevailing 
consensus of opinion was that resistance in bacteria was unlikely to arise to such an 
extent to cause a significant threat to its therapeutic use, as it was believed that the 
required mutations would be complex, specific and unlikely to occur rapidly enough 
[47]. It was regarded that medical science had all but won the battle against such 
infections. This was obviously a premature and optimistic sentiment as the potential for 
the rapid acquisition and dissemination of beneficial mutations, and the mobility of 
genetic elements was unknown at that time [47]. 
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The transfer of resistance genes between bacterial cells allows the rapid spread of 
beneficial traits between bacteria. Usually borne on plasmids, these genes can be highly 
mobile and rapidly deployed to negate antibiotic action.  
As the current rate of development of new antimicrobials would appear to be slower 
than the rate of bacteria developing and spreading resistance, alternative approaches to 
the treatment of bacterial infections would be highly desirable [48].    
1.2.1.  Overview of bacterial antibiotic resistance mechanisms of action  
Bacterial defence mechanisms against antimicrobial agents are ancient and diverse, and 
multiple resistance mechanisms exist for each class of antibiotic.  The major commonly 
found and described mechanisms of action of reducing bacterial susceptibility to 
antibiotics are the enzymatic inactivation of the detrimental antibiotic, antibiotic target 
alteration, alternative metabolic pathways circumventing the ones affected by the 
antibiotic and a reduction of drug accumulation either through efflux or a decrease in 
cell permeability [49-52]. A brief summary of the most common resistance mechanisms 
of action follows: 
1.2.1.1.  Enzymatic inactivation of antibiotics 
A major mechanism of antibiotic susceptibility reduction amongst pathogenic bacteria 
is the production of an enzyme by a bacterium to inactivate an antibiotic [53]. Examples 
of this would include resistance to β-lactam antibiotics through the production of 
β-lactamases which inactivate and degrade β-lactam antibiotics by hydrolysis; 
β-lactamase is discussed in greater detail in section 1.2.2.  A second example of 
enzymatic antibiotic inactivation is the transfer of chemical groups to exposed or 
vulnerable sites on the antibiotic, rendering it ineffective due to steric hindrance [53, 
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54]. Enzymes exhibiting this type of modification include aminoglycoside-modifying 
enzymes, which confer resistance to aminoglycoside antibiotics. 
1.2.1.2.  Antibiotic resistance by target alteration 
Bacterial resistance mediated by alteration of the target site of the antibiotic is another 
commonly found resistance mechanism [53]. Often as a result of spontaneous 
mutation(s), recombination events or the acquisition of exogenous gene(s) encoding the 
targets of an antibiotic, an altered enzyme can be produced with a lower affinity for the 
antibiotic, resulting in a phenotype of reduced susceptibility [55, 56]. One example of 
this is resistance to rifamycins, which interact with RNA polymerase. As these 
antibiotics do not bind at the RNA polymerase active site, and hence are not analogues 
of its substrate, it is believed that altered target-mediated resistance develops more 
readily [55]. Amino acid alterations in the region of RNA polymerase targeted by 
rifamycin antibiotics have been found in a range of different rifampicin-resistant 
isolates [57, 58]. 
1.2.1.3.  Reduction of intracellular antibiotic accumulation by increased efflux or 
decreased permeability  
To reduce susceptibility to certain drugs, bacterial efflux pumps can remove antibiotics 
by actively transporting them out of the cell [52]. Efflux mechanisms specific to a 
particular drug are generally encoded by plasmids and often associated with mobile 
elements and other drug resistance genes, in contrast to multi-drug efflux mechanisms 
which are often highly conserved and mostly chromosome encoded [52]. Active efflux 
of antibiotics was first described as a mechanism of action of tetracycline resistance in 
E. coli in 1980 [59]. Since the initial observation of efflux-mediated tetracycline 
resistance many more efflux-mediated class-specific and multidrug antibiotic resistance 
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mechanisms have been identified [52]. Gram negative bacteria are able to reduce 
susceptibility to porin-mediated antibiotics with the adaptation of outer membrane 
pores. Changes in the number of, and/or specific function of outer membrane pores can 
lead to a reduction in the amount of small hydrophilic antibiotic crossing the membrane 
and can lead to a reduction in susceptibility to multiple antibiotics [60, 61]. Charrel et 
al. identified, from a panel of 80 β-lactam resistant clinical isolates, 23 that had an 
atypical porin content [62]. 
1.2.2.  β-Lactamase 
Resistance to β-lactam antibiotics is mainly acquired in bacteria by the production of a 
β-lactamase enzyme [63] which inactivates β-lactam antibiotics. The first β-lactamase to 
be discovered and described was penecillinase in 1940 - before penicillin had even 
entered into widespread medicinal use [64].  Driven by mutation and selective pressure 
from antibiotic exposure, bacteria have evolved and acquired new, more efficient and 
wider spectrum β-lactamases to match the development of β-lactam antibiotics.  
Thought to be an ancient class of enzymes, first evolving around 2 billion years ago 
[65], β-lactamases bind to, and hydrolyse the β-lactam ring at the core of a β-lactam 
antibiotic. In a two-step, intermediate forming reaction, the β-lactam antibiotic is  
rendered unable to interact and inactivate penicillin-binding proteins [66]. 
β-Lactamases have been grouped and classified by different methods and two 
classification systems are most currently commonly used.  The Ambler molecular 
classification system groups β-lactamases into four categories, A, B, C and D based on 
their amino acid sequence, and thus their evolutionary relationships. Groups A, C and D 
contain serine residues near their active sites, while the class B β-lactamases are the 
metallo β-lactamases that contain a metal ion (Zn+) [67]. Some problems exist with this 
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system as new enzymes are discovered or evolve differences and have features of 
multiple classes, or share no features. All the serine-based β-lactamases share structural 
similarity suggesting either a common ancestor or convergent evolution, but little 
sequence identity at the molecular level [68]. 
Bush, Jacoby and Medeiros classified β-lactamases according to their functional 
characteristics [69]. Their numbered classification system grouped β-lactamases on the 
basis of their preferred substrates and inhibitor profiles. Group 1 β-lactamases in this 
system include cephalosporinases, group 2, the largest grouping which is further refined 
into subgroups, includes extended-spectrum cephalosporinases and serine 
carbapenemases, group 3 includes the metallo-β-lactamases [70]. 
1.2.2.1.  Extended-spectrum β-lactamases 
Adaptations and mutations have led to an increasing array of β-lactamases with 
widening spectrums and resistance ability. First described in enterobacteria 1983 by 
Knothe et. al., extended-spectrum β-lactamases (ESBLs) confer resistance to expanded-
spectrum cephalosporins [71]. Originally discovered in Klebsiella pneumonia, ESBLs 
are now widespread in many bacterial species, including E. coli. 
β-lactamases, such as metallo β-lactamases, have evolved that are able to inactivate a 
wide range of β-lactam antibiotics, including some carbapenems, leaving few treatment 
options [46].  
1.2.2.2.  CTX-M extended-spectrum β-lactamases 
In 1990, gram-negative bacteria with a higher level of resistance to cefotaxime (CTX) 
than to ceftazidime were reported by Bauernfeind et al. (1990).  They were designated 
CTX-M-1 due to their high level of resistance to cefotaxime (CTX), and first observed 
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in Munich [41]. CTX-M-type β-lactamases, classified in group 2be in the Bush et al. 
classification system [69] and Ambler class A [67],  are a group of rapidly spreading 
ESBLs, both geographically and in range of clinical bacteria, and are now the dominant 
family, especially prevalent in such bacteria as E. coli and K. pneumoniae [72]. Sharing 
less than 40% amino acid identity [73], they appear to have a separate evolutionary 
history from other β-lactamases such as TEM and SHV, with which they share similar 
activity, and were originally found in K. cryocrescens [41]. They represent a present and 
growing threat to human health. 
The CTX-M β-lactamases are often carried on large plasmids of around 100 kb, which 
also frequently harbour other antibiotic resistance genes including other β-lactamase 
types, and resistance to other antibiotics [74]. These plasmids are often highly mobile 
and transmissible, and many harbour addiction systems which seem likely to ensure 
their persistence and continued propagation even when released from antibiotic 
selective pressure [74]. Genes encoding CTX-M β-lactamases are frequently associated 
with the insertion sequences IS26 and ISEcp1 [75-79]. The presence of upstream 
insertion sequences are often accompanied by downstream sequences similar to the 
inverted right repeat of ISEcp1, which suggest mobility by transposition events [47, 80]. 
ISEcp1 also has been shown to harbour at least one promoter sequence which drives or 
enhances the expression of blaCTX-M [76, 81, 82]. 
The CTX-M family have been grouped into 5 different subclasses, with members of 
each group sharing greater than 94% amino acid identity [41, 83]. They are clustered 
into groups CTX-M: -1, -2, -8, -9 and -25 [41], the group being designated with the 
name of the first member of that group to be described. 
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Particularly widespread in Europe and the US is the β-lactamase CTX-M-15, a member 
of group 1, conferring resistance to 3rd generation cephalosporin antibiotics.  
1.3.  Methods of tackling resistance to β-lactam antibiotics 
As bacteria acquire resistance to specific antibiotics, the therapeutic solution has been to 
treat the infection with an alternative antibiotic, often a newer generation antibiotic with 
a broader spectrum of activity. As antibiotic resistance becomes increasingly prevalent, 
and with a finite arsenal of antibiotics available, this approach is not a long term 
viability. Either a constant stream of new antibiotics are required to be developed or 
discovered at the same, or faster pace, than resistance develops, or alternative 
antimicrobial therapeutics need to be researched.  
1.3.1.  β-Lactamase inhibitors 
Inhibition of β-lactamase is a proven therapeutic method of tackling bacteria with 
reduced susceptibility to β-lactam antibiotics [84]. This approach allows for the 
continued use of a β-lactam antibiotic after bacteria have evolved resistance strategies 
against it. 
Novel synthetic β-lactamase inhibitors have been shown to enhance the activity of 
certain antibiotics. Avibactam, a synthetic β-lactamase inhibitor, for example, was 
observed to have a synergistic effect with ceftazidime against many resistant species 
[85]. Zhang et al. (2014) reported the effective anti-β-lactamase activity of charged 
metallopolymers which inhibited β-lactamase and also attacked the bacterial cell wall 
[86]. Other chemical agents, such as heterobicyclic compounds [87], have also shown 
inhibitory activity against β-lactamase. Other β-lactamase inhibitors, such as Merck’s 
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relebactam for use in combination with imipenem/cilastatin, are currently in 
development [88]. 
1.3.1.1.   Clavulanic acid, sulbactam and tazobactam 
Clavulanic acid, sulbactam and tazobactam, are suicide competitive β-lactamase 
inhibitors. Clavulanic acid contains a penicillin-like β-lactam ring core structure, 
making it a β-lactamase substrate. First described and named in 1977, clavulanic acid 
was isolated from Streptomyces clavuligerus [89]. It was found to have little 
antimicrobial activity alone, but MICs of ampicillin and cephaloridine were reduced 
when used in combination against β-lactamase producing strains of S. aureus, K. 
aerogenes, P. mirabilis, and E. coli [26, 89, 90]. Clavulanic acid inactivates β-lactamase 
by covalently binding to the active serine residue in the enzyme which causes a 
conformational change in the clavulanic acid to increase its reactivity. This in turn, 
reacts with another residue in the β-lactamase active site causing the enzyme to become 
inactive [91]. The combination of amoxicillin and clavulanic acid has been branded 
under the trade name Augmentin and prescribed to treat bacterial infections that are 
resistant to amoxicillin. This antibiotic/inhibitor combination is active against many 
strains of resistant bacteria [92]. Some adverse effects of therapeutic uses of clavulanic 
acid in human patients such as cholestatic jaundice and acute hepatitis have been 
reported [93]. In addition to these limitations, resistance to the amoxicillin/clavulanic 
acid combination have been observed to have evolved [26, 94] 
Sulbactam is a synthetic β-lactamase inhibitor which, like clavulanic acid, contains a 
penicillin-like β-lactam ring structure. Whilst having reportedly low antimicrobial 
properties alone, sulbactam shows direct activity against Bacteroides and Acinetobacter 
species [95]. When used alone, sulbactam was found to exhibit some bactericidal 
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properties against blaCTX-M-15 producing E. coli (this study) – the concentration required 
for complete growth inhibition was lower for sulbactam alone than it was for 
cefotaxime alone. When used in conjunction with cefotaxime, it was found to have a 
synergistic effect. It is currently clinically co-administered with ampicillin and 
cefoperazone in the US and UK, to restore the activity of these antibiotics against 
bacteria with reduced susceptibility [96].  
Tazobactam also shares a β-lactam ring core structural similarity with β-lactam 
antibiotics [91], and clinically it is currently combined with piperacillin. When the 
properties of tazobactam were investigated in the current study, it was found to exhibit 
weak antibiotic activity when a clinical isolate expressing blaCTX-M-15 was treated with 
tazobactam in the absence of cefotaxime, but a strong synergistic effect was observed 
when combined with cefotaxime.  
Whilst the current range of β-lactamase inhibitors have proved successful in broadening 
the spectrum of activity of certain antibiotics and combating β-lactamase mediated 
resistance [91], there are limitations and drawbacks associated with their widespread 
use. The metabolism of drugs can create stable or transient intermediate chemical 
species, breakdown products, or other metabolites which can be highly reactive, with 
the potential for off-target unwanted interactions with other cellular molecules [97]. 
Drugs which form covalent bonds with other molecules as a part of their mechanism of 
action have been a particular cause of concern for this reason [97]. The three 
β-lactamase inhibitors in clinical use, clavulanic acid, sulbactam and tazobactam, 
produce a variety of intermediates, which also vary in the presence of different 
β-lactamase variant enzymes [98]. Inhibitor-resistant strains have been observed to arise 
amongst Class A β-lactamases as a result of one or more amino acid substitutions in the 
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composition of the enzyme [99]. Occurrences of a single amino acid substitution 
resulting in a clavulanic acid resistant phenotype have been observed in E. coli and 
Klebsiella pneumoniae [100-102]. With only a small number of mutations required to 
produce an inhibitor-resistant enzyme and under selective pressure, it would seem likely 
that resistance to inhibitors would spread rapidly. 
 
Although generally considered tolerable at therapeutic doses, there have been 
observations of side effects following the use of amoxicillin-clavulanic acid 
combinations [103, 104]. The piperacillin-tazobactam combination was linked to an 
increased risk of acute renal failure in adults receiving the drug during two 3 month 
periods in 2009 and 2010 [105]. 
Alternative approaches to the ever-growing problem of β-lactamase-mediated 
resistance, such as the inhibition of the expression of β-lactamase, would be desirable. 
1.4.  Inhibition of enzyme expression by synthetic antisense/antigene 
oligonucleotide analogues 
1.4.1.  Development of synthetic oligonucleotide analogues as gene expression 
inhibition agents 
Early studies, dating back from the late 1970s in a variety of both prokaryotic and 
eukaryotic organisms, demonstrated the ability of short lengths of DNA/RNA and their 
analogues to affect gene regulation and expression [106-109].  
In bacteria, natural antisense/antigene mechanisms are well known to perform a wide 
range of functions, most notably to regulate gene expression [110, 111]. Coleman et al. 
(1984) demonstrated that an inducible plasmid could be designed to express a sequence 
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of complementary RNA to inhibit expression of lipoproteins in E. coli, and also 
observed that the most effective mRNA target region was the Shine-Dalgarno sequence 
[112]. Due to the inherent instability and delivery problems with RNA/DNA and whole 
plasmids respectively, the potential of developing therapeutic applications using this 
method of gene inhibition seemed limited. However, the development of synthetic 
oligonucleotide analogues as antisense agents in the 1990s [113] created the possibility 
of targeted protein inhibition by ribosomal hindrance as a viable therapeutic option 
[114]. A range of synthetic oligonucleotide analogues have now been developed, with 
varying backbone chemical structural modifications. The synthetic antisense 
oligonucleotide analogues, hereafter referred to as antisense oligomers, most widely 
studied in bacteria are peptide nucleic acids (PNA) and phosphorodiamidate morpholino 
oligomers (PMO). 
 
1.4.2.  Polyamide (peptide) nucleic acids 
Described and developed in 1991 by Peter Nielsen et al.[115], a synthetic DNA mimic 
was created by replacing the sugar-phosphate backbone of DNA with a polyamide 
backbone (Figure 1-2). These peptide nucleic acids (PNAs) were demonstrated to be 
able to hybridise and interact with DNA or RNA by Watson-Crick base pairing [116], 
showed a high level of stability and were not degraded by endonucleases [115]. PNAs 
with a net neutral charge in the polyamide backbone, do not suffer from electrostatic 
repulsion associated with natural DNA-RNA (or combinations thereof) interactions 
[117], which contribute to their overall high binding affinity. The flexibility of the 
polyamide backbone is also believed to contribute to the strong affinity for its target 
molecule and the stability of the hybrid complex [115]. 
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Figure 1-2. Comparison of backbone structures of RNA and PNA (adapted from 
Armitage [117]), shown hybridising for illustrative purposes. 
PNAs were developed with the intent to bind to DNA duplexes in the major groove of 
the double helix, via Hoogsteen pairing, in a similar manner to triplex-forming 
oligonucleotides (TFOs) [117]. Experimentation revealed, however, that one strand of a 
poly-thymine:poly-adenosine DNA duplex was displaced by a 10-mer poly-thymine 
PNA. A second PNA strand was also found to hybridise to this complex, also by 
Hoogsteen pairing, resulting in a stable PNA2:DNA complex.   
Antisense oligomers have been shown to inhibit protein expression at the translation 
level. Lecosnier et al. described the effects of anti-insulin-like growth factor 1 receptor 
(IGF-1R) PNA, PMO and another synthetic antisense agent, locked nucleic acid (LNA). 
A 17-mer PNA was found to inhibit expression of IGF-1R by 70-80%, without any 
decrease in mRNA levels, as determined by quantitative RT-PCR [118].They also 
showed that a 17-mer PNA did not induce mRNA degradation, in contrast with an 
equivalent siRNA and also noted the unique ability among the three synthetic antisense 
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agents they tested (PMO, PNA and LNA) of PNA to form a PNA2:mRNA triplex 
structure. 
PNAs have been successfully employed to inhibit the expression of a wide range of 
bacterial genes at the translational level; a representative sample selection of previous 
studies is shown in Table 1-1. Although PNAs have been shown to have strong 
inhibitory effects when used in cell free studies and in bacterial strains with atypically 
permeable cell walls, strains with intact cell walls however were not susceptible to PNA 
translational inhibition. This indicates a requirement for a PNA delivery strategy to 
penetrate this barrier [119]. A common strategy to facilitate the translocation of a PNA 
across the bacterial cell wall is by the covalent attachment to a cell-penetrating carrier 
peptide, which is discussed in section 1.4.6.1.   
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Table 1-1. Previous PNA gene expression inhibition studies in bacteria 
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1.4.3.  Phosphorodiamidate morpholino oligomers  
Phosphorodiamidate morpholino oligomers (PMOs), incorporate natural DNA bases 
with a morpholine-phosphorodiamidate backbone (Figure 1-3) [126]. Like PNAs, they 
are able to bind to their DNA/RNA sequence-specific target through Watson-Crick base 
pairing. A PMO is structurally stable, electrically neutral and resistant to degradation by 
nucleases [126]. 
 
 
Figure 1-3. Comparison of backbone structures of PMO and RNA (adapted from 
Geller et al. [126]) shown hybridising for illustrative purposes. 
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In bacteria, PMOs have been shown to inhibit targeted gene expression in a sequence 
specific manner. For example, Geller et al. (2005) demonstrated an 11 base PMO 
targeted to an essential gene responsible for the biosynthesis of phospholipid (acpP), 
was able to significantly slow the growth of E. coli in culture, and reduced the amount 
of viable colony forming units in infected mice [127].  
Table 1-2 shows some representative examples of previous studies using PMOs as 
targeted gene expression inhibitory agents. 
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Table 1-2. Previous PMO gene expression inhibition studies in bacteria 
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1.4.4.  Antisense oligomer sequence design 
Synthetic antisense oligomer design is, in part, a balance of specificity and efficacy – a 
shorter PMO/PNA, being a smaller molecule, is able to enter a bacterial cell more 
efficiently, however, a longer antisense oligomer can be designed to achieve a higher 
degree of specificity with a reduced chance of unwanted off-target homology. The 
length of an antisense oligomer also affects the translational inhibitory efficiency. 
For maximal engagement with the target sequence by an antisense oligomer, it is 
advantageous to target an exposed, accessible and recognisable region of mRNA. The 
lack of a complementary strand in single-stranded RNA (ssRNA) allows for the 
formation of complex 3D secondary structures such as helices and hairpin loops. This 
presents a challenge to any antisense agent design – the target region must be accessible 
to the antisense agent for hybridisation, or the agent must be able to invade a base-
paired strand. One such candidate region is the sequence at the 5' end of the mRNA 
around the start codon position, and the non-translated region immediately (5 to 20 
bases) upstream of that. In prokaryotic organisms, the Shine-Dalgarno (SD) region is a 
short purine-rich sequence of between 2 and 9 bases complementary to a region on the 
3' tail of the 16s ribosomal RNA subunit, and has been linked with the rate of protein 
synthesis [132]. The SD region and the translational initiation start codon have been 
previously shown to be the most effective areas to target by RNA and synthetic 
antisense agents for maximum translational inhibition, with the hindrance of translation 
initiation a likely mechanism for this inhibition [112, 133]. Coleman and colleagues 
noted that in their RNA experiments it was effective to target an area encompassing the 
Shine-Dalgarno region and the start codon of the mRNA of interest [112]. Dryselius 
et al. (2003) designed a series of 10-mer PNAs spanning the length of β-lactamase and 
acpP mRNA, providing an unbiased head-to-tail coverage and concluded the area most 
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susceptible for translational inhibition was the start codon region [133].  Panchal et al. 
(2012) targeted essential genes acpP and gyrA in the gram-positive bacterium  
Bacillus anthracis using 11-mer PMO antisense agents, and found that the most 
effective region was mRNA location -17 to -7,  upstream from translation initiation 
[129]. Deere et al. (2005) identified the start codon and ribosome binding regions as 
effective for E. coli translational inhibition in a cell-free system, and also noted that 3’ 
regions, or 5’ non-translated regions, other than the SD region, were ineffective target 
sites [134]. 
Experimental evidence presented to date appears to indicate that a PNA oligomer of 9 - 
15 bases is a suitable length for effective protein expression inhibition in bacteria whilst 
maintaining specificity. Deere et al. (2005) tested PMOs of various lengths between 7 
and 20 bases for inhibition efficiency against a luciferase reporter and concluded that in 
a cell-free system longer PMOs exhibited greater inhibitory effects than shorter PMOs. 
In whole cells however, shorter PMOs exhibited greater inhibitory effect than longer 
PMOs [134]. 
1.4.5.  Use of antisense to inhibit antimicrobial resistance and restore the activity 
of antibiotics 
The ability of targeted synthetic antisense oligomers to specifically inhibit the 
translation of particular bacterial genes has been successfully demonstrated against a 
variety of targets. The strategy of combating antibiotic resistant bacteria by inhibiting 
the activity of β-lactamase has been shown to be effective with inhibitors such as 
clavulanic acid, sulbactam and tazobactam [91]. Restoration of antibiotic sensitivity in 
bacteria through translational inhibition of β-lactamase activity therefore potentially 
represents a viable and effective therapeutic solution [135].  
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Previous studies have demonstrated the principle of inhibiting the expression of 
resistance genes in bacteria, some example studies include the following: Good and 
Nielsen (1998) re-sensitised an atypically permeable E. coli strain (AS19) harbouring a 
plasmid (pBR322) carrying an ampicillin resistance gene, by inhibition of the 
β-lactamase transcript with a targeted PNA [136]. Jeon and Zhang (2009) employed a 
targeted PNA to inhibit the expression of the CmeABC multidrug efflux transporter in 
Campylobacter jejuni, which reduced the MICs of the antibiotics erythromycin and 
ciprofloxacin by 4 and 8 fold [137].  Wang et al. (2010) increased the susceptibility of 
multi-drug resistant Pseudomonas aeruginosa to five antibiotics by inhibition of the 
expression of the efflux pump OprM, with a transcript targeted phosphorothioate 
oligodeoxynucleotide [138]. Goh et al. demonstrated the ability of an anti-mecA PNA to 
significantly increase the susceptibility of methicillin-resistant Staphylococcus aureus 
(MRSA) to the β-lactam antibiotic oxacillin [139]. 
1.4.6.  Cell penetration 
Bacteria have many strategies to regulate and combat the intake of foreign material such 
as the impermeability of the lipopolysaccharide outer membrane, efflux pumps and 
selective membrane porins. Field and clinical isolates, with intact non-permeable 
membranes, are not susceptible to PNA/PMO translational inhibition, and it was 
surmised that the LPS membrane represents a significant obstacle to be overcome [119, 
136]. Good and Nielsen (1998) found PNAs were able to inhibit β-lactamase expression 
in E. coli sufficiently to restore ampicillin sensitivity in a strain with an atypically 
permeable cell wall, but much less so in a strain with a typically permeable phenotype 
[136]. Peptides taken up by gram-negative bacteria typically are a maximum size of up 
to 650 Da, around 5 – 6 amino acid residues [140]. At around 2-3kDa [48], a 10-mer 
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oligomer is too large to efficiently enter a bacterial cell by porin-mediated passive 
transport, requiring an alternative delivery mechanism. 
1.4.6.1.  Cell-penetrating peptides 
Cell-penetrating peptides (CPPs) are short chains of amino acids, usually less than 30 
residues in length, and usually consisting of a repeating pattern of positively charged 
and hydrophobic neutral residues which are able to traverse a bacterial cell wall. A 
cargo molecule attached, usually by a direct covalent bond, to a CPP is then 
translocated across the cell membrane into the cytoplasm. This approach has been 
shown to be effective in delivering synthetic antisense cargo molecules in eukaryotic 
cell lines [141] and bacterial strains [120].  
Many different CPPs are known to be effective, naturally derived or artificially 
synthesised, often sharing common features. They typically are comprised of a series of 
repeating, alternating polar and hydrophobic residues with a net overall positive charge, 
required for affinity, and interaction with the bacterial cell wall [142]. Table 1-1 and 
Table 1-2 present a sample selection of PNA and PMO oligomers conjugated to 
cell-penetrating peptides in bacterial gene expression inhibition studies. Figure 1-4 
shows commonly used cell-penetrating peptides and their motifs of alternating amino 
acid residues.  
Page 57 
 
Figure 1-4. Common motifs and sequences of cell-penetrating peptides (adapted from 
Puckett et al. [143]). 
 
The mechanism by which CPPs are able to traverse bacterial cell membranes has yet to 
be fully elucidated, with some disagreement and conflicting evidence relating to the 
proposed energy-dependent or energy independent mechanism of cell penetration [144]. 
Most cell-penetrating peptides do not show any cell specificity [145], which may 
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suggest that the translocation pathway is not dependent on any specific cell receptor 
[144, 146].  
The lipopolysaccharide (LPS) component of the outer membrane layer of gram-negative 
bacteria such as E. coli is polyanionic, stabilised with cationic bridges [147].  
Polycationic molecules, such members of the polymixin group, are able to form a 
complex with the LPS and disorganise and disrupt the outer membrane [148]. It would 
appear, however, due to a range of permeabilisation activity of similar polycationic 
agents, that cationicity alone is an insufficient explanation for the outer membrane 
permeabilisation effects. It is likely that the structure and position of the positive 
charges within the molecule contribute to this permeabilisation effect [148]. 
Cell-penetrating peptides bear a resemblance to antimicrobial peptides, both in terms of 
charge/structure and in their ability to translocate across a biological membrane [149]. 
Antimicrobial peptides (AMPs) are a group of short, variable length peptide chains, 
typically  less than 10 kDa, have an overall net positive charge, are heat stable and have 
an affinity for prokaryotic membranes[150, 151]. AMPs often act against their target by 
their strong affinity for a bacterial membrane, and the formation of large transient pores 
[152] resulting in a compromised, permeabilised membrane [153]. This 
channel-forming, membrane perturbation effect has been proposed as a possible 
mechanism of energy-independent translocation of CPPs in bacteria [144].  
Inner membrane transport protein SbmA has been implicated in the translocation and 
importation of peptides including cell-penetrating peptides [143], certain peptide 
antibiotics  [154], and proline-rich antimicrobial peptides [155, 156]. Puckett et al. 
reported some bacteria developing resistance to PMOs conjugated to cell-penetrating 
peptides (P-PMOs) [143]. It was proposed that the spontaneous development of 
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resistance to P-PMOs was a result of an observed mutation in sbmA, and that this 
mutation prevented the translocation of the CPP, and as a consequence, the entire 
conjugate. In their study, sbmA mutants were challenged with a PMO targeting the 
essential gene acpP, conjugated to 6 different CPPs. Four CPP variants were found to 
be ineffective whilst two retained their activity compared with a non-sbmA mutant. The 
four CPPs found to be ineffective against the sbmA mutant varied in amino acid 
composition, and all motifs were either C-N-N or C-N-C (C-cationic, N-non-polar). 
Two cell-penetrating peptides were shown to be unaffected by the sbmA mutation with 
motifs C-N and C-N-C. It was suggested that the active transporter SbmA was at least 
partially responsible for the translocation of the four P-PMOs sensitive to the sbmA 
mutation, and that amino acid composition as well as residue properties of the CPP were 
an important factor in the function of cell-penetrating peptides [143]. The observation of 
two CPP-PMO conjugates which retained their activity in sbmA mutants may suggest at 
least one alternate/additional inner-membrane translocation pathway, and more studies 
are required to elucidate this further. Whilst Puckett et al. demonstrated that an sbmA 
mutant strain was less susceptible to a PMO targeting an essential gene when 
conjugated to certain CPPs, other studies have provided evidence that transportation of 
CPP-antisense oligomer conjugates based on specificity to the cell-penetrating peptide 
portion of the conjugate by SbmA is not necessarily a complete explanation. 
Observations to date, as partly discussed above, indicate that SbmA is flexible in its 
substrate specificity. Ghosal et al. conducted a series of studies to  determine if a PNA, 
the CPP or the entire conjugate was a suitable SbmA substrate [157]. Their findings 
strongly suggested that SbmA was the transporter for an unmodified PNA across the 
inner membrane - an unmodified PNA showed specific activity against its target in 
E. coli mutant strains with a compromised outer membrane, and this activity was 
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significantly lower in sbmA deletion mutants. Further studies suggested the degradation 
of the PNA’s peptide carrier within the periplasmic space by proteases when strains 
with a typical cell wall were challenged with a PNA conjugated to a biodegradable 
cell-penetrating peptide. In the case of a PNA conjugated to a stable peptide carrier, less 
susceptible to degradation by proteases, a proposed alternate penetration pathway of 
direct outer and inner membrane perturbation may be likely. 
It is not known if an unmodified PMO is a suitable substrate for SbmA, and as 
Ghosal et al. studied the relationship between SbmA and a shorter antisense agent of a 
differing chemistry (an 11-mer PNA), the study conducted by Puckett et al. is not 
directly comparable. It would appear to be likely that there are multiple pathways of cell 
penetration by peptide-conjugated antisense agents, including the SbmA pathway, other 
possible active transporters and the direct penetration of the inner membrane by the 
same mechanism by which they penetrate the outer membrane. A quantifiable assay to 
determine the uptake of unmodified antisense oligomers, CPPs, and peptide conjugated 
antisense oligomers would be highly desirable to resolve this uncertainty surrounding 
the mechanism of cellular uptake of CPP conjugated antisense oligomers.  
1.4.6.2.  Experimental evidence of the efficacy of cell-penetrating peptides in 
E. coli 
Good et al. increased the potency of 9 - 12-mer PNAs targeting the essential gene acpP 
and ribosomal RNA (rRNA) by two orders of magnitude by the conjugation of the 
PNAs to the cell-penetrating peptide (KFF)3K [121].  Eriksson et al. showed that when 
challenged with a CPP-PNA conjugate, the membrane of the cell was permeabilised 
[158], indicating a level of disruption of the lipid membranes, as well as the efficacy of 
cell-penetrating peptides as carriers for PNAs. Kurupati et al. designed antisense PNAs 
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to target two essential genes, gyrA and ompA, in Klebsiella pneumonia. Unmodified 
PNAs were found to be ineffective, whereas the CPP-PNA conjugate was able to inhibit 
the target genes in a dose-dependent manner [123].  
The cell penetrating peptide (KFF)3K was shown to act synergistically with certain 
antibiotics in enteric gram-negative bacteria, for example in E. coli the MIC for the 
antibiotic rifampin was reduced 300-fold, with outer membrane disruption and a 
resultant increase in cell permeability the suggested cause [147]. Eriksson et al. studied 
membrane permeabilisation and peptide-PNA uptake in E. coli and demonstrated the 
efficacy of (KFF)3K. They also described an unexpected synergistic effect of the PNA 
component of the conjugate over the free peptide [158]. 
These studies demonstrated the ability of cell-penetrating peptides to penetrate a 
bacterial cell wall and deliver its covalently bound cargo to the cytoplasm. This 
suggests that cell-penetrating peptides could be a suitable carrier for anti-blaCTX-M-15 
agents for the inhibition of β-lactamase expression in field isolates in the current study. 
However, previous studies noting either a cell-permeabilisation effect or a synergistic 
effect of the cell-penetrating peptide with certain antibiotics may suggest membrane 
perturbation as the most likely mechanism of cell penetration, potentially contributing 
to bacterial culture growth inhibition.  
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1.5.  Thesis Hypothesis 
Resistance in E. coli to the 3rd generation cephalosporin cefotaxime is typically 
achieved through the expression of blaCTX-M [41, 159]. The hypothesis of the current 
project was that a targeted anti-blaCTX-M synthetic oligomer would inhibit expression of 
this enzyme, and the sensitive phenotype of the host bacterium would be restored. To 
achieve translational inhibition, PNA and PMO chemistries were chosen to be evaluated 
for efficacy.  
1.5.1.  Project Aims 
The specific aims of this project were: 
1. Development of assays for the quantification of β-lactamase activity  
(Chapter 3). 
 A sensitive, quantifiable and specific β-lactamase activity assay was required to 
evaluate the level of β-lactamase expression, and the efficacy of translational inhibition. 
Assays developed for β-lactamase quantification were a colourimetric nitrocefin based 
assay and high-pressure liquid chromatography (HPLC). Nitrocefin is a chromogenic 
β-lactamase substrate which undergoes a colour change from yellow (λmax = 390 nm) - 
intact nitrocefin, to red (λmax =  480 nm) - degraded. It is routinely used to detect the 
presence of β-lactamase and is rapid, inexpensive and quantifiable [160]. It is not 
specific, however, to any one type of β-lactamase. An HPLC assay for CTX degradation 
was adapted from a method developed to separate seven cephalosporins [161]. The 
assay developed by the current study was CTX specific, sensitive and reproducible and 
suitable for the quantification of cefotaximase activity.  
 
Page 63 
 
2. Design and construction of plasmids carrying blaCTX-M-15 as a suitable test 
subject for inhibition studies in a cell-free system, and the inhibition of 
β-lactamase expression by synthetic antigene oligomers in a cell-free 
translation-transcription coupled system (Chapter 4). 
A plasmid harbouring β-lactamase from CTX-M group 1 was required for initial 
translational inhibition experiments. E. coli field isolates with a reduced-susceptibility 
(to CTX) phenotype often carry many different resistant genes on large plasmids, 
including different classes of β-lactamase. To avoid these potential confounding factors, 
two plasmids were constructed, each carrying a single copy of blaCTX-M-15 cloned from 
field isolates. The expression vector chosen to carry these genes, pET-9a (Novagen) 
featured a T7 promoter and terminator region flanking the multi-cloning site, enabling 
cell-free protein expression in translation/transcription coupled systems utilising viral 
T7 polymerases. 
Cell-free translational inhibition experiments were carried out in a cell-free 
translation/transcription coupled system. These commercially available systems 
typically employ T7 viral polymerases combined with E. coli whole cell extracts, and 
enable expression of proteins from linear or circular DNA without the need for living 
cells. Initial proof-of-concept studies were conducted with a range of three PNAs and 
one PMO of different sizes with different target regions. These were found to exhibit 
blaCTX-M-15 activity inhibition under these conditions.  
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3. Inhibition of β-lactamase CTX-M activity in whole cells (Chapter 5). 
Lipopolysaccharide layer defective mutant strain E. coli AS19 was transformed with 
the expression vector constructed to carry blaCTX-M-15. This strain has previously been 
shown to have a permeable membrane, and take up unmodified antisense/antigene 
agents without any additional cell penetration strategies. It has been successfully used as 
a test subject in previous gene expression inhibition experiments in whole cells. The 
translational inhibition effects of the PMO and PNA shown to be effective in a cell-free 
system were investigated in this transformed AS19 strain. 
With enzyme expression inhibition demonstrated in AS19, the translational inhibition 
effects of the PMO and PNA were investigated in a panel of CTX resistant field 
isolates. In order to achieve sufficient delivery of the antisense agents into the 
cytoplasm, these agents were each attached to a cell-penetrating peptide. Cell-
penetrating peptides have been demonstrated in previous studies to be able to carry a 
cargo molecule across the bacterial cell wall without impeding their inhibition 
properties. Inhibition of β-lactamase expression was inferred by the increased sensitivity 
of the isolates to cefotaxime, established by growth curve assays. Minimum inhibitory 
concentrations were established by a spectrophotometric measurement of growth over 
an 18-24 hour period.  
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4. Exposure to β-lactam antibiotics stimulates an increase of β-lactamase activity 
in strains harbouring blaCTX-M-3 and blaCTX-M-15 (Chapter 6).  
Suspected differential expression levels of blaCTX-M were investigated: 
i)  by exposing both field isolates and AS19 transformed with the  
blaCTX-M-15 plasmid vector to varying concentrations of a 3rd generation 
cephalosporin (ceftriaxone) followed by supernatant incubation with 
cefotaxime. Resultant β-lactamase activity was quantified by HPLC.  
ii) by the quantification of the rate of cefotaxime degradation in E. coli 
cultures. Whole cells were exposed to varying concentrations of 
cefotaxime and rates of degradation established by HPLC.   
 
5. Development of a bacterial intracellular delivery vector for targeted synthetic 
antisense/antigene oligomers (Chapter 7). 
A tetrahedral nucleic acid 3D structure was designed and developed as a carrier and 
delivery vehicle for PMO and PNA antisense oligomers. Its efficacy as a vector was 
evaluated by an evaluation of the re-sensitisation of field isolates to cefotaxime, and in 
comparison with cell penetrating peptide conjugates. 
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Chapter 2.   
Materials and Methods 
2.1.  E. coli strains used in the current study 
Strains used in this study are shown in Table 2-1. E. coli strains of human origin were 
obtained from Public Health England (Salisbury, UK), AS19 was donated by Liam 
Good (RVC, London), BZ693/P, B3804 and LREC525 were from the collection of 
strains at the Animal and Plant Health Agency (Addlestone, UK). LREC90, used for 
control studies, carried a plasmid harbouring blaCTX-M-14, which encoded β-lactamase 
from CTX-M-group 9. All other CTX resistant strains used in this study harboured 
variants of CTX-M-group 1. 
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Table 2-1. E. coli strains used in study. 
Designation Plasmid bla Resistance Source and Notes Ref 
NEB DH5α™ None None Chemically competent lab strain [162] 
NEB Turbo None None Chemically competent, rapid growth  
DH5α™-T1® None None 
Chemically competent, 
enhanced uptake 
efficiency  
 
AS19 None None Atypically permeable strain [163] 
NCTC10418 None None Reference sensitive strain  
NCTC13351 Not known TEM-3 ESBL ref strain  
LREC115 Not known Amp AmpC hyper producer  
LREC460 pEK516 CTX-M-15 Human [74] 
LREC461 pEK204 CTX-M-3  Human [74] 
LREC454 pEK499 CTX-M-15  Human pandemic strain [74] 
LREC525 Not known CTX-M-15 Turkey [164] 
LREC90 Not known CTX-M-14 Cattle  
BZ693/P Not known CTX-M-3 Chicken  
B3804 pIFM3804 CTX-M-1 Pig [165] 
21/C0188/02/13 Not known Oxa1 Bull Calf  
12/B0118/10/11 Not known CTX-M-1 Chicken  
2013-6404 Not known TEM-1 Not known  
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2.2.  Plasmids used during study 
Table 2-2. Plasmid vectors used during the study 
Plasmid Features Resistance Source 
pCR2.1  TA Cloning vector Ampicillin, Kanamycin Invitrogen 
pET-9A Expression vector Kanamycin Novagen 
 
2.3.  Synthetic antisense oligomer sequence design and synthesis 
PNA and PMO antisense oligomers (Table 2-3) were designed to target and span the 
start and/or Shine-Dalgarno (SD) region of blaCTX-M-group 1 mRNA. PNA1 and PNA3 
were synthesised by, and purchased from Cambridge Research Biochemicals 
(Cleveland, UK, purity = 99.9%), and PMO1 was purchased from Genetools, LLC 
(Philomath, USA, estimated purity > 92%). PNA4 was synthesised by Cellmano 
Biotech (Hefei, China, purity = 95.51%). Peptide conjugated antisense oligomers (Table 
2-4) were synthesised by Cambridge Research Biochemicals. Alignments of the group 1 
CTX-M β-lactamases targeted in this study are shown in Figure 2-1. Figure 2-1 also 
shows the sequence and regions of complementarity with blaCTX-M-group 1 of the antisense 
oligomers used in this study. 
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Table 2-3. Antisense oligomer sequences.  
The PNAs are written from their N- (amino) to C- (carboxy) termini, with the 
N-terminus corresponding to the 5' end of a conventional oligonucleotide [123]. PMOs 
are commonly described as having 5’ and 3’ ends, corresponding to those of 
DNA/RNA. * - estimated. 
Designation Sequence (5’ – 3’) Purity 
PNA1 attccttattctg 99.9% 
PNA3 catgggattcctt 99.9% 
PNA4 ttccttattctgg 95.51% 
PMO1 gcgcagtgattttttaaccatggga > 92%* 
 
 
Figure 2-1. Alignments of blaCTX-M-15/1/3/33 mRNA with PMO1, PNA1, PNA3 and 
PNA4. 
Asterisks (*) represent base homology between the blaCTX-M variants. 
Table 2-4. Peptide conjugated antisense oligomer sequences. 
Name Sequence  Purity 
P-PNA4 KFFKFFKFFK-ethylenediamine-[5’-ttccttattctgg-3’-[Cys]-maleimido-β-Ala] >90% 
P-PMO1 KFFKFFKFFK-ethylenediamine-[5’-gcgcagtgattttttaaccatggga-3’-maleimido-β-Ala] >90% 
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2.4.  DNA Oligonucleotides 
2.4.1.  PCR Primers 
Oligonucleotide primer pairs (Table 2-5) designed for the amplification of DNA from 
genomic or plasmid DNA were supplied and synthesised by Sigma Custom Products 
(Suffolk, UK). Primers were suspended in sterile nuclease-free water (Qiagen, 
Manchester, UK) to a final concentration of 100 µM. Bold lower case text denotes 
restriction enzyme recognition sites incorporated into the primer. 
 
Table 2-5. PCR primer pairs for the amplification of blaCTX-M-15 and associated 
upstream region.  
Bold text represents restriction enzyme recognition sites. 
Reference DNA Sequence (5’ to 3’) Amplicon Amplicon Size (bp) 
CTX-M-
pEK516 
Forward actcaagatctgaaattcagctttcacccattg CTX-M-15 and 
IS26 from 
pEK516,  
2552 
 
Reverse ccatgtcctaggccgtttccgctattacaaac 
CTX-M-
pEK499 
Forward tactggcatatgcgcttgtgattcgccgccgtcaggttga CTX-M-15 and 
ISEcp1 from 
pEK499 
2119 
Reverse gagcgtggatccccgtttccgctattacaaac 
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2.4.1.1.  Sequencing/screening primers 
Table 2-6. Primers for PCR screening, and sequencing. 
Reference DNA Sequence (5’ to 3’) Region Target 
M13 
Forward cgccagggttttcccagtcacgac 
M13  
Reverse tcacacaggaaacagctatgac 
CTX-M-SEQ 
Forward01 ccttcgaccagaacccgg 
Cloned region 
sequencing/ 
screening primers 
Forward02 gcacggcccggtacagatac 
Reverse03 cggcatcagttaccgtgagc 
Reverse04 cgggcgaacgcggtgacg 
T7 
Forward taatacgactcactataggg Region between T7 
promoter and 
terminator Reverse gctagttattgctcagcgg 
 
2.4.1.2.  Primers for site-directed mutagenesis 
Table 2-7. Primers for site-directed mutagenesis and for SDM screening. 
Reference DNA Sequence (5’ to 3’) Description 
SDM 
Forward atacatcgcgacggctttctgccttaggttg SDM primers for the area 
surrounding the single base 
mutation. Primers incorporate 
mutation correction (bold). Reverse caacctaaggcagaaagccgtcgcgatgtat 
SDM-SCREEN 
Forward cttcctttcgggctttgtta PCR primers for the 
amplification of 164bp region 
surrounding mutation for RE 
digestion and screening Reverse tggccaaaagatcgtgcgcc 
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2.4.1.3.  DNA sequences for tetrahedron construction 
The sequence of single-stranded DNA (ssDNA) forming the structural frame of each 3D 
tetrahedral vector was designed with areas on each strand to be complementary to 
regions on the other structural strands (Table 2-8). These regions of complementarity 
facilitated the formation of the rigid 3D double-stranded DNA (dsDNA) tetrahedron 
structure. ssDNA strands were checked for unwanted hetero and homo dimerisation 
using Multiple Primer Analyzer (ThermoFisher Scientific) [166]. 
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Table 2-8. DNA sequences used to form a 3D tetrahedron structural framework to carry 
antisense oligomers. 
Tetrahedron 
Designation Description Reference DNA Sequence (5’ to 3’) 
JBRPMOP 
Prototype design 
– single 25-mer 
PMO forming 
one tetrahedron 
face. Each edge 
= 9 bp. 
JBRPMOP-F1 ggtaccctgtcactaagtaggattg 
JBRPMOP-F2 agcgtccccttagtgaccgcgtcac 
JBRPMOP-F3 gggacgcttaaaaaattcaatccta 
JBRCPMOP1 
25-mer 
PMO-carrying 
tetrahedron, 
18 bp edges. 
Total size = 
108 bp 
JBRCPMOP1-A gcggtgagttgtatccaccacggtgtgcc 
JBRCPMOP1-B cgattagcctaagatcgggttctcaccgccttgccaaccgctcccatggttaaa 
JBRCPMOP1-C ccgtggtggatacaactctggcaaggcggtgagaactgtcctacgaagagtgta 
JBRCPMOP1-D ccgatcttaggctaatcgaaatcactgcgcggcacatacactcttcgtaggaca 
JBRCPMOP1-PMO gcgcagtgattttttaaccatggga 
JBRSPNAP2 
13-mer 
PNA-carrying 
tetrahedron, 
18 bp edges. 
Total size = 
108 bp 
JBRSPNAP2-A actccagacccgttcactccctccgttgtcctaacgctaag 
JBRSPNAP2-B cgcgacttaggtccataatcaaggggccggtgagatgggagtgaacgggtctgg 
JBRSPNAP2-C tagcgttaggacaacggaatctcaccggccccttgatacgtgcgggtctgataa 
JBRSPNAP2-D ttatggacctaagtcgcgagtccagaataaggaactttatcagacccgcacgta 
JBRSPNAP2-PNA ttccttattctgg 
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2.5.  Chemicals and antimicrobials 
All reagents, chemicals and antimicrobial agents were obtained from Sigma-Aldrich 
(Dorset, UK) unless otherwise stated. 
2.6.  Bacterial Methodology 
2.6.1.  Storage of E. coli strains 
All bacterial strains were stored at -80° C using the Protect Microorganism Preservation 
System (Technical Service Consultants, Lancs, UK). A single colony from an overnight 
culture grown on LB agar media was selected and typically suspended in 5 ml LB at 
37° C with shaking at 200 rpm. When the culture had reached approximately O.D. 600 nm 
0.3, 200 µl of liquid from a single Protect Microorganism Preservation System vial was 
replaced with 200 µl bacterial suspension and stored at -80° C. 
2.6.2.  Bacterial culture 
Unless otherwise stated, E. coli strains were cultured in lysogeny broth (LB) or on LB 
solid agar with antibiotic supplements where required. Cultures were grown at 37° C, 
and liquid cultures with the addition of shaking at 200 rpm. Typical final antibiotic 
selection concentrations were: cefotaxime – 2 µg/ml, ampicillin – 100 µg/ml, 
kanamycin – 40 µg/ml. 
2.6.3.  Estimation of DNA concentration 
Concentration of circular and linear DNA preparations and purifications were estimated 
by spectrophotometric analysis using a Thermo Scientific NanoDrop™ 1000 
Spectrophotometer (Thermo Fisher Scientific, MA, USA). 
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2.6.4.  Plasmid preparation and purification 
Plasmids were extracted and purified from E. coli cultures using the peqGOLD Plasmid 
Miniprep Kit (Peqlab Ltd, Southampton), and the manufacturer’s protocol followed. 
Plasmid DNA was typically prepared from a 2 - 4 ml overnight culture. A 
manufacturer’s estimation of 80 - 95% of plasmid DNA was obtained with two ddH2O 
elutions of 25 - 50 μl each. Plasmid purity and concentration was verified and estimated 
by agarose gel analysis, and by spectrophotometric analysis using a Thermo Scientific 
NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific). 
2.6.5.  Establishment of minimum inhibitory concentration (MIC) values for 
E. coli strains 
E. coli strains were cultured in 96-well microtiter plates (Falcon) and incubated at 37°C 
in a Fluostar Optima (BMG Labtech, Aylesbury, UK) spectrophotometer, with a 
constant temperature of 37° C. Growth was monitored at O.D. 600 nm for 18 – 24 hours. 
MIC values were reported as the minimum concentration of an agent or agents required 
to inhibit growth (O.D. 600 nm < 0.1) in a minimum of 50% of replicates after 18 hours 
incubation at 37° C. 
2.6.6.  Restriction endonuclease digestion of DNA 
All restriction enzymes were supplied by NEB (New England BioLabs, Herts, UK) or 
Promega (Southampton, UK) unless otherwise stated. Typically, 1 µg DNA was 
incubated with 10% (v/v) manufacturer’s supplied reaction buffer and the 
manufacturer’s recommendation of 1 µl enzyme in a 50 µl reaction at 37° C for between 
15 and 60 minutes. 
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2.6.7.  Separation of DNA fragments by agarose gel electrophoresis 
Agarose gels were typically prepared with approximately 1.5% (w/v) agarose in TAE 
buffer (40 mM Tris-acetate, 2 mM EDTA) and stained with ethidium bromide or 
SYBR® Safe DNA gel stain (Invitrogen, Paisley, UK) at a concentration of 1:10,000. 
Unless otherwise stated, TAE was used for the running buffer and samples were 
typically run at 80V. DNA fragments were visualised and photographed using a 
Syngene GeneGenius UV Transilluminator (Syngene, Cambridge, UK). A 100 bp or 
1 kb DNA marker ladder (Promega) was used to estimate fragment sizes and DNA 
quantity. 
2.6.8.  Polymerase Chain Reaction (PCR) 
Typically 10 - 100 ng DNA template was used in a 50 μl reaction consisting of 0.5 μl of 
50 mM dNTPs, 1 μl of each primer (10μM), 1 μl of polymerase (1 unit/μl), concentrated 
reaction buffer to a final concentration of 1x, and water to a final volume of 50 μl. The 
PCR reaction was completed using a GeneAmp® PCR System 9700 (PE Applied 
Biosystems) PCR thermocycler under the cycle conditions shown in Table 2-9.  
Table 2-9. Typical PCR cycle conditions. 
Iterations Temperature Time Purpose 
Throughout Heat Lid 100° C - Condensation prevention 
Once 94° C  5 minutes Initial cell breakage and DNA denaturation 
Loop (32-35x) 92° C 30 seconds Denaturation 
 X° C 40 seconds Annealing 
End Loop 72° C 60-150 seconds Extension (~ 1kb/min for Taq) 
Once 72° C 5 minutes Final Extension 
Forever 4° C  ∞ Storage/end 
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2.6.9.  Colony PCR 
Typically, colony PCR was performed in a 50μl reaction using a GeneAmp® PCR 
System 9700 (PE Applied Biosystems) PCR thermocycler, using typical PCR cycle 
conditions (Table 2-9). A colony was selected, re-streaked and dipped into a typical 
PCR reaction mixture. 
2.6.10.  Culture of transformants 
Individual colonies were selected from incubated plates and a sterile loop was used to 
transfer the selected colonies into a 50 ml culture tube containing 10 ml LB medium 
with appropriate selective antibiotics. They were then incubated overnight at 37° C with 
continuous shaking at 200 rpm. 
2.6.11.  Vector/Insert Ligation 
Molar ratios of vector:insert typically ranged between 1:1 and 1:3. Molar ratio 
calculations were verified and assisted with the NEBioCalculator™ v1.3.9 [167]. 
Ligations were typically performed in a 30 µl reaction in the presence of 10x T4 buffer 
(Promega; 3 µl) and T4 DNA ligase (3 µl), the volume adjusted with nuclease-free 
water. The ligation reaction was incubated at 4° C for 14 - 16 hours. 
2.6.12.  Construction of expression plasmid vector carrying cloned blaCTX-M-15 and 
associated upstream regions 
2.6.12.1.  PCR amplification of blaCTX-M-15 from pEK499 and pEK516 
Two suitable, fully sequenced  resistance plasmids were selected as donor plasmids for 
the cloning of blaCTX-M-15, LREC454 field isolate harboured the resistance plasmid 
pEK499 [74] and isolate LREC460 harboured the resistance plasmid pEK516 [74]. The 
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open reading frames for blaCTX-M-15 shared 100% sequence identity, but differed in the 
upstream genetic environment, including promoter loci and composition. Primers were 
designed to amplify the entire gene and the upstream insertional elements associated 
with blaCTX-M-15. To facilitate the incorporation of the resultant amplicon into the 
expression vector pET-9a, restriction enzyme recognition sites were incorporated into 
the primer design (Table 2-5). Primers designed for the amplification of blaCTX-M-15 
from pEK499 incorporated the restriction enzyme site recognised by NdeI in the 
forward primer, and BamHI in the reverse primer. Primers designed to amplify 
blaCTX-M-15 from pEK516 incorporated XbaI in the forward primer and BamHI in the 
reverse. The PCR reactions took place under typical conditions. The use of two different 
restriction recognition sites in each of the PCR primer pairs used to amplify the target 
region facilitated the directional insertion of blaCTX-M-15 in the correct, functional 
orientation in the expression plasmid pET-9a. 
2.6.12.2.  Non-directional incorporation of PCR products into pCR™2.1-TOPO® 
cloning vector 
The ligation of PCR products with the linear cloning vector, pCR™2.1-TOPO 
(Invitrogen) was carried out using the Quick Ligation™ Kit (NEB) under the following 
conditions: approximately 50 ng amplified and purified DNA PCR product was 
incubated with between 25 and 100 ng of the linear vector backbone pCR™2.1-TOPO, 
dH2O to 10 µl, 2x Quick Ligation Buffer (2 µl), Quick T4 DNA Ligase (1 µl). This 
reaction mixture was incubated at 25° C for 5 minutes, and then chilled on ice. This was 
then used to transform One Shot® MAX Efficiency™ DH5α-T1® E. coli (Invitrogen). 
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2.6.12.3.  Blue-white screening of recombinant bacteria 
LB agar plates were prepared, supplemented with CTX (2 µg/ml) and KAN (40 µg/ml), 
and allowed to dry. X-Gal (100 µl; 20 mg/ml) was spread onto the surface and allowed 
to dry. IPTG was not required for the chromogenic reaction when using E. coli strain 
DH5α™-T1®. Transformation reactions were spread onto the plate and cultured 
overnight at 37° C. The next morning the plates were incubated at 4° C for 1 hour to 
enhance the development of the blue colour. Successful transformants appeared white 
and were selected, cultured and stored at -80° C. 
2.6.12.4.  Screening of recombinant plasmid for successful insertion of cloned 
region 
Plasmids were extracted and purified using the peqGOLD Plasmid Miniprep Kit 
(Peqlab), and used as the DNA template in a typical PCR reaction. M13 forward and 
reverse primers (Table 2-6) were used to amplify the entire section of DNA ligated into 
pCR™2.1-TOPO. The PCR products were analysed by gel electrophoresis with a 1kb 
reference DNA ladder (Promega). Plasmids containing inserts of the correct size 
(2552 bp for the section cloned from pEK516, and 2119 bp for the section cloned from 
pEK499) were selected and sequenced for verification of successful incorporation of the 
cloned region. These plasmids were designated pCR2.1-CTX-M499 and 
pCR2.1-CTX-M516 respectively. 
2.6.12.5.  Restriction enzyme digestion of recombinant plasmids 
pCR2.1-CTX-M499 and pCR2.1-CTX-M516   
Recombinant plasmids pCR2.1-CTX-M499 and pCR2.1-CTX-M516 were extracted and 
purified using peqGOLD Plasmid Miniprep Kit. pCR2.1-CTX-M499 was digested with 
BamHI and NdeI, to release the cloned sections, under the following conditions: 
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approximately 1 µg of plasmid DNA was incubated with 5 µl buffer 3.1 (NEB), 0.5 µl 
BSA, 1 µl BamHI-HF® (NEB), 1 µl NdeI (NEB) and ddH2O to a final reaction volume 
of 50 µl, at 37° C for 60 minutes. The DNA was purified with the peqGOLD MicroSpin 
Cycle Pure Kit (Peqlab) with one elution of 20 µl in ddH2O. pCR2.1-CTX-M516 was 
digested with BamHI and XbaI, to release the cloned sections, under the following 
conditions: approximately 1 µg of plasmid DNA was incubated with 2 µl restriction 
enzyme reaction buffer (Promega), 0.2 µl BSA, 0.5 µl XbaI (Promega) at 37° C for 
60 minutes. This reaction was purified with the peqGOLD MicroSpin Cycle Pure Kit 
(Peqlab) with one ddH2O elution (46 µl). The purified DNA was then incubated with 
10x NEB restriction enzyme buffer 3 (5 µl) and BamHI-HF (NEB; 1 µl) at 37° C for 10 
minutes. The DNA was purified with the peqGOLD MicroSpin Cycle Pure Kit (Peqlab) 
with one ddH2O elution (25 µl). 
2.6.12.6.  Separation and purification of cloned DNA sequences by agarose gel 
excision 
The products of the restriction enzyme digestion reactions were loaded onto a 1.5% 
(w/v) agarose in TAE buffer and stained with SYBR® Safe DNA gel stain (Invitrogen) 
at a concentration of 1:10,000 and run at 80V until the marker dye had travelled 
approximately two thirds of the total length of the gel. They were visualised for less 
than 10 seconds under UV illumination and the bands corresponding to the sizes of the 
released insert was excised with a sterile scalpel blade. The peqGOLD Gel Extraction 
Kit (Peqlab) was used to release the DNA fragments from the agarose gel, following the 
manufacturer’s protocol, with one ddH2O elution (30 µl). 
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2.6.12.7.  Linearisation of pET-9a by restriction enzyme digestion  
Expression plasmid vector pET-9a was digested with restriction enzymes, leaving 
compatible staggered cuts with the overhangs generated in the insert released from the 
recombinant plasmids pCR2.1-CTX-M499 and pCR2.1-CTX-M516. To generate a 
suitable linearised vector for the ligation of blaCTX-M-15 cloned from pEK499, pET-9a 
was digested under the following conditions: approximately 1 µg of plasmid DNA was 
incubated with buffer 3.1 (5 µl) (NEB), BSA (0.5 µl), BamHI-HF® (1 µl) (NEB), NdeI 
(1 µl) (NEB) and ddH2O to a final reaction volume of 50 µl, at 37° C for 60 minutes. 
The DNA was purified with the peqGOLD MicroSpin Cycle Pure Kit (Peqlab) with one 
ddH2O elution (20 µl).  
To provide a compatible backbone for the region amplified from pEK516, pET-9a was 
digested under the following conditions: plasmid DNA (approximately 1 µg) was 
incubated with restriction enzyme reaction buffer (2 µl) (Promega), BSA (0.2 µl), XbaI 
(Promega; 0.5 µl) at 37° C for 60 minutes. This reaction was purified with the 
peqGOLD MicroSpin Cycle Pure Kit (Peqlab) with one ddH2O elution (46 µl). The 
purified DNA was then incubated with 10x NEB restriction enzyme buffer 3 (5 µl) and 
BamHI-HF (1 µl; NEB) at 37° C for 10 minutes. The DNA was purified with the 
peqGOLD MicroSpin Cycle Pure Kit (Peqlab) with one ddH2O elution (25 µl). 
The digested plasmids were verified for size and purity by agarose gel electrophoresis, 
and concentration determined by spectrophotometry using a NanoDrop™ 1000 
Spectrophotometer (Thermo Fisher Scientific). 
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2.6.12.8.  Ligation of blaCTX-M-15 and upstream insertional elements with linearised 
pET-9a expression vector 
Gel purified inserts and the linearised vector backbone pET-9a were ligated using the 
Quick Ligation™ Kit (NEB) under the following conditions: gel purified insert DNA 
(approximately 50 ng) was incubated with linearised vector backbone pET-9a (between 
25 and 100 ng), dH2O to 10 µl, 2x Quick Ligation Buffer (2 µl), Quick T4 DNA Ligase 
(1 µl). This reaction mixture was incubated at 25° C for 5 minutes and then chilled on 
ice. The recombinant plasmids were designated pJBRCTX499 and pJBRCTX516.  
2.6.12.9.  Screening of recombinant plasmid for successful insertion of cloned 
region 
E. coli strains harbouring pJBRCTX499 and pJBRCTX516 were cultured overnight on 
LB agar supplemented with CTX (final concentration: 2 µg/ml) and KAN (40 µg/ml) at 
37° C. Multiple single colonies of each transformant were selected and cultured 
separately in LB (10 ml) with CTX (1 µg/ml) at 37° C with shaking at 200 rpm until 
culture growth, measured by spectrophotometry at a wavelength of 600 nm, reached an 
optical density of 0.6. Plasmids were extracted and purified using the peqGOLD 
Plasmid Miniprep Kit (Peqlab). They were screened for successful incorporation of the 
inserted sequence by 3 methods: 
1. pJBRCTX516 was digested with the restriction enzymes BamHI and XbaI under 
typical conditions, and analysed for size by agarose gel electrophoresis. 
pJBRCTX499 was digested with the restriction enzymes BamHI and NdeI under 
typical conditions, and analysed by agarose gel electrophoresis.  
2. Plasmids were screened by PCR under typical conditions, using T7-forward and 
T7-reverse primers (Table 2-6) to amplify the plasmid region between the T7 
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promoter and T7 terminator, corresponding to the DNA ligated into the vector. 
The amplicons were analysed for size by agarose gel electrophoresis. 
3. The plasmids were sequenced (APHA sequencing dept) using the dideoxy chain 
termination / cycle sequencing method using CTX-M-SEQ primers (Table 2-6). 
2.6.12.10.  Site-directed mutagenesis 
To correct a point mutation discovered in pJBRCTX499 the GENEART® Site-Directed 
Mutagenesis System (Invitrogen) was used. Primers were designed containing the 
corrected mutation in a central position, 100% complementary with no overhangs 
(Table 2-7). Both primers were 31 nucleotides in length. The reaction mixture was 
prepared as follows: 10x AccuPrime™ Pfx reaction mix (5 µl), 10x enhancer (5 µl), 
10 µM forward primer (1.5 µl), 10 µM reverse primer (1.5 µl), DNA methylase (4 U/µl, 
1 µl), 25x SAM (2 µl), AccuPrime™ Pfx (2.5 U/µl, 0.4 µl), plasmid DNA 
(approximately 20 ng), ddH2O to a final volume of 50 µl. The PCR methylation and 
mutagenesis reaction took place under the PCR conditions shown in Table 2-10. 
Table 2-10. SDM mutagenesis PCR conditions. 
Iterations Temperature Time 
Throughout Heat Lid 100° C - 
Once 37° C  15 minutes 
Once 94° C 2 minutes 
Loop (15x) 94° C 20 seconds 
 57° C 30 seconds 
End Loop 68° C 20 minutes 
Once 68° C 5 minutes 
Forever 4° C  ∞ 
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The recombination reaction mixture was prepared as follows: 5x reaction buffer (4 µl), 
ddH2O (10 µl), PCR reaction (4 µl), 10x enzyme mix (2 µl). This reaction was 
incubated at 20° C for 10 minutes, and then placed on ice. The reaction was used to 
transform DH5α™-T1® using typical heat shock transformation conditions. 
2.6.12.11.  Screening for successful site-directed mutagenesis  
Colonies from an overnight culture were selected and plasmids extracted using the 
peqGOLD Plasmid Miniprep Kit. A 164 bp section surrounding the mutation site was 
amplified by PCR under typical conditions using primers SDM-SCREEN-Forward and 
SDM-SCREEN-Reverse (Table 2-7). The amplified section was digested with the 
restriction enzyme CviKI-1 (NEB): approximately 1 µg DNA, 10x CutSmart buffer 
(5 µl), restriction enzyme (2 µl) and ddH2O to a final volume of 50 µl. The digestion 
reaction was incubated at 37° C for 60 minutes and loaded onto an agarose gel prepared 
with approximately 2.0% (w/v) agarose in TBE buffer (Tris-borate-EDTA) and stained 
with ethidium bromide at a concentration of 1:10,000. The samples were run at 80V 
until the dye marker had travelled a distance to indicate sufficient separation. DNA 
fragments were visualised using a Syngene GeneGenius UV Transilluminator 
(Syngene). A 100 bp (Promega) DNA marker ladder was used to estimate fragment 
sizes. 
2.6.13.  Transformation of E. coli with plasmid DNA by heat shock 
Chemically competent E. coli strain, NEB DH5α™ (NEB), was typically used for 
transformations, although other similar commercially obtained chemically competent 
strains, such as DH5α™-T1® (NEB) or One Shot® INVαF’ (Invitrogen) were often 
substituted. The manufacturer’s (NEB) high efficiency transformation protocol was 
followed. Cells were stored at -80° C until required and thawed on ice for 10 minutes. 
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Approximately 10 - 50 ng purified plasmid DNA (estimated from agarose gel band 
intensity or spectrophotometry) was mixed with 50 μl of chemically competent cells and 
incubated on ice for 30 minutes. They were then heat-shocked at 42° C for exactly 
30 seconds and returned to ice for 5 minutes. 950 μl room temperature super optimal 
broth with catabolite repression (SOC) medium was added and incubated at 37° C for 
1 hour with rotation at 200 rpm. In a deviation from the protocol, the cells were then 
concentrated by centrifugation and resuspended in 100 μl LB medium and plated onto 
room temperature LB agar supplemented with selective antibiotics, and incubated at 
37° C overnight until colonies were evident.  
2.6.14.  Preparation of electrocompetent AS19 
Typically, AS19 was cultured in LB until mid-log phase (O.D. 600 nm = 0.3 - 0.6). All 
tubes, cuvettes and solutions were pre-chilled on ice. Aliquots (1 ml) were chilled on ice 
for 10 - 15 minutes. The aliquots were centrifuged for 2 minutes at 13,000 rpm in a 
bench top micro-centrifuge and each aliquot resuspended in 1 ml 10% glycerol solution. 
The centrifugation step was repeated and the cells were resuspended in 500 µl 10% 
glycerol. The centrifugation step was repeated and the cells were resuspended in 100 µl 
10% glycerol.  
2.6.15.  Transformation of AS19 with plasmid DNA by electroporation  
Aliquots (100 µl) of electrocompetent AS19 were mixed with 50 - 200 ng pre-chilled 
plasmid DNA, and transferred to Gene Pulser® 0.1 cm electrode cuvettes (Bio-Rad, 
Herts, UK). Mixtures were pulsed at 1.8kV, 25 µF, 200 ohms in a Bio-Rad Gene Pulser 
(Bio-Rad). Pre-warmed SOC (900 µl; 37° C) was added to the mixture and incubated 
for 30 minutes. They were then diluted and recovered onto LB agar supplemented with 
appropriate antibiotics for selection of successful transformants. They were incubated 
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overnight at 37° C and single colonies selected and screened for successful 
transformation by plasmid extraction followed by PCR characterisation of the plasmid, 
restriction enzyme digestion and sequencing. 
2.6.16.  Assay for the quantification of protein expression in E. coli 
To determine the protein concentration of microbial supernatant extracts, the following 
assay was used. Working standards of BSA of 1, 0.5, 0.25, 0.1, 0.05 and 0 mg/ml BSA 
were prepared. In duplicate, 250 µl of each standard and each test sample was incubated 
with Bradford reagent (1 ml) for not more than 30 minutes. The optical densities of the 
reactions were then measured at 600 nm and the protein concentration of the test 
samples established by reference to the standard curve, interpolated by Prism® 6 
software (GraphPad).  
2.6.17.  Nitrocefin based colourimetric assay for β-lactamase activity 
quantification 
E. coli strains were typically cultured from frozen glycerol stocks until early log phase 
(O.D. 600 nm = 0.1 – 0.2) was reached. Cultures were split into equal aliquots and 
supplements or growth media added where required. The aliquots were cultured for 
pre-determined times and cells were disrupted by bead milling. Supernatants were 
separated by centrifugation and samples added to wells in a 96-well microtiter plate 
pre-prepared with nitrocefin solution. Optical density measurements were taken at a 
light wavelength of 492 nm approximately every 30 seconds over 30 – 60 minutes. 
Rates of nitrocefin hydrolysis were calibrated using a standard curve constructed from 
dilutions of the commercial purified β-lactamase M02075 (Fluorochem, Derb, UK). 
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2.6.18.  Reverse-phase HPLC assay for the quantification of cefotaxime in 
solution 
The reverse-phase HPLC (RP-HPLC) method was adapted from Nemutlu et al. for the 
detection of cefotaxime and other cephalosporins [161]. RP-HPLC was performed using 
an Xterra C18 (250 mm x 4.6 mm, 5 μm i.d.) column using Agilent Technologies 1100 
series liquid chromatography system comprising of automated solvent delivery, sampler 
and array detector system. Analysis and quantification of cefotaxime was performed 
with ChemStation software (Agilent Technologies). Standard calibration curves were 
constructed using cefotaxime dilutions (typically 1 – 400 µg/ml). Cefotaxime dilutions 
were prepared using MHB, ddH2O or LB. Analysis was performed with ChemStation 
software (Agilent Technologies) which generated a graphical visualisation of a single 
peak representing cefotaxime quantity.  Standards were prepared and quantified for each 
study from the same cefotaxime stock used, and diluted in the carrier medium used in 
the study. Cefotaxime amounts in test samples were quantified with reference to 
reported size of the area under the resolved curve calibrated against the standard curve.  
Chromatographic conditions were as follows: phosphate buffer  (sodium dihydrogen 
orthophosphate dihydrate 40 mM; pH 3.2)  was mixed with MeOH during automated 
analysis with a gradient pump to the following amounts (MeOH: Phosphate buffer) ; t=0 
mins 18:82%, t=5 mins  18:82%; t= 15 mins 45:55%; t=16 mins 55:45%; t= 21 mins 
55:45 %; t=22 mins 18: 82%; t = 30 next injection at a flow rate of 0.85 ml/min, with an 
injection volume of 25 µl per sample.  Cefotaxime was detected at a light wavelength of 
254 nm. 
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2.6.19.  Cell-free blaCTX-M inhibition studies by antisense agents in a 
translation/transcription coupled system 
The Expressway™ Mini Cell-Free Expression System (Invitrogen) was used for all cell 
free inhibition studies. This system utilised a translation/transcription coupled reaction 
to produce active proteins from naked linear or circular DNA.  The system contained 
E. coli extract and amino acids to provide the translation machinery to express proteins, 
and T7 RNA polymerase. The use of viral polymerase required the incorporation of a 
T7 promoter in the template DNA.  A T7 terminator is also desirable downstream of the 
gene to be expressed to facilitate the release of the T7 polymerase. 
The manufacturer's supplied protocol was followed; briefly, a reaction master mix was 
made up in a 1.5 ml reaction tube consisting of the manufacturer’s supplied reagents: 
E. coli SlyD- extract (20 μl), 2.5x IVPS E. coli buffer without amino acids (20 μl), 
50mM amino acids minus methionine (1.25 μl), 70mM methionine (1 μl), T7 enzyme 
mix (1 μl) and plasmid DNA (500-1000 ng). The reaction was incubated at 30° C with 
rotation at 300rpm for 30 minutes. After 30 minutes, a feed buffer was added 
comprising of: 2x IVPS feed buffer (25 μl), 50 mM amino acids minus methionine 
(1.25 μl), 70 mM methionine (1 μl), and nuclease free water to a final volume of 100 μl. 
This reaction was continued at 30° C with 300 rpm rotation for 3 - 5 hours and then 
rapidly chilled on ice. 
2.6.20.  Evaluation of the effects of β-lactamase activity inhibition by antisense 
agents in AS19 E. coli transformants by growth curves produced by 
spectrophotometry 
AS19 transformed with recombinant plasmid carrying blaCTX-M-15 was cultured 
overnight at 37° C in a shaking incubator from frozen glycerol/bead stocks in MHB 
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(Mueller-Hinton Broth) supplemented with CTX (2 µg/ml). The next morning, the 
culture was used to inoculate fresh MHB (10 ml) supplemented with CTX (final 
concentration 2 µg/ml) and cultured until early to mid-log phase was observed 
(O.D. 600 nm = 0.1 - 0.3). Cells were separated from their growth medium by 
centrifugation at 13,000 rpm in a Heraeus™ Biofuge™ centrifuge (Thermo Fisher 
Scientific) and resuspended in fresh MHB media. The cell suspension was diluted to 
achieve a concentration of 100,000 CFU/ml. The cell culture was diluted 1:10 in MHB 
and 10 – 30 µl were cultured overnight on LB agar at 37° C to verify CFU/ml. Aliquots 
(50 µl) were added to wells of a 96-well microtiter plate (Falcon) in duplicate. Growth 
medium (50 µl) was transferred to each well, comprising of MHB supplemented with 
CTX and antisense inhibitory agents where appropriate. The plate was transferred to a 
Fluostar Optima (BMG Labtech) automated spectrophotometer, controlled at 37° C, and 
optical density readings taken over 18-24 hours. The culture turbidity, measured at 
O.D. 600 nm, was recorded over 250 cycles, with 15 flashes per well per cycle 
approximately every 5 minutes, the plate was rotated at 220 rpm for 6 seconds every 
cycle. Growth curves and statistical analyses were produced using Prism® 6 software 
(GraphPad). 
2.6.21.  Evaluation of the effects of β-lactamase expression inhibition by antisense 
agents in field and clinical isolates by growth curves produced by 
spectrophotometry 
Typically, strains were cultured from either a single colony from an overnight culture 
grown on LB agar supplemented with CTX (final concentration 2 µg/ml) at 37° C, or 
from glycerol bead stocks, in 10 ml MHB supplemented with CTX at 37° C with 
shaking at 200 rpm until optical density measured at a light wavelength of 600 nm 
reached 0.1 - 0.3. Calibration curves had previously been constructed for each strain to 
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establish a linear correlation between culture turbidity measured at O.D. 600 nm, and 
colony forming units in this range. The culture was diluted in fresh MHB to yield 
approximately 100,000 CFU/ml. The cell culture was diluted 1:10 in MHB and 10 – 
30 µl were cultured overnight on LB agar at 37° C to verify CFU/ml. Aliquots (50 µl) 
were added to wells of a 96-well plate (Falcon) in duplicate. Growth medium (50 µl) 
was transferred to each well, comprising of MHB supplemented with CTX and 
antisense agents where appropriate. The plate was transferred to a Fluostar Optima 
(BMG Labtech) automated spectrophotometer, controlled at 37° C, and optical density 
readings taken over 18 - 24 hours. Culture turbidity was measured at O.D. 600 nm over 
250 cycles, with 15 flashes per well per cycle followed by shaking (6 seconds; 220rpm) 
approximately every 5 minutes. Growth curves and statistical analyses were produced 
using Prism® 6 software (GraphPad). 
2.6.22.  Controls used in the evaluation of inhibition of β-lactamase activity 
inhibition by unmodified and peptide-conjugated PNA4/PMO1 
Specificity and any inherent toxicity of peptide-conjugated and unmodified PNA4 and 
PMO1 were demonstrated in the following studies.  A scrambled non-specific 25-mer 
PMO was incubated in the presence of pJBRCTX516 in a cell-free 
translation/transcription coupled system followed by the quantification of cefotaximase 
activity. AS19/pJBRCTX516 was cultured in the presence of the scrambled PMO in the 
presence and absence of CTX and growth measured by spectrophotometry over 18 – 24 
hours. Field isolates harbouring blaCTX-M-group 1 were cultured in the presence of 
P-PMO1 or P-PNA4 in the absence of CTX and growth measured by spectrophotometry 
over 18 – 24 hours. Field isolate LREC90 harbouring blaCTX-M-14 (non-complementary 
with anti-blaCTX-M-15 PNA4 and PMO1) was cultured in the presence and absence of 
P-PNA4, P-PMO1 and CTX, and growth measured by spectrophotometry over 
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18 - 24 hours. Minimum inhibitory concentrations (CTX) were established for LREC90 
in the presence and absence of P-PNA4.  
2.6.23.  Evaluation of bactericidal effects of P-PNA4 on E. coli field isolate 
LREC525 cultures  
Field isolate LREC525 harbouring blaCTX-M-15 was cultured from glycerol stocks in 
MHB (5 ml) supplemented with cefotaxime (final concentration 2 µg/ml), until 
early-mid log phase (O.D. 600 nm = 0.2 - 0.3). Four aliquots of 92 µl cell suspension were 
taken and made up to 100 µl with supplements or carrier medium to yield the following 
combinations: a) no P-PNA4 or CTX; b) CTX (48 µg/ml); c) P-PNA4 (3.2 µM); and d) 
P-PNA4 (3.2 µM) and CTX (48 µg/ml). The aliquots were incubated at 37° C with 
shaking (200 rpm) and 10 µl samples removed approximately every 10 minutes. The 
samples were diluted between 10,000 and 100,000 fold and 10 µl was spread onto LB 
agar plates and cultured overnight at 37° C. The next day, visible colonies were 
counted.  
2.6.24.  Quantification of CTX induced β-lactamase expression upregulation by 
colourimetric nitrocefin based assay 
AS19/pJBRCTX516 was cultured overnight at 37° C with shaking at 200 rpm from 
frozen glycerol/bead stocks in MHB supplemented with CTX (2 µg/ml) and KAN 
(40 µg/ml) until early log phase (O.D. 600 nm = 0.1) was reached. The culture was diluted 
1:500 and split into 5 equal (7.5 ml) aliquots. Each aliquot was cultured in the presence 
of CTX (final concentrations =  0, 2, 16, 32 and 64 µg/ml) and cultured at 37° C. 
Aliquots (2 ml) were removed at 60 minute intervals and the optical density at a 
wavelength of 600 nm was recorded. Bacterial cells were collected by centrifugation at 
13,000 rpm in a Heraeus™ Biofuge™ centrifuge (Thermo Fisher Scientific) and the 
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supernatant retained. In a 96-well microtiter plate (Falcon), aliquots of each supernatant 
(20 µl) were added to ddH2O and nitrocefin solution (20 µl x 1 mM) to yield a final 
volume of 100 µl and nitrocefin final concentration of 200 µM. Each culture was 
prepared in duplicate. The 96-well  plate was transferred to a Fluostar Optima (BMG 
Labtech) automated spectrophotometer, controlled at 37° C, and optical density 
readings taken over 60 minutes at O.D. 492 nm, with 15 flashes per well per cycle (250 
cycles in total), and rapid rotation (220 rpm) for 5 seconds every cycle, approximately 
every 30 seconds. 
2.6.25.  Quantification of cefotaxime induced β-lactamase activity upregulation in 
AS19/pJBRCTX516 by RP-HPLC 
E. coli strain AS19/pJBRCTX516 was cultured in MHB (100 ml) from frozen 
glycerol/bead stocks until early log phase (O.D. 600 nm = 0.1 - 0.2) was reached. The 
culture was diluted 1:500 in fresh MHB and split into 5 equal (20 ml) aliquots. Each 
aliquot was supplemented with CTX, or carrier medium, to achieve the following final 
concentrations: 0, 2, 16, 32 and 64 µg/ml and incubated at 37° C. At approximately 
1 hour intervals, culture growth was measured by spectrophotometry and aliquots (1 ml) 
were removed. The acidity of each aliquot was increased to pH 2.2 by the addition of 
1M HCl (85 µl) to halt enzymatic activity. The cells were then centrifuged at 10,000 g 
for 2 minutes and the supernatant collected. Supernatant (700 µl) was then incubated at 
37o C with 700 µl cefotaxime (800 µg/ml) with shaking at 200 rpm. Aliquots (125 µl) 
were removed at 10 - 20 minute time intervals and added to pre-prepared HPLC vials 
containing 125 µl phosphate buffer/ HCl, pH 2.2. The cefotaxime degradation, 
correlating with β-lactamase expression levels, was quantified by RP-HPLC.  
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2.6.26.  Quantification of ceftriaxone induced β-lactamase activity upregulation 
by RP-HPLC 
E. coli strains were cultured overnight in MHB (50 ml) from frozen glycerol/bead 
stocks until early log phase (O.D. 600 nm = 0.1 - 0.2) was reached. Aliquots (2 ml) were 
removed from the culture and incubated with increasing final concentrations of 
ceftriaxone (0 – 384 µg/ml) for 30 minutes at 37° C with shaking at 200 rpm. Cells were 
disrupted by bead milling in a Retsch Mixer MM301 shaking homogeniser (F. Kurt 
Retsch GmbH, Haan, Germany) at full speed for 5 minutes with 0.2 - 0.4 mm glass 
beads. The cells were then centrifuged at 10,000 g for 2 minutes and the supernatant 
collected. 700 µl supernatant was then incubated at 37o C with 700 µl cefotaxime 
(800 µg/ml) with shaking at 200 rpm. 125 µl aliquots were removed at 10 - 20 minute 
time intervals and added to pre-prepared HPLC vials containing 125 µl phosphate 
buffer/ HCl, pH2.2. The cefotaxime degradation, and hence β-lactamase activity, was 
quantified by HPLC.  
2.6.27.  Assembly of 3D DNA tetrahedron 
In a method adapted from Pei et al.[168], single stranded DNA oligonucleotides were 
mixed with either a 13-mer PNA or a 25-mer PMO antisense oligomer in equimolar 
amounts in a 20 mM Tris, 50 mM MgCl2, annealing buffer (pH 8.0). The mixture was 
heated to 95° C for 4 minutes and immediately transferred to ice for 30 minutes. 
Assembly of the tetrahedron was verified by gel electrophoresis. 
2.6.28.  Verification of assembly of DNA tetrahedral antisense oligomer delivery 
vehicle by gel electrophoresis 
Assembly of the tetrahedron was verified on a 2% w/v TBE gel, and 100V applied until 
sufficient separation was observed.  Individual DNA strands, and combinations of 
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strands:  strand A + B, strand A + B + C, strand A + B + C + D and strand A + B + C + 
D + PMO/PNA4, were visualised on a gel, and single discreet bands of increasing size 
were regarded as evidence of successful annealing and complete tetrahedron formation. 
2.6.29.  Statistical analysis 
All results are presented as standard deviations of the mean. Comparisons between 
treatment group growth means were performed using an unpaired two-tailed t-test by 
GraphPad Prism software version 6.01 (GraphPad Software, Inc.), not assuming equal 
standard deviations and using Welch’s correction, as used by Geller et al. [127]. All 
other statistical comparisons were made using a Wilcoxon signed-rank non-parametric 
test (GraphPad Software, Inc.). A p-value of less than 0.05 was taken to represent 
statistical significance. 
2.6.30.  Determination of synergistic relationship between inhibitory agents 
The fractional inhibitory concentration index (FICI) is commonly used to determine a 
synergistic, antagonistic or neutral interaction between inhibitory compounds. In the 
current study it was defined as: MIC of the combination of CTX and antisense 
oligomer/MIC of CTX alone + MIC of the combination of CTX and antisense 
oligomer/MIC of antisense oligomer alone: 
 
The FICI was interpreted as: less than or equal to 0.5: synergistic, between 0.5 and 1: no 
synergy (additive), greater than 1: antagonistic [169].  
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Chapter 3.   
Development of assays for the quantification of β-lactamase CTX-M activity 
3.1.  Introduction 
Methods for quantifying β-lactamase were required to assess the effect of 
antisense/antigene agents on β-lactamase activity in E. coli strains. The current study 
established two assays for this purpose: a colourimetric nitrocefin based assay, and an 
HPLC assay to quantify the degradation of cefotaxime. These assays both indirectly 
measured β-lactamase expression levels by determining enzyme activity based on the 
quantification of a β-lactamase substrate. Assays were validated to ensure the reaction 
was linear with time and enzyme concentration under saturating substrate 
concentrations. The substrates, nitrocefin and cefotaxime, used in the colourimetric and 
HPLC assays respectively, were both shown to have a practical relationship with 
β-lactamase levels and, as such, were suitable for its quantification. These assays 
enabled an evaluation of the efficacy of downstream β-lactamase inhibition studies. 
3.1.1.  Nitrocefin based colourimetric assay for β-lactamase activity 
quantification 
The chromogenic cephalosporin nitrocefin is a commonly and routinely used reporter 
substrate for β-lactamase activity. Nitrocefin undergoes a colour change reaction from 
yellow (λmax = 390 nm), to red (λmax = 480 nm) when hydrolysed by β-lactamase in a 
rapid reaction [170]. It is inexpensive and quantifiable, however it is hydrolysed by all 
four Ambler classes of β-lactamases and as such, not specific to any one β-lactamase – 
multiple β-lactamase enzyme variants affect the colour change reaction. For inhibition 
studies of β-lactamase produced by artificially constructed plasmids harbouring a single 
blaCTX-M-15 with no other β-lactamase-producing genes present, this was a suitable 
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substrate. Field isolates however, frequently harbour multiple β-lactamase variants, 
requiring an alternative β-lactamase detection assay specific for the enzyme in these 
situations. 
Typically, a 96-well plate format was used for the quantification of nitrocefin 
degradation measured by spectrophotometry at a wavelength of 492 nm, the endpoint of 
the colour-change reaction. In the first instance, the operational range of the 
colourimetric assay and the proportional relationship between β-lactamase quantity and 
nitrocefin reaction was ascertained using commercially available and purified 
β-lactamase, M02075 (Fluorochem, Derb, UK). M02075 was isolated and purified from 
Bacillus cereus. 
To establish the operational range of the assay, the minimum detection levels, saturating 
concentrations and reaction times, a range of concentrations of nitrocefin and a range of 
β-lactamase concentrations were incubated in the presence of nitrocefin and the reaction 
monitored by optical density measurement in an automated spectrophotometer at a 
wavelength of 492 nm. M02075 and supernatant extracts obtained from a panel of 
β-lactamase producing strains of E .coli were used to establish typical reaction rates and 
assay ranges. 
E. coli strains were typically cultured from frozen glycerol stocks until early log phase 
(O.D. 600 nm = 0.1 – 0.2) was reached. Cultures were split into equal aliquots and 
supplements or growth media added where required. The aliquots were cultured for pre-
determined times and cells were disrupted by bead milling. Supernatants were separated 
by centrifugation and samples added to wells in a 96-well plate pre-prepared with 
nitrocefin solution. Optical density measurements were taken at 492 nm approximately 
every 30 seconds over 30 – 60 minutes. 
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3.1.2.  Quantification of cefotaxime as a marker for β-lactamase activity by 
RP-HPLC 
Reverse-phase high-pressure liquid chromatography (RP-HPLC) was used to separate 
and detect cefotaxime from degradation products. These fractions were identified by 
their retention time, and quantified as they exited the column by UV-vis 
spectrophotometry. An assay was established for the specific quantification of 
cefotaxime, adapted from Nemutlu et al. [161], as the reporter substrate for blaCTX-M 
activity. This was found to be highly sensitive with CTX detection limits ranging from 
around 1 µg/ml to greater than 800 µg/ml, making this a suitable assay for the specific 
quantification of blaCTX-M activity. Typically strains were cultured from glycerol stocks 
until early log phase (O.D. 600 nm = 0.1- 0.2) was reached. The culture was diluted and 
supplements, or an equivalent volume of supplement carrier solvent for experimental 
control, added where required. The cultures were incubated for pre-determined amounts 
of time and aliquots were transferred to solid agar and cultured overnight to establish 
the number of colony-forming units present in each sample. Cells were disrupted by 
bead milling and cell debris separated by centrifugation. Supernatants were removed 
and aliquots were transferred to a cefotaxime solution (typically yielding a final 
concentration of 400 µg/ml) and incubated at 37 °C. Samples were removed at regular 
time intervals and transferred to HPLC vials containing phosphate buffer (pH 2.2). 
Cefotaxime in solution was quantified by RP-HPLC. A standard calibration curve was 
constructed using cefotaxime dilutions (typically 1 – 400 µg/ml) for each study. 
Analysis was performed with ChemStation software (Agilent Technologies) which 
generated a graphical visualisation of a single peak representing cefotaxime quantity 
(Figure 3-1).  Cefotaxime was quantified by the reported size of the area under the 
resolved curve, and calibrated with reference to a standard curve. 
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Figure 3-1. Sample chromatograms each showing a single resolved peak representing 
cefotaxime with a retention time of approximately 15 minutes.  
a) Cefotaxime concentration = 3.125 µg/ml, b) cefotaxime concentration = 25 µg/ml, c) 
cefotaxime concentration = 200 µg/ml. 
The optimum pH for β-lactamase activity has been shown to be in the range of 
pH 7.0 - 7.2 (Figure 3-2). Experimentation with methods of inactivating β-lactamase 
activity was undertaken in the current study including heat inactivation and the 
adjustment of the acidity/alkalinity of the incubation solution. The activity of 
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β-lactamase was completely inhibited in conditions of low pH (< 3) and high pH (> 10). 
To halt enzymatic reactions at specific time points for a determination of β-lactamase 
activity, solutions were treated with HCl (1 M) sufficient to yield an increase in acidity 
to pH 2.2.   
 
Figure 3-2. Operational pH range of β-lactamase [171]. 
3.2.  Results 
3.2.1.  Nitrocefin based colourimetric assay validation for β-lactamase 
quantification 
The nitrocefin 96-well plate assay was validated and the operational detection ranges 
established by two methods. Supernatant extracts were prepared as previously described 
and diluted 1 to 256-fold. Commercial β-lactamase M02075 (concentration: 5 units/ml) 
was also diluted 1 – 256-fold. 50 µl of each supernatant / M02075 dilution was added to 
200 µl nitrocefin solution (final concentration 190 µM) and the reaction monitored at 
O.D. 492 nm (Figure 3-3). Results showed a dose dependant response to enzyme 
concentration. 
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Figure 3-3. Nitrocefin reaction (final concentration 190 µM) with commercial 
β-lactamase M02075 and supernatant extract dilutions originating from E. coli strain 
LREC99 harbouring blaCTX-M-15. 
Filled circles (●) denote M02075, concentration: 20 = 5 units/ml, hollow circles (○) 
denote LREC99, concentration: 20 = supernatant used neat. 
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Supernatant dilutions were prepared, as previously described, from a panel of five 
E .coli strains (AS19/pJBRCTX499, 21/C0188/02/13, 12/B0118/10/11, NCTC10418 
and LREC99). Supernatant dilutions and commercial β-lactamase M02075 dilutions 
(100 µl) were each added to nitrocefin solution (final concentration 200 µM) in separate 
incubations (final volumes of 250 µl), and the reaction monitored by spectrophotometry 
over 2 hours at a wavelength of 492 nm (Figure 3-4; Figure 3-5; Figure 3-6). Results 
showed a dose dependant response to enzyme concentration.  
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Figure 3-4. Nitrocefin reaction with E. coli strains AS19/pJBRCTX499 and 
21/C0188/02/13 supernatant extract dilutions. 
Dilutions: Thick solid line: neat supernatant, thick dashed line: 1.33-fold dilution, thick 
dotted line: 1.6-fold dilution, thick dash-dot line: 2-fold dilution, thick dash-dot-dot 
line: 2.66-fold dilution, thin solid line: 4-fold dilution, thin dashed line: 8-fold dilution. 
a) Supernatant preparation dilutions originating from E. coli strain AS19/pJBRCTX499 
harbouring blaCTX-M-15, b) Supernatant preparation dilutions originating from E. coli 
strain 21/C0188/02/13 harbouring blaOXA-1. Error bars indicate ± 1 standard deviation 
(n=3). 
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Figure 3-5. Nitrocefin reaction with E. coli strains 12/B0118/10/11 and NCTC10418 
supernatant extract dilutions. 
Dilutions: thick solid line: neat supernatant, thick dashed line: 1.6-fold dilution, thick 
dotted line: 2-fold dilution, thick dash-dot line: 2.66-fold dilution, thick dash-dot-dot 
line: 4-fold dilution, thin solid line: 4-fold dilution. a) Supernatant preparation dilutions 
originating from E. coli strain 12/B0118/10/11 harbouring blaCTX-M-1, b) Supernatant 
preparation dilutions originating from E. coli strain NCTC10418 (negative control 
strain). Error bars indicate ± 1 standard deviation (n=2). 
Page 104 
 
Figure 3-6. Nitrocefin reaction with E. coli strain LREC99 supernatant extract dilutions 
and commercial β-lactamase dilutions. 
Dilutions: thick solid line: neat supernatant / commercial β-lactamase preparation, thick 
dashed line: 1.33-fold dilution, thick dotted line: 2-fold dilution, thick dash-dot line: 
4-fold dilution, thick dash-dot-dot line: 10-fold dilution, thin solid line: negative control 
(growth media only). a) Commercial β-lactamase M02075 (5 units/ml), b) Supernatant 
preparation dilutions originating from E. coli strain LREC99 harbouring blaCTX-M-15. 
Error bars indicate ± 1 standard deviation (n=2). 
Page 105 
3.3.  High-Pressure Liquid Chromatography 
3.3.1.  Validation of HPLC assay for cefotaxime quantification as a marker for 
β-lactamase activity 
The HPLC assay was validated by quantification of cefotaxime at concentrations 
ranging from 0.78 µg/ml to 2000 µg/ml (Figure 3-7). The cefotaxime standard curve 
data presented in Figure 3-7 were accumulated from separate experiments with each 
experiment consisting of two biological and two procedural replicates for each sample. 
 
Figure 3-7. Cefotaxime standard curves, quantified by HPLC. 
Standard curves were produced by the preparation of CTX dilutions (0.78 - 2000 µg/ml) 
and HPLC quantification. CTX quantity was determined by the area reported under the 
resolved peak, generated with ChemStation (Agilent Technologies) software. a) CTX 0 
– 10 µg/ml, b) CTX 0 – 50 µg/ml, c) CTX 0 – 200 µg/ml, d) CTX 0 – 2000 µg/ml. 
Error bars indicate ± 1 standard deviation (n=8). 
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3.3.2.  Validation of HPLC assay for specific cefotaximase activity 
To verify and validate the ability of the HPLC assay to discriminate cefotaximase 
activity from other β-lactamase activity, supernatant extracts (1.5 ml), prepared from 
five E. coli strains harbouring different β-lactamase variants, were incubated with CTX 
solution (1.5 ml; 800 µg/ml) and 120 µl aliquots removed at regular intervals between 0 
and 65 minutes. Total protein content was quantified (section 2.6.16.) to normalise the 
results. Results showed supernatant preparations from the two strains harbouring 
blaCTX-M variants degraded CTX. No significant degradation of CTX was observed in 
supernatant preparations from strains harbouring blaOXA-1, and blaTEM-1. Supernatant 
preparations from strain LREC115 harbouring blaAMP demonstrated a small but 
significant (P < 0.05) amount of CTX degradation (Figure 3-8). This was not 
unexpected as hyper AmpC β-lactamase producers can be confused for 
extended-spectrum β-lactamases due to over-expression conferring some reduced 
susceptibility to 3rd generation cephalosporins [66]. 
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Figure 3-8. Cefotaxime degradation by E. coli supernatants from five E. coli strains, and 
commercial β-lactamase M02075. 
Filled circles (●) – Blank (HPLC control – growth media only), filled squares (■) – 
negative control (NCTC10418), triangles (▲) – 21/C0188/02/13 (blaOXA-1), down-
pointing triangles (▼) – 12/B0118/10/11 (blaCTX-M-1), diamonds (♦) – LREC115 
(blaAMP), hollow circles (○) - 2013-6404 (blaTEM-1), hollow squares (□) – 
AS19/pJBRCTX499(blaCTX-M-15). Error bars indicate ± 1 standard deviation (n=2). 
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3.4.  Discussion 
Both the HPLC and the nitrocefin based assays developed were suitable for the 
detection and quantification of β-lactamase. Both assays quantified reporter substrates 
as markers for β-lactamase activity, nitrocefin and CTX, both were sensitive and 
reproducible. β-Lactamase activity was shown by experiments with the commercial 
purified β-lactamase M02075 to have a direct proportional relationship with 
β-lactamase quantity, validating the use of a reporter substrate to determine β-lactamase 
quantity present.  
The nitrocefin based assay was rapid and inexpensive, but the lack of ability to 
differentiate between β-lactamase variants made it useful only in a single gene 
environment. The HPLC assay was sensitive to the detection of cefotaxime from less 
than 1 µg/ml to greater than 800 µg/ml and was highly reproducible. The optimum 
range for accurate reproducible CTX quantification was observed to be 30 – 500 µg/ml, 
and the data show a consistently reproducible linear relationship between cefotaxime 
concentration and peak height / area under the curve in this range. Subsequent studies 
utilised concentrations within this range. The HPLC assay, quantifying the blaCTX-M 
substrate (CTX) was a specific and suitable assay for downstream studies evaluating the 
inhibitory ability of anti-blaCTX-M agents. Standards and quality assurance samples were 
run with every subsequent study.  
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Chapter 4.  Design and construction of expression plasmids carrying 
blaCTX-M-15 and the inhibition of β-lactamase expression by PNA/PMO 
oligomers in a cell free translation-transcription coupled system  
4.1.  Introduction 
4.1.1.  Design and construction of expression plasmids carrying blaCTX-M-15 as a 
suitable test subject for translational inhibition experiments in cell-free 
translation/transcription coupled systems and in whole cells 
β-lactamase resistance genes are most often carried on large (>100 kb) plasmids which 
commonly harbour multiple copies and different resistance genes, including different 
β-lactamase classes [74]. Initial proof-of-concept of the efficacy of PNAs and PMOs to 
inhibit the expression of β-lactamase was required without the inherent confounding 
factors associated with field and clinical isolates such as, for example cell 
impermeability, multiple β-lactamase genes, and the presence of functional efflux 
pumps. This necessitated the construction of a plasmid harbouring blaCTX-M-15 which 
could be used in a cell-free translation/transcription coupled system, and also 
subsequently used to transform a range of sensitive E. coli strains to yield a resistant 
phenotype with a controlled genotype. 
To construct a suitable plasmid, two representative field isolates harbouring blaCTX-M-15 
were selected, and PCR primers were designed to amplify blaCTX-M-15 and associated 
upstream regions, incorporating restriction enzyme recognition sites to facilitate 
directional cloning. ISEcp1 harbours at least one blaCTX-M-15 promoter [76, 81, 82]. To 
ensure all native regulatory elements were included in the recombinant plasmid and to 
ensure that a valid genetic environment was replicated for an evaluation of the 
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inhibitory potential of the antisense oligomers, blaCTX-M-15 and the associated upstream 
insertional element ISEcp1 was amplified by PCR.  
The amplified region, incorporating blaCTX-M-15 and upstream regions, were TA cloned 
into a commercial cloning vector. This was used to transform a chemically competent 
lab strain which was cultured and the recombinant plasmids extracted. The plasmids 
were digested with the restriction enzymes recognising the sites incorporated into the 
PCR primers. DNA fragments were separated and purified by agarose gel excision. A 
commercially available expression vector, pET-9a, was digested with the restriction 
enzymes used to release the blaCTX-M-15 fragment from the cloning vector, leaving 
compatible overhanging DNA ends, and ligated with the blaCTX-M-15 fragment.  
4.1.1.1.  β-lactamase expression and inhibition in a cell-free 
translation/transcription coupled system 
Commercially available translation/transcription coupled systems such as the 
Expressway™ Cell-Free E. coli Expression System (Invitrogen), containing all the 
E. coli cellular machinery required to express proteins in a single reaction, and utilise a 
T7 bacteriophage RNA polymerase. This system utilises an optimised E. coli extract 
[172], an optimised reaction buffer composing of an ATP regenerating system [173, 
174], amino acids, and viral T7 RNA polymerase [175]. Using this system, proteins can 
be expressed from linear or circular DNA. T7 RNA polymerase exhibits a high 
specificity and affinity for its own promoter sequences, which do not occur naturally in 
other E. coli genes [175]. Therefore, in these cell-free systems, a T7 promoter sequence 
is required to drive this specific gene/protein expression. Additionally, it is desirable to 
position a T7 terminator sequence downstream of the DNA sequence to be transcribed, 
resulting in only the gene(s) of interest being transcribed. 
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4.1.1.2.  Selection of a plasmid for the expression of blaCTX-M-15 in cell-free T7 
based systems and for the transformation of CTX sensitive E. coli strains 
The commercially available expression plasmid, pET-9a (Novagen) was selected as a 
suitable vector for the expression of blaCTX-M-15 in a cell-free system, and also for 
transformation of CTX sensitive strains for downstream experimentation using whole 
cells. pET-9a is a 4341bp plasmid harbouring the required T7 promoter and terminator 
sequences for T7 based cell-free systems flanking its multi-cloning site (Figure 4-1). 
For selection purposes, it also harbours a single kanamycin resistance gene, in the 
reverse orientation to the T7 promoter/terminator sequences to prevent unintended 
transcription. 
 
Figure 4-1. Expression Plasmid pET-9a.  
The kanamycin resistance gene is in the reverse orientation to the T7 system to 
minimise any unintended expression. 
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4.1.1.3.  Selection of blaCTX-M-15 genes for cloning 
It has been observed that blaCTX-M-15 is differentially expressed depending upon its 
genetic environment. Dhanji et al. (2011) ascribed these differential expression levels to 
differences in the number and positions of promoter sequences, and also the distance 
from the promoter sequence to the translational start region, affecting the amount of 
transcript available for translation [81]. Two donor plasmids from field isolates were 
selected on the basis of availability and previously published complete sequences as 
suitable examples of blaCTX-M-15  and its genetic environment: pEK499 is a large plasmid 
of 117,536 bp and harbours ten antibiotic resistance genes, including three β-lactamases 
– CTX-M-15, OXA-1 and TEM-1, pEK516 is a plasmid of 64,471bp, and harbours 
seven antibiotic resistance genes, including the β-lactamases CTX-M-15, OXA-1 and 
TEM-1 [74].   
4.1.2.  Inhibition of β-lactamase expression by antisense oligomers in a cell free 
translation-transcription coupled system 
For initial proof-of-concept studies, demonstrating the ability of synthetic antisense 
agents to inhibit the expression of blaCTX-M-15 with a minimum amount of potential 
confounding factors (such as cell wall penetration, efflux removal of antisense agents, 
and biological activity within a live cell), in the first instance antisense oligomers were 
evaluated in a cell-free translation / transcription coupled system. The Expressway™ 
Mini Cell-Free Expression System (Invitrogen) was used for all cell free inhibition 
experiments. This system contains all of the bacterial cellular machinery required to 
express functional proteins without any requirement for living cells. Circular or linear 
DNA can be used to express proteins in this system. For these initial experiments, the 
two previously constructed plasmids; pJBRCTX516 and pJBRCTX499 (Chapter 4) 
were used to express blaCTX-M-15, and to evaluate the protein expression inhibition 
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properties of anti-blaCTX-M PMO and PNA antisense agents. Both of these plasmids 
harboured identical blaCTX-M-15 genes, but differed in their surrounding genetic 
environment. pJBRCTX499 harboured the cloned region from pEK499 complete with 
the upstream insertional sequence IS26 and a truncated ISEcp1. Due to promoter 
positions, and reports from previous studies [76, 81], this genetic environment was 
expected to result in a higher level of β-lactamase expression than pJBRCTX516. 
pJBRCTX516 harboured the blaCTX-M-15 gene cloned from the resistance plasmid 
pEK516.  
4.1.2.1.  Design of antisense PMO and PNA oligomers targeting the translation 
initiation region of blaCTX-M-15 mRNA 
The length of antisense oligomers are hereafter defined by the number of their 
constituent nucleotide-like units – for example, a PMO comprising of 25 nucleotides is 
referred to as a 25-mer PMO. 
A 25-mer PMO (PMO1) was designed to target the translational start codon region and 
a series of three 13-mer PNAs were designed to target the Shine-Dalgarno (SD) 
ribosome binding site, with one PNA (PNA3) spanning both the SD and the start codon 
region (Figure 4-2.). Previous antisense/antigene studies have revealed these target areas 
to be optimal for translational inhibition efficacy [133].  
Initial PMO sequence designs for blaCTX-M covering both of these regions were revised 
under the advice of the manufacturer (Gene Tools LLC) due to a high probability of 
self-dimerisation and hairpin loop formation. The final PMO design had a low 
probability of these issues and BLAST searching revealed negligible homology with 
any other E. coli genes. As a result of the short length of PNA1, PNA3 and PNA4 (13 
bases each), combined with their extra-genic target regions, each PNA shared partial 
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sequence similarity (12/13 bases) with four off-target bacterial gene transcripts, and 
multiple mammalian transcripts. 
PNA4 was designed and synthesised after the initial testing of PMO1, PNA1 and PNA3 
had been completed in a cell-free environment. It was expected that PNA4, targeting a 
region shifted 1 base upstream and encompassing the SD region (Figure 4-2), would not 
have significantly greater or lesser inhibitory properties than PNA1. The slightly altered 
design of PNA1 to create PNA4 allowed for potential downstream inhibition studies 
combining PMO1 with PNA4 with no overlapping areas, and allowed for a greater 
target region (38 bases) to be covered by antisense agents if desired. This design could 
also potentially reveal any unknown synergistic effects of utilising PMO and PNA 
chemistries combined. 
 
Figure 4-2. PMO and PNA antisense oligomer design. 
Three 13-mer PNA and one 25-mer PMO were designed to base-pair and bind to the 
region of blaCTX-M messenger RNA and prevent translation by steric hindrance of the 
ribosome. All antisense agents targeted the Shine-Dalgarno (SD) region, the start codon, 
or both. 
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4.2.  Results 
4.2.1.  Design and construction of expression plasmids carrying blaCTX-M-15 as a 
suitable test subject for translational inhibition experiments in cell-free 
translation/transcription coupled systems and in whole cells 
4.2.1.1.  Amplification of blaCTX-M-15 from field isolates 
Primers were designed to amplify blaCTX-M-15 and the upstream region incorporating 
promoters, insertional elements IS26 and ISEcp1 [74], and incorporating restriction 
enzyme recognition sites to facilitate directional cloning into expression vector pET-9a. 
blaCTX-M-15 and associated upstream regions were amplified by colony PCR under 
typical conditions (section 2.6.9.) from two field isolates, LREC454 and LREC460, 
harbouring respectively pEK499 and pEK516,  using CTX-M-pEK499-forward and 
-reverse primers for LREC454 and CTX-M-pEK516-forward and -reverse primers for 
LREC460 (Figure 4-3; Table 2-5). PCR products were visualised by gel electrophoresis 
for an estimation of size and DNA concentration (Figure 4-4).   
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Figure 4-3. Diagram showing the genetic environment surrounding blaCTX-M-15 in two 
donor plasmids, pEK499 and pEK516 [81].  
Relative PCR primer positions for the amplification of each region are shown in the 
indicated positions. 
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Figure 4-4. Amplification of blaCTX-M-15 region by colony PCR from field isolates, 
visualised by agarose gel electrophoresis and ethidium bromide or SYBR® Safe 
(Invitrogen) staining.  
a) 1; Promega 1 kb DNA Ladder. 2; 2526 bp PCR product amplified from pEK516 in 
E. coli strain LREC460.  b) 1; Promega 1 kb DNA Ladder. 2; 2113 bp PCR product 
amplified from from pEK499 in E. coli strain LREC454.   
4.2.1.2.  Non-directional TA cloning of PCR products into pCR™2.1-TOPO® 
cloning vector 
Taq polymerase, used in the PCR to amplify blaCTX-M-15, adds a single deoxyadenosine 
to both the 3’ ends of the PCR products. This allows quick and efficient incorporation 
of PCR products into commercially available cloning vectors. Amplicons were ligated 
with the linearised plasmid pCR™2.1-TOPO® (Invitrogen; Figure 4-5; 
section 2.6.12.2.) using the Quick Ligation™ Kit (NEB) under the manufacturers 
recommended conditions.  
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Figure 4-5. pCR™2.1-TOPO® (Invitrogen) cloning vector [176].  
Commercially available cloning vector, supplied pre-linearised with single overhanging 
thymine to each 5’ end for TA cloning. 
The ligation reaction was used to transform chemically competent E. coli One Shot® 
INVαF’ (Invitrogen) following the One Shot™ transformation protocol (Invitrogen). 
The transformation reaction was cultured overnight at 17° C on solid LB supplemented 
for selection of successful transformants with kanamycin (40 µg/ml) and with X-Gal for 
blue-white screening (section 2.6.12.3.). White colonies were selected and cultured in 
liquid LB. Plasmids were extracted and purified from E. coli strains using the 
peqGOLD Plasmid Miniprep Kit (Peqlab, section 2.6.4.).The plasmids were screened 
for successful PCR amplicon incorporation by a PCR reaction using M13 forward and 
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reverse primers (Table 2-6), and by a PCR reaction using M13 forward primers and the 
reverse primer to used amplify blaCTX-M-15 from field isolates (Table 2-5; Table 2-6). 
M13 sequences in pCR™2.1-TOPO® (Invitrogen; Figure 4-5) flank the insertion site of 
the vector, and thus a PCR reaction utilising primers complementary to these sequences 
amplify any sequence between these regions. A PCR reaction using one primer 
complementary to a sequence on the plasmid backbone and one complementary to a 
sequence on the insert will yield a product if the insert is present and none if it is absent. 
Figure 4-6 shows the result of PCR reaction to verify the incorporation of DNA 
fragment amplified from pEK499, fragments separated and visualised by agarose gel 
electrophoresis. 
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Figure 4-6. Agarose gel showing the results of PCR reactions to screen for the presence 
and size of DNA fragments amplified from pEK499 incorporated into 
pCR™2.1-TOPO® (Invitrogen).  
All lanes were taken from the same gel, for clarity only the relevant lanes are shown. 
Lane 1: Promega 1 kb DNA Ladder, sizes of fragments shown adjacent (bp). Lane 2: 
PCR products amplified from plasmid preparation 1 with M13-forward and –reverse 
primers (Table 2-6). Lane 3: PCR products amplified from plasmid preparation 2 with 
M13-forward and –reverse primers. Lane 4: PCR products amplified from plasmid 
preparation 1 with M13-forward primer and CTX-M-pEK499-reverse (Table 2-5; Table 
2-6). Lane 5: PCR products amplified from plasmid preparation 2 with M13-forward 
primer and CTX-M-pEK499-reverse.  
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Purified recombinant pCR™2.1-TOPO®/blaCTX-M-15 plasmids were digested with 
restriction endonucleases BamHI and NdeI for the recombinant plasmid harbouring the 
amplified region from LREC454, and BamHI and XbaI for the recombinant plasmid 
harbouring the amplified region from LREC460 (section 2.6.12.5.2.6.12.5. ). The 
digested fragments were separated by gel electrophoresis, and the blaCTX-M-15 fragment 
was excised and purified with the peqGOLD Gel Extraction Kit (Peqlab, section 
2.6.12.6.).  
Plasmid pET-9a was digested with BamHI and NdeI to leave compatible overhanging 
ends with the fragment originating in LREC454, and BamHI and XbaI to leave 
compatible overhanging ends with the fragment originating in LREC460. blaCTX-M-15 
fragments were ligated with pET-9a under typical conditions (section 2.6.12.8.), which 
was then used to transform chemically competent E. coli DH5α-T1® (Invitrogen). The 
transformants were recovered onto LB agar supplemented with cefotaxime (1 µg/ml) 
and kanamycin (40 µg/ml) overnight at 37° C. Colonies observed on cefotaxime 
(1 µg/ml) and kanamycin (40 µg/ml) selection plates (Figure 4-7) were sampled, 
cultured, and recombinant plasmids extracted.  
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Figure 4-7. Resultant colonies from transformation of DH5α with pET-9A/CTX-M-15 
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The purified plasmids were screened for successful incorporation of the desired insert 
by restriction enzyme digestion and visualisation of fragment sizes by gel 
electrophoresis (Figure 4-8; Figure 4-9); and by sequencing (APHA sequencing dept) 
using the dideoxy chain termination/cycle sequencing method using CTX-M-SEQ 
primers (Table 2-6).  
 
Figure 4-8. Gel showing screening restriction enzyme digestion of 
pET-9A/CTX-M15-499.  
i): Lane 1: Promega 1 kb DNA Ladder, sizes of fragments shown adjacent. Lanes 2-6: 
plasmid miniprep. Lane 7): Promega 1 kb DNA Ladder. Lanes 8-12:  Plasmid miniprep 
digested with BamHI and XbaI. 
ii): Lane 14): Promega 1 kb DNA Ladder, sizes of fragments shown adjacent (bp). 
Lanes 15-19: Plasmid miniprep digested with XbaI. Lane20: Promega 1 kb DNA 
Ladder. Lanes 21-25: Plasmid miniprep. 
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Figure 4-9. Gel showing screening restriction enzyme digestion of 
pET-9A/CTX-M15-516. 
Restriction enzyme digestion screen for successful incorporation of blaCTX-M-15 region 
into expression vector pET-9a. Lane 1: plasmid linearised with single XbaI disgestion. 
Lane 2: plasmid digested with XbaI and BamHI, cleaving either side of insert to release 
2 fragments. Lane 3: Promega 1 kb DNA Ladder, sizes of fragments shown adjacent 
(bp). 
The insert originating from E. coli strain LREC460, harbouring pEK516, was found to 
have been ligated with pET-9a in the correct orientation and position. Sequencing 
revealed no unexpected mutations. This recombinant plasmid was designated 
pJBRCTX516. The insert originating from E. coli strain LREC454, harbouring 
pEK499, was found to have been ligated with pET-9a in the correct orientation and 
position. However, sequencing revealed 2 point mutations, possibly due to the use of 
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non-proof-reading Taq DNA polymerase, which has a higher mis-incorporation rate 
compared with other polymerases [177]. The two mutations were both single base 
substitutions: one in an extragenic non-coding region 138 bp downstream of the 
insertional element IS26; and one intragenic mutation at blaCTX-M-15 locus +822. The 
intragenic mutation was an adenine to guanine substitution and would result in a 
translated amino acid change of serine to glycine in the expressed enzyme. This 
mutation could have potentially altered the conformation and function of the enzyme 
and so it was deemed necessary to restore this to its original sequence.  This was 
corrected with site-directed mutagenesis. 
4.2.1.3.  Site-Directed Mutagenesis 
Site-directed mutagenesis (SDM) is PCR based technique by which mutations can be 
introduced or corrected in plasmids. The commercially available GENEART® 
Site-Directed Mutagenesis System (Invitrogen) was used to correct the intragenic point 
mutation. Two overlapping primers, SDM-forward and –reverse (Table 2-7; Figure 
4-10) were designed which were, in accordance with the manufacturer's (Invitrogen) 
recommendations, 31 nucleotides in length with the corrected mutation located 
centrally, 100% complementary with no overhangs and with the desired mutation 
located centrally (Figure 4-10). The SDM reaction proceeded under manufacturer’s 
(Invitrogen) recommended conditions (section 2.6.12.10.). 
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4.2.1.4.  SDM Primer Design 
pJBRCTX499  5’ ...atacatcgcgacggcgttctgccttaggttg...  3’ 
Primer-R      3’    tatgtagcgctgccgAaagacggaatccaac      5’ 
Primer-F       5’    atacatcgcgacggcTttctgccttaggttg      3’ 
pJBRCTX499  3’ ...tatgtagcgctgccgcaagacggaatccaac...  5’ 
Figure 4-10. SDM Primer Design.  
Point mutation in the recombinant plasmid shown in bold lowercase, corrected in the 
mutagenic primers shown in bold uppercase. 
4.2.1.5.  Screening for successful mutation 
Screening for the correction of a single point mutation by restriction enzyme digestion 
relies on the point mutation being located with a recognition site. Restriction enzyme 
digestion and visualisation by gel electrophoresis is then able to reveal the presence or 
absence of a corrected mutation. One restriction enzyme, CviKI-1 (NEB), was found to 
cleave the DNA if a successful mutation correction had occurred, and not recognise, and 
therefore not cleave, if the original mutation had not been corrected. CviKI-1 recognises 
a 4 base-pair sequence, RGCY (R=A or G, Y=C or T) and cuts between G and C. This 
enzyme, being a frequent (4-base recognition site) cutter, recognised many sites in the 
surrounding area - the longest section between recognition sites flanking the mutation 
site was 164 bp. Plasmids were extracted, purified and the 164 bp area surrounding the 
site at the point mutation was amplified by PCR using primers SDM-SCREEN-forward 
and -reverse (Table 2-7). This amplicon was digested with CviKI-1 under 
manufacturer’s recommended condition (NEB). A successful mutation, when visualised 
with gel electrophoresis, would yield two bands of 65 bp and 99 bp, whereas an 
unsuccessful mutation would generate a single band of 164 bp. To visualise bands of 
such diminutive size, samples were run on 3% high resolution agarose in TBE. Under 
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these conditions, however, it was not possible to resolve such small fragments, and so 
colonies were selected at random and sequenced. Sequencing data revealed 
approximately 50% of the colonies selected carried a plasmid with a successfully 
corrected mutation. E. coli strain DH5α-T1® (Invitrogen) harbouring this corrected 
plasmid, designated pJBRCTX499, were cultured and stored for use in subsequent 
studies. 
4.2.2.  Inhibition of β-lactamase expression by PNA and PMO antisense agents 
in a cell free translation-transcription coupled system 
Initial experiments were undertaken to evaluate the relative expression levels of the 
previously constructed plasmids, pJBRCTX499 and pJBRCTX516 in the Expressway™ 
Mini Cell-Free Expression System (Invitrogen), and the inhibitory properties of PNA1, 
PNA3, PNA4 and PMO1. The four antisense agents were evaluated for inhibition 
efficacy using each of the constructed plasmids pJBRCTX516 and pJBRCTX499 as the 
DNA template in a cell-free translation/transcription coupled system. Plasmids 
pJBRCTX499 and pJBRCTX516 were incubated in the cell-free system in the presence 
and absence of a range of antisense agent concentrations (50 – 1000 nM), and the 
reaction proceeded for the manufacturer’s recommended amount of time (3 – 4 hours). 
After the allotted incubation period, β-lactamase activity was quantified by HPLC - 
each reaction was incubated in the presence of cefotaxime (400 - 800 µg/ml final 
concentration) and aliquots removed at regular time intervals. The CTX concentration 
was quantified by HPLC and the β-lactamase quantity and, thus, inhibition efficacy was 
determined by the amount of observed cefotaxime hydrolysis. 
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4.2.2.1.  Evaluation of the reduction of blaCTX-M-15 expression by PNA1 and 
PMO1 in a cell-free system using pJBRCTX499 as DNA template 
Plasmid pJBRCTX499 (271 ng, as determined by spectrophotometry) was incubated in 
the cell-free expression system in the presence of PMO1 (500 nM), PNA1 (500 nM) or 
an equivalent volume of ddH2O (control) and the reaction allowed to proceed for 3 
hours. An aliquot of each reaction (70 µl) was taken from each reaction and added to 
cefotaxime solution (1.5 ml; 800 µg/ml) and incubated at 37° C. At regular time 
intervals, aliquots (120 µl) were removed and added to pre-prepared HPLC vials 
containing phosphate buffer (120 µl; pH 2.2). CTX hydrolysis that had occurred at each 
time point was quantified by HPLC (Figure 4-11). Cell-free reactions in the presence of 
PMO1 and PNA1 both resulted in a lower rate of CTX degradation than the reaction 
that occurred in the absence of antisense agents. There was no significant difference 
(p = 0.803) in the rate of CTX degradation observed in the reactions occurring in the 
presence of PMO1 and PNA1. In relation to the cell-free reaction in the absence of 
antisense agents, the presence of PMO1 (500 nM) was observed to have inhibited CTX 
degradation by 82% and PNA1 (500 nM) by 81%. 
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Figure 4-11. β-Lactamase activity after expression in a cell-free system using 
pJBRCTX499 as DNA template in the presence of PNA1 (500 nM) and PMO1 
(500 nM). 
271 ng plasmid (pJBRCTX499) was used in each 3 hour reaction. Filled squares (): 
control reaction (no antisense agent), hollow squares (): reaction in the presence of 
PMO1 (500 nM), filled circles (): reaction in the presence of PNA1 (500 nM), 
inverted filled triangles (): HPLC control (CTX solution and the equivalent volume of 
cell-free reaction growth media in the absence of plasmid DNA template). Error bars 
indicate +/- 1 standard deviation (n=2).  
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4.2.2.2.  Reduction of β-lactamase activity by inhibition of blaCTX-M-15 expression 
by PNA1, PNA3 and PMO1 in a cell-free system using pJBRCTX516 as DNA 
template 
Plasmid pJBRCTX516 (285 ng, as determined by spectrophotometry) was incubated in 
the cell-free expression system in the presence of PMO1 (500 – 1000 nM), PNA1 
(500 – 1000 nM), PNA3 (500 – 1000 nM) or an equivalent volume of ddH2O (control) 
and the reaction and subsequent HPLC quantification of remaining cefotaxime 
proceeded as previously described (section 4.2.2.1.). 
Cell-free reactions in the presence of PMO1, PNA1 and PNA3 resulted in a lower rate 
of CTX degradation than the reaction that occurred in the absence of antisense agents 
and a dose-dependent effect was observed. There was no significant difference 
(p > 0.05) in the rate of CTX degradation observed in the reactions occurring in the 
presence of PMO1 and PNA1 at concentrations of either 500 nM or 1000 nM. A dose 
dependent response was observed in the rate of CTX degradation in the cell-free 
reaction inhibited by PNA3. However, the rate of β-lactamase activity inhibition was 
consistently lower than that observed in reactions incubated in the presence of either 
PMO1 or PNA1 (Figure 4-12), although not significantly different (p > 0.05) when 
compared with both PNA1 and PMO1 at concentrations of 500 nM and 1000 nM). 
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Figure 4-12. β-Lactamase activity after expression in a cell-free system using 
pJBRCTX516 as DNA template in the presence of PMO1, PNA1 and PNA3. 
285 ng plasmid (pJBRCTX499) was used in each 3 hour reaction. a) Squares (): 
control reaction (antisense agent absent), dash-dot line, triangle ():PMO1 (500 nM), 
dotted line, circles (): PNA1 (500 nM), dashed line, diamonds (): PNA3 (500 nM). 
b) : squares (): control reaction (no antisense agent), dash-dot line, triangle (): 
PMO1 (1000 nM), dotted line, circles (): PNA1 (1000 nM), dashed line, diamonds 
(): PNA3 (1000 nM). Error bars indicate +/- 1 standard deviation (n=2). 
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The amount of β-lactamase expression inhibition, quantified by cefotaxime degradation, 
relative to the reaction incubated in the absence of any antisense agent (uninhibited 
reaction = 100%), is presented in Figure 4-13. 
 
Figure 4-13. Observed inhibition of β-lactamase activity in a cell-free 
translation/transcription coupled system with PMO1, PNA1 and PNA3. 
Rates of CTX hydrolysis were derived from the linear section of each curve (Figure 
4-12) and inhibition amount calculated in comparison with the rate of hydrolysis of the 
uninhibited reaction (in the absence of antisense agents). 
4.2.2.3.  Reduction of β-lactamase activity by inhibition of blaCTX-M-15 expression 
by PNA4 and PMO1 in a cell-free system using pJBRCTX516 as DNA template. 
PMO1 and PNA4 were evaluated using pJBRCTX516 as the DNA template, for anti-
blaCTX-M-15 activity in a cell-free translation/transcription coupled system. A range of 
concentrations of each antisense agent (50 – 1000 nM) was added to each reaction (with 
final reaction volumes normalised with carrier medium). Each reaction consisted of an 
equal quantity of purified plasmid pJBRCTX516 (485 ng total quantity, quantified by 
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spectrophotometry), and was incubated at 30° C for 4 hours. After the protein 
expression reaction incubation had proceeded for 4 hours, 70 µl aliquots were taken and 
added to 1.2 ml cefotaxime solutions (800 µg/ml) and incubated at 37° C. At regular 
time intervals, aliquots (120 µl) were removed and added to prepared HPLC vials 
containing phosphate buffer (pH 2.2). The CTX remaining in solution was then 
quantified by HPLC and the β-lactamase activity in each incubation determined by the 
amount of observed CTX degradation.  
The amount of activity, quantified by HPLC analysis of cefotaxime degradation, is 
presented in Figure 4-14a (in the presence and absence of PMO1) and Figure 4-15a (in 
the presence and absence of PNA4). Figure 4-14b (PMO1) and Figure 4-15b (PNA4) 
represent β-lactamase activity inhibition in relation to uninhibited reactions. 
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Figure 4-14. Observed β-lactamase activity resulting from expression in a cell-free 
translation/transcription coupled system in the presence of PMO1 using pJBRCTX516 
as template DNA.  
485 ng plasmid (pJBRCTX516) was used in each 4 hour reaction. a) Squares (): 
control reaction (no antisense agent), circles (): PMO1 (50 nM), triangles (): PMO1 
(100 nM), inverted triangles (): PMO1 (250 nM), diamonds (): PMO1 (500 nM), 
crosses (): PMO1 (1000 nM). Error bars indicate +/- 1 standard deviation (n=4). b) 
Representation of data as percentage inhibition calculated as a comparison with 
maximum rate of uninhibited reaction (no antisense agent). 
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Figure 4-15. Observed β-lactamase activity resulting from expression in a cell-free 
translation/transcription coupled system in the presence of PNA4 using pJBRCTX516 
as template DNA. 
485 ng plasmid (pJBRCTX516) was used in each 4 hour reaction. a) Squares (): 
control reaction (no antisense agent), circles (): PNA4 (50 nM), triangles (): PNA4 
(100 nM), inverted triangles (): PNA4 (250 nM), diamonds (): PNA4 (500 nM), 
crosses (): PNA4 (1000 nM). Error bars indicate +/- 1 standard deviation (n=4). b) 
Representation of data as percentage inhibition calculated as a comparison with 
maximum rate of uninhibited reaction (no antisense agent). 
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4.3.  Discussion 
4.3.1.  Design and construction of expression plasmids carrying blaCTX-M-15 
Two plasmids were constructed, pJBRCTX499 (Figure 4-16), and pJBRCTX516 
(Figure 4-17). The plasmids both harboured a single blaCTX-M-15 sequence, cloned from 
two different field isolates, LREC454 and LREC460 respectively. They differed only in 
the upstream regions which contain associated insertional elements and blaCTX-M-15 
promoters. These plasmid were both suitable for blaCTX-M-15 expression in a cell-free 
translation/transcription coupled system as the cloned region was flanked by T7 
promoter and terminator sequences, and also for blaCTX-M-15  expression in transformed 
strains as they included the naturally occurring promoter and putative regulatory 
sequences from their original host strains. 
 
Figure 4-16. Recombinant plasmid pJBRCTX499. 
Showing the incorporation of amplified section from resistance plasmid pEK499 into 
expression vector pET-9a. 
Page 137 
  
 
Figure 4-17. Recombinant plasmid pJBRCTX516. 
Showing the incorporation of amplified section from resistance plasmid pEK516 into 
expression vector pET-9a. 
4.3.2.  Inhibition of β-lactamase expression by antisense oligomers in a cell free 
translation-transcription coupled system 
The results demonstrated the ability of PMO and PNA antisense agents to inhibit the 
expression of β-lactamase in a cell-free environment. A high level of inhibition was 
observed with PMO1 (observed inhibition of 100% at 1000 nM using pJBRCTX516 as 
the DNA template), PNA1 (96% at 1000nM using pJBRCTX516 as the DNA template) 
and PNA4 (89% at 1000 nM using pJBRCTX516 as the DNA template). PNA3, which 
was designed to be complementary to the region spanning both the Shine-Dalgarno 
region and the translational start region, was unexpectedly the least effective inhibition 
agent. As both of these regions had previously shown to be the most effective areas to 
target for antisense inhibition, a PNA that spanned both of these regions had been 
hypothesised to be the most likely to yield the greatest effect.  
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Another notable observation from cell-free inhibition studies was the amount of 
difference in inhibition efficacy that a relatively minor change in the target region made. 
The maximum observed inhibition of PNA3, the same length as PNA1, shifted six bases 
upstream was 84% at a concentration of 1000 nM, PNA1 achieved 96% in directly 
comparable experiments conducted under the same conditions with the same protein 
expression reagents, at the same time. This would suggest that there would be scope to 
increase inhibition effectiveness by target region and antisense oligomer size 
optimisation. Time and financial constraints, however, did not allow for a larger range 
of PNA/PMO sizes and target regions to be evaluated.  
 
Table 4-1 summarises the observed inhibition efficiencies in anti-blaCTX-M-15 antisense 
agents (500 nM) used in cell-free studies in plasmids pJBRCTX499 and pJBRCTX516.   
 
Table 4-1. Summary of observed reduction of β-lactamase activity by inhibition of 
blaCTX-M-15 by all antisense agents (500 nM) in a cell-free translation/transcription 
coupled system. 
 Maximum observed β-lactamase inhibition (%) 
Antisense Agent 
(500 nM) pJBRCTX499 pJBRCTX516 
PMO1 81.85 97.1 
PNA1 81.39 91.3 
PNA3 Not tested 75.9 
PNA4 Not tested 82.4 
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PNA4 was a slight variation on PNA1, differing in only 1 base of the target region, and 
designed with the potential for complementary studies with PMO1 - the combination of 
PNA4 and PMO1 with no overlapping areas would span a 38 base target region, and 
would also provide the option for PMO/PNA synergy studies. 
For subsequent studies in whole cells, a PMO and a PNA were selected as 
representatives of the two different chemistries. PMO1 and PNA4 were selected as the 
antisense agents of interest for the greatest potential of inhibitory activity in whole cells 
- PMO1 had demonstrated the greatest amount of β-lactamase activity inhibition in a 
cell-free system, and PNA4, with a difference of a single base shift in target region from 
PNA1, had the potential to be used alone or in combination with PMO1 to span a 38-nt 
target region. 
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Chapter 5.   
Effects of antisense oligomers on sensitivity to cefotaxime in E. coli strains 
with reduced susceptibility to CTX 
5.1.  Introduction 
Anti-blaCTX-M synthetic antisense PNA/PMOs were previously found in the current 
study to be effective in reducing CTX degradation after expressing blaCTX-M-15 in the 
presence and absence of antisense oligomers in a cell-free translation/transcription 
coupled system. This effectively demonstrated inhibition of blaCTX-M activity, and hence 
a reduction in the expression levels of β-lactamase by the presence of antisense agents. 
The template DNA used in the initial cell-free studies was the plasmid constructed in 
this study, pJBRCTX516, which carried a single copy of blaCTX-M-15 cloned from field 
isolate LREC460. 
To evaluate efficacy of inhibition of protein expression by synthetic antisense agents in 
live E. coli cultures, a growth assay was established. Increases in biomass, and hence 
culture growth, was quantified by optical density measurement by spectrophotometry at 
a light wavelength of 600 nm. The assay revealed that, in all strains, the presence of 
CTX at sub-inhibitory concentrations caused a lengthening of the time taken to achieve 
logarithmic growth phase of the culture’s growth cycle. The length of the increase time 
taken to reach log phase was related to the concentration of CTX (Figure 5-4), and was 
strain-variable. Under these conditions the terminal biomass level when stationery phase 
was reached, on occasion showed a decrease when inoculated with increasing 
concentrations of CTX and/or antisense agents. The observation of differences in 
terminal culture turbidity, measured at O.D. 600 nm, was not reliably reproducible and 
typically did not correlate well with media supplement dose. The diagnostic criteria for 
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establishing the growth inhibitory effects of CTX exposure on E. coli growth, observed 
in all experiments, was therefore determined to be the extension of the time taken to 
achieve logarithmic growth phase of the culture. 
As previously discussed, the bacterial cell wall has been well established to be a 
significant obstacle to gene expression inhibition by synthetic antisense agents [119]. 
To enable a preliminary evaluation of the efficacy of PNA/PMOs in live cultures, 
atypically permeable E. coli strain AS19 transformed with pJBRCTX516 cultures were 
treated with combinations of CTX and PNA4/PMO1, and CTX sensitivity due to the 
presence of antisense agents was evaluated by growth curve assays. A range of field and 
clinical isolates known to express blaCTX-M- group 1 were selected and the efficacy of 
PNA4 and PMO1 were evaluated by co-administering with CTX/PNA/PMO 
combinations. To achieve efficient cell penetration, cell-penetrating peptide (KFF)3K 
was covalently bound to PNA4 and PMO1 to form peptide conjugated PMO1 
(P-PMO1) and PNA4 (P-PNA4). The effects of P-PMO1 and P-PNA4 on field and 
clinical isolates were evaluated by the co-administration of peptide-conjugated antisense 
agents and CTX, and cell culture growth was measured by spectrophotometry. 
Stein and Krieg highlighted several problems in demonstrating efficacy of antisense 
agents relating to non-specific effects of antisense agents, and suggested a minimum 
requirement of the use of two control oligomers in addition to the antisense oligomer, as 
well as noting the importance of demonstrating a decrease of the target protein [178]. 
The current study attempting the inhibition of the non-essential β-lactamase enzyme 
was able to investigate the effects of anti-blaCTX-M agents tested in the absence of CTX 
as a highly suitable control.  
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A range of field and clinical isolates expressing CTX-M-group 1 β-lactamases were 
selected for PNA/PMO inhibition studies (Table 5-1). 
Table 5-1. CTX-M Group 1-expressing field and clinical isolates used in studies. 
Designation Plasmid bla Resistance Source Species 
LREC460 pEK516 [74] CTX-M-15 Human 
LREC461 pEK204 [74] CTX-M-3  Human 
LREC454 pEK499 [74] CTX-M-15  Human pandemic strain 
LREC525[164] Not known CTX-M-15 Turkey 
BZ693/P [164] Not known CTX-M-3/33 Chicken 
B3804 [165] Not known CTX-M-1 Pig 
LREC90 Not known CTX-M-14 Cattle 
 
The region surrounding the Shine-Dalgarno and translational initiation region are highly 
conserved in group 1 CTX-M β-lactamases. PNA4 was designed to be 100% 
complementary with blaCTX-M-15 , blaCTX-M-3/33 and blaCTX-M-1 transcripts, and PMO1 was 
designed to be 100% complementary with blaCTX-M-15 and blaCTX-M-3/33, and 96% (24 out 
of 25 bases) complementary with blaCTX-M-1 transcript (Figure 5-1). 
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Figure 5-1. Alignment of blaCTX-M-15, blaCTX-M-3/33 and blaCTX-M-1 transcript sequences. 
Shine-Dalgarno (SD) region is shown in bold lowercase and translational start codon is 
shown in bold uppercase. Translated region of mRNA is shown in upper case. Asterisks 
indicate regions of shared homology between CTX-M types. 
5.1.1.  Experimental controls used for the evaluation of sequence specificity of 
antisense effects in field isolates 
Specificity and any inherent toxicity of peptide-conjugated and unmodified PNA4 and 
PMO1 were demonstrated in whole cells in the following studies:   
i. AS19/pJBRCTX516 was cultured in the presence of a scrambled non-specific PMO 
in the presence and absence of CTX and growth measured by spectrophotometry 
over 18 – 24 hours.  
ii. Field isolates harbouring blaCTX-M-group 1 were cultured in the presence of P-PMO1 or 
P-PNA4 in the absence of CTX and growth measured by spectrophotometry over 
18 - 24 hours. The targeting of non-essential blaCTX-M allowed the use of P-PMO1 
and P-PNA4 in the absence of CTX as a highly suitable control for isolating the 
effects of the antisense agents and/or cell-penetrating peptide on growth. 
Additionally, studies typically included a set of control replicates of the antisense 
agent in the absence of CTX. 
A field isolate, LREC90, was selected for control studies to isolate non-specific effects 
of P-PMO1 and P-PNA4. LREC90 carried a plasmid harbouring blaCTX-M-14, which 
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encoded β-lactamase from CTX-M-group 9. All other CTX resistant strains used in this 
study harboured variants from CTX-M-group 1. P-PMO1 and P-PNA4 were 
non-complementary to blaCTX-M-14 mRNA - PNA4 shared 15.4% sequence 
complementarity (2 out of 13 bases) over the target region and PMO1 shared 56% (14 
out of 25 bases) sequence complementarity over the target region (Figure 5-2) making 
this an equivalent control to a non-specific scrambled antisense oligomer with 
blaCTX-M-15. This control option was considered preferable to a scrambled or mismatched 
antisense conjugate as the subject itself was assessed for potential non-specific effects in 
the control strain.  
Field isolate LREC90 was cultured in the presence and absence of P-PNA4, P-PMO1 
and CTX, and growth measured by spectrophotometry over 18 – 24 hours. Minimum 
inhibitory concentrations (CTX) were established for LREC90 in the presence and 
absence of P-PNA4.  
CTX-M-14 mRNA 5’.gaccguauugggaguuugagAUGGUGACAAAGAGAGUGCAA.3’ 
pmo1                             agggtaccaattttttagtgacgcg 
pna4                ggtcttattcctt 
                    *         *  *   ***** * ***   * ***   
                                
Figure 5-2. Region of maximum complementarity between PMO1, PNA4 and 
blaCTX-M-14 mRNA. 
Translational start region is shown in bold uppercase. Asterisks represent 
complementary bases. blaCTX-M-14 is a mismatched control with anti-blaCTX-M-15 
PNA4 and PMO1. Best alignment of PMO1 = 56% complementarity. Best alignment 
of PNA4 = 15% complementarity. Asterisks represent complementary bases. 
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Table 5-2. Conversion tables of commonly used concentrations to facilitate antisense 
oligomer/CTX dose comparison. 
PMO1   PNA4   CTX  
µM µg/ml  µM µg/ml  µg/ml µM 
10 85.1  10 36.2  2 4.2 
20 170.3  20 72.4  8 16.8 
30 255.4  30 108.6  10 20.9 
40 340.6     12 25.1 
      16 33.5 
P-PMO1   P-PNA4   24 50.3 
µM µg/ml  µM µg/ml  32 67.0 
10 102.2  1.6 8.3  48 100.5 
20 204.4  3.2 16.6  64 134.0 
30 306.6  5.0 26.0  96 201.1 
40 408.8     128 268.1 
 
5.2.  Results 
Minimum inhibitory concentrations (to CTX) were established by spectrophotometry 
for each E. coli strain, and was determined to be the minimum concentration of CTX 
required to inhibit growth  (O.D. 600 nm < 0.05) in a minimum of 50% of replicates over 
18 hours. A characteristic observation of increasing CTX concentrations in all strains 
was the lengthening in time taken to achieve logarithmic growth phase of the culture’s 
growth cycle (Figure 5-4). Additionally, cultures incubated with an increasing, but 
sub-lethal, concentration of CTX were observed to display an increase in the numbers of 
replicates that were completely inhibited (Figure 5-3). The replicates able to grow under 
these conditions, although displaying an increased lag phase, often achieved a similar 
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terminal optical density to those at lower CTX concentrations. Minority surviving 
replicates were analysed for the presence of contaminants by recovery onto diagnostic 
media such as Brilliance™ UTI Clarity (ThermoScientific), and 5% sheep blood agar. 
Minority surviving replicates were also recovered into fresh media, split into equal 
aliquots, and each aliquot supplemented with an increasing amount of CTX to 
investigate the possibility of revertants or mutants with a reduced CTX susceptibility. In 
all cases, the aberrant cultures able to survive in conditions that inhibited the growth of 
the majority of the other replicates were found to have the same CTX susceptibility 
profile of the parent cultures, and no contaminants were observed. The explanation for 
the observed growth by some replicates and no growth in other replicates remains 
undefined but is likely to be due to biological variation more apparent at CTX levels 
approaching inhibitory concentrations – illustrated in Figure 5-3. 
 
Figure 5-3. Survival graph showing survival of E. coli AS19/pJBRCTX516 replica 
cultures in increasing concentrations of cefotaxime.  
Number of replicates for each CTX concentration = 7; dead = no growth (O.D. 
600 nm < 0.05) measured spectrophotometrically after 18 hours; alive = O.D. 600 nm > 0.5 
after 18 hours.  
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Atypically permeable cell-wall mutant E. coli strain AS19 allows the uptake of small 
molecules that would otherwise be unable to achieve cellular penetration in field 
isolates. It has previously been used extensively as a model organism for gene 
expression inhibition by synthetic antisense oligomers [122, 127, 135, 136, 179]. AS19 
was transformed with recombinant plasmids pJBRCTX499 and pJBRCTX516 by 
electroporation. Growth curves determined by culture turbidity, measured by 
spectrophotometry, revealed the minimum inhibitory concentration (to CTX) of AS19/ 
pJBRCTX516 under these conditions to be greater than 64 µg/ml, and less than 
128 µg/ml (Figure 5-4). After further refinements in this concentration range, the MIC 
(to CTX) was observed to be approximately 80 µg/ml.  
 
Figure 5-4. Growth curves showing the sensitivity of AS19/pJBRCTX516 to CTX 
(0 - 128 µg/ml).  
Increasing CTX concentrations (2 – 128 µg/ml) result in an extension in time taken to 
achieve logarithmic growth phase in a dose dependant manner. Bacterial growth curves 
from left to right: CTX (0 µg/ml), CTX (2 µg/ml), CTX (4 µg/ml), CTX (8 µg/ml), 
CTX (16 µg/ml), CTX (32 µg/ml), CTX (64 µg/ml), CTX (128 µg/ml; no growth). 
Error bars indicate ± 1 standard deviation (n=3). 
Page 148 
5.2.1.  Levels of blaCTX-M activity in a laboratory cell-wall mutant strain of E. coli 
are reduced by antisense oligomer treatment 
AS19/ pJBRCTX516 was challenged with PMO1 (0 – 40 µM) in combination with 
cefotaxime (4 µg/ml). The results showed an increasing sensitivity to cefotaxime in a 
PMO1 dose dependant manner (0 – 40 µM; Figure 5-5). Complete inhibition of growth 
was observed at a CTX concentration of 4 µg/ml when combined with PMO1 at a 
concentration of 40 µM. The cultures showing no growth were recovered onto LB agar 
to confirm the bactericidal effects. No colony growth was observed after an overnight 
incubation at 37° C. When incubated with PMO1 (5 – 30 µM) in the absence of CTX, 
no inhibitory effects were observed (Figure 5-6), indicating that the PMO alone had no 
inherent inhibitory properties.  
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Figure 5-5. Growth curves showing the increasing sensitivity of AS19/pJBRCTX516 to 
CTX (4 µg/ml) in the presence PMO1 (0-40 µM). 
All samples were treated with 4µg/ml CTX and increasing PMO concentrations 
(0-40 µM). At 40 µM PMO concentration, growth was completely inhibited. Solid line: 
CTX (4 µg/ml), dashed line: CTX (4 µg/ml) + PMO1 (10 µM), dotted line: CTX 
(4 µg/ml) + PMO1 (20 µM), dash-dot line: CTX (4 µg/ml) + PMO1 (30 µM), dash-dot-
dot line: CTX (4 µg/ml) + PMO1 (40 µM). Error bars indicate ± 1 standard deviation 
(n=2). 
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Figure 5-6. Growth curves showing the insensitivity of AS19/pJBRCTX516 to PMO1 
alone (0 - 30 µM). 
Graph showing no effect on growth when cultures were treated with PMO1 alone at any 
concentration (5 - 30 µM). Six curves shown (5, 10, 15, 20 and 30 µM) with no 
significant differences between any. Error bars indicate ± 1 standard deviation (n=2). 
AS19/ pJBRCTX516 was challenged with the combination of cefotaxime (4 µg/ml) and 
PNA4 at concentrations of 0, 10 and 20 µM (Figure 5-7). In contrast with the higher 
inhibitory efficacy of PMO1 observed in a cell-free translation/transcription coupled 
system, PNA4 completely inhibited growth at 20 µM - half the concentration required 
of PMO1 to yield complete growth inhibition. Recovery was again attempted on 
non-selective media of the cultures observed to have shown no growth, and no colonies 
were observed, affirming the bactericidal effects of the combination of CTX and PNA4. 
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Figure 5-7. Growth curves showing the sensitivity of AS19/pJBRCTX516 to CTX 
(4 µg/ml) in the presence and absence of PNA4 (0-20 µM). 
Increase in sensitivity to CTX by the addition of PNA4. 4 µg/ml and 20 µM PNA4 
inhibited growth. Solid line: CTX (4 µg/ml), dashed line: CTX (4 µg/ml) + PNA4 
(10 µM), dotted line: CTX (4 µg/ml) + PNA4 (20 µM). Error bars indicate ± 1 standard 
deviation (n=2). 
When challenged with PNA4 alone, a significant inhibitory growth effect was observed 
in a dose dependent manner (Figure 5-8) suggesting an inherent bactericidal or 
inhibitory property of PNA4. A significant inhibitory effect on growth was noted at 
concentrations range greater than 5 µM. 
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Figure 5-8. Growth curves showing the sensitivity of AS19/pJBRCTX516 to PNA4 
(5 - 30 µM) in the absence of CTX. 
Cultures treated with PNA4 (5 – 30 µM) alone showed a dose dependant increase in the 
time taken to achieve logarithmic growth phase, indicating inherent toxicity. Solid line: 
PNA4 (0 µM), dashed line: PNA4 (5 µM), dotted line: PNA4 (10 µM), dash-dot line: 
PNA4 (20 µM), dash-dot-dot line: PNA4 (30 µM). Error bars indicate ± 1 standard 
deviation (n=3). 
5.2.2.  Levels of blaCTX-M activity in field isolate strains of E. coli are effectively 
reduced by treatment with antisense oligomers conjugated to a cell-penetrating 
peptide  
Field isolate LREC461 was evaluated in the presence of CTX and unmodified PNA4 
and PMO1 for evidence of increased antibiotic susceptibility. Cultures were incubated 
with either PMO1 (5 - 20 µM) or PNA4 (5 - 40 µM) and CTX (16 µg/ml) at 37° C for 
18 hours and optical density measured at a light wavelength of  600 nm at 5 minute 
intervals. No significant increased sensitivity to CTX, evidenced by a lack of any 
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increased duration in time taken to achieve logarithmic growth, was observed at any 
concentration of either PMO1 or PNA4 (Figure 5-9;  Figure 5-10 respectively).  This 
was consistent with the expectation that an unmodified PNA or PMO would be unable 
to efficiently penetrate a typical bacterial cell wall. 
 
Figure 5-9. Growth curves showing effect of CTX (16 µg/ml) in the presence of PMO1 
(5 – 20 µM) on field isolate LREC461 harbouring blaCTX-M-3. 
LREC461 incubated with CTX (16 µg/ml) and PMO1 (5, 10 and 20 µM).  LREC461 
incubated with CTX (16 µg/ml) and PMO1 (5, 10 and 20 µM). Solid line: CTX (16 
µg/ml), dashed line: CTX (16 µg/ml) + PNA4 (5 µM), dotted line: CTX (16 µg/ml) + 
PMO1 (10 µM), dash-dot line: CTX (16 µg/ml) + PMO1 (20 µM). Error bars indicate ± 
1 standard deviation (n=3). 
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Figure 5-10. Growth curves showing effect of CTX (16 µg/ml) in the presence of PNA4 
(10 – 30 µM) on field isolate LREC461 harbouring blaCTX-M-3. 
Growth curves showing effect on growth of field isolate LREC461 incubated with CTX 
and PNA4. Solid line: Control, dashed line: CTX (16 µg/ml), dotted line: CTX 
(16 µg/ml) + PNA4 (10 µM), dash-dot line: CTX (16 µg/ml) + PNA4 (20 µM), dash-
dot-dot line: CTX (16 µg/ml) + PNA4 (30 µM). Error bars indicate +/- 1 standard 
deviation (n=2). 
To facilitate the entry of PNA4 and PMO1, these antisense oligomers were covalently 
attached to the cell-penetrating peptide, (KFF)3K. This cell-penetrating peptide has 
previously been shown by many studies to be an effective bacterial delivery vehicle for 
both PMO and PNA chemistries.   
Peptide-conjugated PMO1 (P-PMO1) and peptide-conjugated PNA4 (P-PNA4) were 
evaluated in combination with CTX for growth inhibitory effects in a panel of field 
isolates (LREC460, LREC461, LREC454, B3804, LREC525, BZ693/P and LREC461; 
Table 5-1). E. coli strain LREC90, used for control studies, carried a plasmid 
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harbouring blaCTX-M-14, which encoded β-lactamase from CTX-M-group 9. All other 
CTX resistant strains used in this study harboured variants of CTX-M-group 1. 
Cefotaxime concentrations were selected based on estimations of the concentrations 
required to create inhibitory conditions with the presence of P-PMO1 (10 – 30 µM), and 
P-PNA4 (2 – 5 µM). Cefotaxime concentrations observed to be favourable to optimum 
effect when combined with peptide-conjugated antisense oligomers were the 
concentrations required to delay the exponential growth phase of the culture by 
approximately 2 – 4 hours. If a larger or smaller than expected effect size was observed, 
CTX concentration, antisense oligomer concentration, or both, were adjusted 
accordingly. Peptide-conjugated antisense oligomer concentrations were initially 
selected based upon AS19/pJBRCTX516 studies at maximum levels used which were 
observed to have no significant effect on the growth of the cultures when the cultures 
were treated in the absence of CTX.  
All isolates showed an increased sensitivity to CTX when treated with anti-blaCTX-M 
P-PMO1 (30 µM) ranging from a reduction in the MIC (to CTX) in 
blaCTX-M-3-harbouring strain from 35 µg/ml to 16 µg/ml (2.19-fold increase in 
sensitivity), to a strain harbouring blaCTX-M-1 from 48 µg/ml to 10 µg/ml (4.8-fold 
increase in sensitivity). The same isolates when treated with P-PNA4 (3.2 µM) had an 
observed increase in CTX sensitivity ranging from a reduction in MIC (to CTX) in 
blaCTX-M-3/33-harbouring strain BZ693/P from 40 µg/ml to 12 µg/ml (3.3-fold) to a strain 
harbouring blaCTX-M-15 (LREC454) from 110 µg/ml to 2 µg/ml (55-fold). Growth curves 
representing these findings are presented in Appendix A from Figure A-1 to Figure A-
12. Wherever resources allowed, dose response data was experimentally obtained. All 
replicates were independent cultures. Table 5-3 summarises the reduction in MICs (to 
CTX) observed in these strains.   
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Table 5-3. Summary of findings of increased sensitivity of field and clinical E. coli 
isolates to CTX when treated with anti-blaCTX-M-15 peptide-conjugated antisense agents. 
† P-PNA4 concentration = 5 µM, ‡ P-PMO1 concentration = 40 µM 
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5.2.3.  Evaluation of the sequence specificity of antisense effects on expression of 
CTX-M-15 activity in field isolates 
A series of control studies were undertaken to establish and isolate any non-specific 
effects of peptide-conjugated antisense oligomers on the growth on E. coli strains with 
intact cell walls. It had been previously established in studies using AS19/pJBRCTX516 
that PMO1 had no significant negative effects on growth when administered in the 
absence of cefotaxime (Figure 5-6). This would suggest that PMO1 alone had no 
non-specific inhibitory activity, and was non-toxic to the bacteria cultured in its 
presence. 
E. coli field isolate, LREC454, harbouring plasmid pEK499, expressing blaCTX-M-15, was 
cultured in the presence of P-PMO1 (10 – 30 µM) in the absence of cefotaxime. Results 
showed a dose-dependent inhibitory effect (Figure 5-11). 
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Figure 5-11. Growth curves showing effect of P-PMO1 (10 - 30 µM) in the absence of 
CTX on field isolate LREC454 harbouring blaCTX-M-15. 
LREC454 incubated with P-PMO1 (10 - 30 µM). Solid line: control, dashed line: 
P-PMO1 (10 µM), dotted line: P-PMO1 (20 µM), dash-dot line: P-PMO1 (30 µM). 
Error bars indicate ± 1 standard deviation (n=2). 
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To isolate non-specific effects of P-PMO1 or effects of peptide portion of the P-PMO1 
conjugate, field isolate LREC90 harbouring blaCTX-M-14, a member of CTX-M-group 9, 
was cultured in the presence and absence of CTX and in the presence of P-PMO1. 
PMO1 shared 56% sequence complementarity (14/25 bases) with blaCTX-M-14 (Figure 
5-2) making this, as previously noted, an equivalent control to a non-specific scrambled 
antisense oligomer with blaCTX-M-15. A dose-dependent inhibitory effect of similar size to 
that previously observed in the growth of LREC454 (Figure 5-11) was observed when 
LREC90 was cultured in the presence of P-PMO1 alone (Figure 5-12).                    
 
  
Figure 5-12. Growth curves showing effect of P-PMO1 (10 - 30 µM) in the absence of 
CTX on field isolate LREC90 harbouring blaCTX-M-14. 
LREC90 incubated with P-PMO1 (10 - 30 µM). Solid line: control, dashed line: 
P-PMO1 (10 µM), dotted line: P-PMO1 (20 µM), dash-dot line: P-PMO1 (30 µM). 
Error bars indicate ± 1 standard deviation (n=2). 
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Control strain LREC90 was cultured in the presence of P-PMO1 and CTX (3 µg/ml; 
Figure 5-13) and an effect  greater than that observed when LREC90 was cultured in the 
presence of P-PMO1 alone (Figure 5-12), was observed. This was potentially 
attributable to the combined additive effects of CTX and the peptide portion of the 
P-PMO1 conjugate previously observed. 
 
Figure 5-13. Growth curves showing effect of P-PMO1 (10 - 30 µM) in the presence of 
CTX (3 µg/ml) on field isolate LREC90 harbouring blaCTX-M-14. 
LREC90 incubated with CTX (3 µg/ml) and P-PMO1 (10 - 30 µM). Solid line: CTX 
(3 µg/ml), dashed line: CTX (3 µg/ml) + P-PMO1 (10 µM), dotted line: CTX (3 µg/ml) 
+ P-PMO1 (30 µM). Error bars indicate ± 1 standard deviation (n=2). 
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To evaluate specific effects of P-PNA4, E. coli field isolate LREC90 (control strain), 
harbouring blaCTX-M-14 was incubated in the presence of CTX (2 – 20 µg/ml) and 
minimum inhibitory concentrations established (Figure 5-14). In the presence of CTX 
(2 – 20 µg/ml) and P-PNA4 (3.2 µM), the MIC (to CTX) was not reduced (Figure 
5-15). 
 
Figure 5-14. Growth curves showing effect of CTX (2 - 20 µg/ml) on growth of control 
strain LREC90 harbouring blaCTX-M-14. 
Bacterial growth curves from left to right: CTX (0 µg/ml), CTX (2 µg/ml), CTX (5 
µg/ml), CTX (8 µg/ml), CTX (11 µg/ml), CTX (14 µg/ml), CTX (17 µg/ml), CTX (20 
µg/ml; no growth). Error bars indicate ± 1 standard deviation (n=2). 
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Figure 5-15. Growth curves showing effect of CTX (2 - 20 µg/ml) and P-PNA4 
(3.2 µM) on growth of control strain LREC90 harbouring blaCTX-M-14. 
Curves from left to right: CTX (0 µg/ml) + P-PNA4 (3.2 µM), CTX (2 µg/ml) + 
P-PNA4 (3.2 µM), CTX (5 µg/ml) + P-PNA4 (3.2 µM), CTX (8 µg/ml) + P-PNA4 
(3.2 µM), CTX (11 µg/ml) + P-PNA4 (3.2 µM), CTX (14 µg/ml) + P-PNA4 (3.2 µM), 
CTX (17 µg/ml) + P-PNA4 (3.2 µM), CTX (20 µg/ml) + P-PNA4 (3.2 µM). Error bars 
indicate ± 1 standard deviation (n=2). 
 
E. coli field isolate LREC90 (control strain), harbouring blaCTX-M-14 was treated with 
P-PNA4 (1.6 - 5 µM) in the absence of CTX (Figure 5-16) and treated with P-PNA4 
(1.6 - 5 µM) in combination with CTX (2 µg/ml; Figure 5-17). No significant 
differences were observed between the cultures incubated in the presence of P-PNA4 
and CTX and the cultures incubated in the presence of P-PNA4 alone. 
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Figure 5-16. Growth curves showing effect of P-PNA4 (1.6 - 5 µM) on growth of 
control strain LREC90 harbouring blaCTX-M-14. 
Solid line: control, dashed line: P-PNA4 (1.6 µM), dotted line: P-PNA4 (3.2 µM), 
dash-dot line: P-PNA4 (5 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure 5-17. Growth curves showing effect of P-PNA4 (1.6 - 5 µM) and CTX (2 µg/ml) 
on growth of control strain LREC90 harbouring blaCTX-M-14. 
Solid line: CTX (2 µg/ml), dashed line: CTX (2 µg/ml) + P-PNA4 (1.6 µM), dotted 
line: CTX (2 µg/ml) + P-PNA4 (3.2 µM), dash-dot line: CTX (2 µg/ml) + P-PNA4 
(5 µM). Error bars indicate ± 1 standard deviation (n=2). 
For a direct comparative study of specificity of anti-blaCTX-M-15 P-PNA4, E. coli field 
isolate LREC454 harbouring blaCTX-M-15 was incubated under the same conditions as the 
previous control study with strain LREC90, in the presence of P-PNA4 (1.6 - 5 µM) and 
in the absence and presence of CTX (2 µg/ml). A comparable effect on growth to that 
observed with LREC90 incubated in the presence of P-PNA4 alone (1.6 - 5 µM; Figure 
5-16) was observed with strain LREC454 incubated in the presence of P-PNA4 alone 
(1.6 – 5 µM; Figure 5-18). However, in contrast with the control study using strain 
LREC90, when LREC454 was cultured in the presence of CTX (2 µg/ml) and P-PNA4 
Page 165 
(1.6 - 5 µM) a greater negative effect on growth was observed (Figure 5-19), suggesting 
a CTX potentiating effect of P-PNA4. 
 
 
Figure 5-18. Growth curves showing effect of P-PNA4 (1.6 - 5 µM) on growth of 
control strain LREC454 harbouring blaCTX-M-15. 
Solid line: control, dashed line: P-PNA4 (1.6 µM), dotted line: P-PNA4 (3.2 µM), 
dash-dot line: P-PNA4 (5 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure 5-19. Growth curves showing effect of P-PNA4 (1.6 - 5 µM) and CTX (2 µg/ml) 
on growth of control strain LREC454 harbouring blaCTX-M-15. 
Solid line: CTX (2 µg/ml), dashed line: CTX (2 µg/ml) + P-PNA4 (1.6 µM), dotted 
line: CTX (2 µg/ml) + P-PNA4 (3.2 µM), dash-dot line: CTX (2 µg/ml) + P-PNA4 
(5 µM). Error bars indicate ± 1 standard deviation (n=2). 
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5.2.4.  Effects of the combination of P-PNA4 and CTX on E. coli field isolate 
LREC525 cultures 
Previous studies had demonstrated the growth-inhibitory properties of the CTX / 
peptide-conjugated antisense oligomer combination in field and clinical isolates. To 
observe any effects of P-PNA4 on established cultures, field isolate LREC525 
harbouring blaCTX-M-15 was cultured until early-mid log phase (O.D. 600 nm 0.2 - 0.3) was 
achieved, and then split into 4 aliquots and treated as follows: control; CTX (48 µg/ml); 
P-PNA4 (3.2 µM), and P-PNA4 (3.2 µM) and CTX (48 µg/ml). The aliquots were 
incubated and samples removed approximately every 10 minutes. The samples were 
diluted and spread onto LB agar plates and cultured overnight. The next day, visible 
colonies from each time point were counted. Colony counts indicated the cultures 
exposed to P-PNA4 / CTX combination declined between 13 and 94 minutes, from 
1.04x105 CFU/µl to 2.9x104 CFU/µl, but were then able to recover and achieve 
logarithmic growth. The samples treated with P-PNA4 alone showed an overall increase 
in the colony forming units, although a static period of no growth was observed between 
40 and 70 minutes. The culture sample not treated with any antibiotic or P-PNA4 
increased steadily in number over 90 minutes. The aliquot treated with cefotaxime alone 
showed a slight decline in colony forming units between 10 and 70 minutes after 
exposure, before increasing in number (Figure 5-20). 
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Figure 5-20. Results of treating an established early log-phase culture with 
CTX/P-PNA4 combinations. 
Cultures were grown until culture turbidity reached a level indicating early log phase 
(O.D. 600 nm = 0.2). The culture was split and aliquots were treated with CTX, P-PNA4 
or both, at the concentrations specified. Solid line: control, dashed line: CTX 
(48 µg/ml), dotted line: P-PNA4 (3.2 µM), dash-dot line: CTX (48 µg/ml) + P-PNA4 
(3.2 µM). 
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5.2.5.  Effects of β-lactamase inhibitors clavulanic acid, tazobactam and 
sulbactam on E. coli field isolate growth 
For comparative evaluation of the efficacy of P-PNA4 and P-PMO1, field isolates were 
exposed to the β-lactamase inhibitors clavulanic acid, tazobactam and sulbactam in the 
presence and absence of cefotaxime. 
Clavulanic acid (64 – 444 µg/ml) was found to be a weak inhibitor of β-lactamase when 
evaluated in combination with cefotaxime (48 µg/ml) in cultures of field isolate 
LREC454 (the concentration of 48 µg/ml was selected as a CTX concentration that was 
sub-inhibitory, but which had an observable negative growth effect to enable any 
inhibitory effects to be readily apparent). At a CTX concentration of 48 µg/ml, a dose 
dependent response to clavulanic acid was observed, although there was no 
concentration of clavulanic acid tested (64 - 444 µg/ml) sufficient for the combination 
of antibiotic and clavulanic acid to completely inhibit growth (Figure 5-21).   
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Figure 5-21. Effects of CTX (48 µg/ml) and clavulanic acid (0 – 444 µg/ml) on 
LREC454 harbouring blaCTX-M-15. 
LREC454 incubated with CTX (48 µg/ml) and/or clavulanic acid. Solid line: control, 
dashed line: CTX (48 µg/ml), dotted line: CTX (48 µg/ml) + clavulanic acid (64 µg/ml), 
dash-dot line: CTX (48 µg/ml) + clavulanic acid (256 µg/ml), dash-dot-dot line: CTX 
(48 µg/ml) + clavulanic acid (444 µg/ml). Error bars indicate ± 1 standard deviation 
(n=2). 
In contrast, all concentrations of sulbactam of 1 µg/ml and above were found to be 
inhibitory when co-administered with CTX (48 µg/ml) in E. coli field isolate LREC525, 
harbouring blaCTX-M-15 (Figure 5-22). Aliquots of the same culture were treated with 
sulbactam alone, and sulbactam was observed to exhibit inherent antimicrobial 
properties; concentrations of 32 µg/ml and higher were sufficient to completely inhibit 
growth (Figure 5-23).  
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Figure 5-22. Effects of CTX (48 µg/ml) and sulbactam (1 – 4 µg/ml) on LREC525 
harbouring blaCTX-M-15. 
LREC525 incubated with CTX (48 µg/ml) and/or sulbactam (1 – 4 µg/ml). Solid line: 
control, dashed line: CTX (48 µg/ml), dotted line (no growth): CTX (48 µg/ml) + 
sulbactam (1 µg/ml), dash-dot line (no growth): CTX (48 µg/ml) + sulbactam (2 µg/ml), 
dash-dot-dot line (no growth): CTX (48 µg/ml) + sulbactam (4 µg/ml). Error bars 
indicate ± 1 standard deviation (n=3). 
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Figure 5-23. Effects of sulbactam (1 – 64 µg/ml) on growth of LREC525 harbouring 
blaCTX-M-15. 
LREC525 incubated with sulbactam (1 – 64 µg/ml). Curves from left to right: 
sulbactam (1 µg/ml), sulbactam (2 µg/ml), sulbactam (4 µg/ml), sulbactam (8 µg/ml), 
sulbactam (16 µg/ml), sulbactam (32 µg/ml; no growth), sulbactam (64 µg/ml; no 
growth). Error bars indicate ± 1 standard deviation (n=3). 
Tazobactam was found to be effective in inhibiting growth of field isolate LREC525 
when co-administered with CTX (Figure 5-24), but weak antimicrobial activity was 
observed when administered in the absence of CTX (Figure 5-25). 
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Figure 5-24. Effects of CTX (48 µg/ml) and tazobactam (1 – 4 µg/ml) on the growth of 
field isolate LREC525. 
Solid line: control, dashed line: CTX (48 µg/ml), dotted line: CTX (48 µg/ml) + 
tazobactam (1 µg/ml), dash-dot line: CTX (48 µg/ml) + tazobactam (2 µg/ml), dash-dot-
dot line: CTX (48 µg/ml) + tazobactam (4 µg/ml). Error bars indicate ± 1 standard 
deviation (n=3). 
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Figure 5-25. Effects of tazobactam (1 – 64 µg/ml) alone on the growth of field isolate 
LREC525 harbouring blaCTX-M-15. 
Curves from left to right: tazobactam (1 µg/ml), tazobactam (2 µg/ml), tazobactam 
(4 µg/ml), tazobactam (8 µg/ml), tazobactam (16 µg/ml), tazobactam (32 µg/ml), 
tazobactam (64 µg/ml). Error bars indicate ± 1 standard deviation (n=3). 
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5.3.  Discussion 
5.3.1.  Observed increase in CTX sensitivity in AS19/pJBRCTX516 cultured in 
the presence of unmodified antisense oligomers PMO1 and PNA4  
Transformation of atypically permeable mutant E. coli strain AS19 with plasmid 
pJBRCTX516 harbouring blaCTX-M-15 enabled the evaluation of PMO1 and PNA4 
β-lactamase expression inhibition without the necessity of cell penetration strategies. 
Studies revealed an increase in CTX susceptibility in AS19/pJBRCTX516 when treated 
with CTX (4 µg/ml) in the presence of PMO1 and PNA4. PNA4 (20 µM) was found to 
reduce the MIC (to CTX) of AS19/pJBRCTX516 from 80 µg/ml to 4 µg/ml whereas a 
PMO1 concentration of 40 µM was required to achieve the same reduction in MIC (to 
CTX). This contrasted with cell-free inhibition studies which demonstrated a slightly 
higher cefotaximase inhibitory effect of PMO1 over PNA4. The observation that PNA4 
was 2-fold more effective over PMO1 in increasing CTX susceptibility in 
AS19/pJBRCTX516 was potentially attributable to multiple factors. Previous bacterial 
experimental studies appear to indicate that the optimum size of synthetic antisense 
agents would be between 9 and 15 bases in length [134]. PNA4 at 13 nt in length fell 
within this range whereas PMO1 at 25 nt in length was larger. Additionally, the uptake 
efficiency of PMO1 and PNA4 by the partially permeable strain AS19/pJBRCTX516 is 
unknown, and likely to contribute to the differences observed in CTX re-sensitisation by 
antisense oligomer gene expression inhibition. The shorter length of the PNA 
potentially facilitates greater cell wall penetration efficiency; it would not be an 
unreasonable assumption that a much smaller molecule would be able to cross the 
partially permeable cell wall with greater ease. Differences in PNA/PMO chemistries 
may also have potentially contributed to differences in cell wall penetration efficiency, 
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as well as cellular efflux efficiency relative to the differences (size and structure) of the 
two different antisense agent types.  
AS19/pJBRCTX516 was treated with PMO1 in the absence of CTX and no effects on 
cell growth were observed. However, when treating AS19/pJBRCTX516 with PNA4 
alone, a dose-dependent growth inhibitory effect was noted. The deleterious effect of 
PNA4 alone can potentially be ascribed to off-target gene transcript matches: the target 
sequence was checked by BLAST searching and found to be to have four bacterial 
off-target matches with 92.3% (12 out of 13 bases) sequence complementarity. PNA4 
was found by a BLAST search to share 92.3% complementarity to the SD region 
upstream of one of these off-target matches, the universal stress protein UspC. This is 
potentially significant, being an mRNA region sensitive to expression inhibition by 
antisense agents. To extenuate this, PNA4 was subsequently administered at a 
maximum concentration (5 µM) shown to have an insignificant effect on the growth of 
AS19/pJBRCTX516 in the absence of CTX. 
5.3.2.  Observed increase in CTX sensitivity in field isolates cultured in the 
presence of peptide-conjugated antisense oligomers P-PMO1 and P-PNA4 
Unmodified antisense agents PNA4 and PMO1 were shown to have no significant effect 
on the susceptibility to cefotaxime, or to the growth characteristics of field isolates with 
intact cell walls. This was not unexpected as previous studies have shown that 
unmodified antisense oligomers do not efficiently penetrate E. coli strains with intact 
cell walls [119]. To overcome this barrier, the anti-blaCTX-M oligomers PMO1 and 
PNA4 were covalently attached to the cell-penetrating peptide, (KFF)3K, which has 
been shown to be effective in promoting uptake across the bacterial cell wall and 
delivering a cargo molecule to the cytoplasm [121, 141].   
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Peptide conjugated PNA4 (P-PNA4) and PMO1 (P-PMO1) both increased the effects of 
CTX as evidenced by the effects on growth of a range of field and clinical isolates 
harbouring β-lactamase genes from CTXM group 1. The amount of observed increase in 
sensitivity to CTX varied in each strain, and between the effects observed with P-PMO1 
and P-PNA4 antisense oligomers. P-PNA4 was found to be between 9 and 56-fold more 
effective in decreasing minimum inhibitory concentrations to CTX than P-PMO1 (Table 
5-3) which could be attributable to two potential explanations:  
1. The shorter length of the PNA potentially contributes to greater cell penetration 
efficiency which would be of interest to investigate further. Methods of 
evaluating this would necessitate labelling of the molecules with a quantifiable 
reporter molecule, and determining the amount that gained access to the 
bacterial cytoplasm. The disadvantage of labelling with a reporter is that the 
reporter molecule itself increases the overall size of the labelled complex, 
affecting cell penetration efficiency. Attempts were made in the course of the 
current study to visualise internalised PMO molecules labelled with a 
fluorescent marker (fluorescein), however fluorescence microscopic outcomes 
were of insufficient intensity to be distinguishable from the background. 
2. PNA4 was found to have some inherent toxicity, as previously discussed, and 
not observed with PMO1. This is likely due to the shorter length of the PNA 
resulting in unwanted sequence complementarity and the target region - PNA4, 
13 nucleotides in length, and targeting an extragenic downstream region, was 
found to share some sequence identity with other genes not intentionally 
targeted. It is likely that these off target matches are the reason for the inherent 
toxicity of PNA4. However, the growth inhibitory effects of PNA4 alone were 
relatively small in comparison with the effect in combination with cefotaxime – 
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at concentrations required to significantly increase sensitivity to cefotaxime 
(2 - 5 µM), PNA4 alone typically had no significant effect on culture growth. 
This would suggest a potentiating effect on CTX of P-PNA4, and that the 
primary and preferential target of P-PNA4 was blaCTX-M of group 1. 
5.3.3.  Control studies to isolate non-specific effects of anti-blaCTX-M-15 P-PMO1 
and P-PNA4 in field isolates 
Previous studies have shown limited or no effect of scrambled or mismatch control 
peptide-conjugated PNAs on bacterial growth, including mismatch controls containing 
as few as two base substitutions [120]. Studies with the peptide (KFF)3K attached to 
PNA oligomers have demonstrated the efficacy of synthetic antigene oligomers in 
bacteria, and their specificity by demonstrating low inhibition of target and reporter 
genes when challenged with scrambled non-specific peptide-conjugated PNAs [121]. 
Specific anti-blaCTX-M-15 activity was demonstrated in this study, in the first instance by 
studies in a cell-free environment using blaCTX-M-15–harbouring recombinant plasmid 
pJBRCTX516. Cefotaximase activity was inhibited by the presence of PNA4 and 
PMO1. There was no observed increase in CTX sensitivity when atypically permeable 
strain AS19/pJBRCTX516 was challenged with the combination of non-blaCTX-M 
specific control PMO and CTX. In the absence of CTX, no effects on growth were 
observed when AS19/pJBRCTX516 was challenged with PMO1 alone (10 – 30 μM; 
Figure 5-6). In the absence of CTX, significant effects on growth were observed when 
AS19/pJBRCTX516 was challenged with PNA4 alone at concentrations higher than 
5 μM (Figure 5-8). This was potentially attributable to unintended off-target partial 
complementarity with other bacterial genes. Consequently, PNA4 concentrations in 
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subsequent studies did not exceed a concentration of 5 μM, typically cultures were 
treated with 3.2 µM P-PNA4 and controls in the absence of CTX were included.  
Additional control studies, equivalent to the use of a scrambled non-specific P-PNA or 
P-PMO1, were undertaken in E. coli strain LREC90 harbouring blaCTX-M-14. PMO1 and 
PNA4, having only 56% and 15% complementarity with the blaCTX-M-14 target region 
respectively, were regarded as non-specific to blaCTX-M-14 expressed by LREC90.  
A comparable effect on the growth of LREC90 (blaCTX-M-14) and LREC454 (blaCTX-M-15) 
was observed when each strain was cultured in the presence of P-PMO1 (10 – 30 μM) 
alone. As PMO1 (unmodified; 10 – 30 μM) previously been shown to have no 
significant effect on the growth of AS19/pJBRCTX516, it would be reasonable to 
attribute the effects on growth of LREC454 and LREC90 in the presence of P-PMO1 
alone to either non-specific toxic effects of the peptide portion of the conjugate, or a 
result of cell wall perturbation. The cell-penetrating peptide (KFF)3K alone has been 
previously shown to have a synergistic effect with certain antibiotics [147]. 
The negative effect of P-PMO1 on the growth of control strain LREC90 was increased 
in an additive manner (estimated fractional inhibitory concentration index (FICI) 
between 0.5 and 1) when LREC90 was cultured in the presence of 
P-PMO1 (10 - 30 μM) and CTX (3 µg/ml; Figure 5-13). In contrast, the negative effect 
on growth of P-PMO1 on the growth of field isolate LREC454 was increased in a 
synergistic manner (estimated FICI < 0.5) when LREC454 was cultured in the presence 
of P-PMO1 and CTX (24 µg/ml; Figure A-1). A similar, comparable effect was 
observed on the growth of both LREC454 (blaCTX-M-15) and LREC90 (blaCTX-M-14) when 
cultured in the presence of P-PNA4 (1.6 - 5 µM; Figure 5-17; Figure 5-18). No 
significant differences were observed between the effects on growth of LREC90 
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cultured in the presence of P-PNA4 alone (1.6 – 5 μM), and P-PNA4 (1.6 – 5 μM) co-
administered with CTX (2 µg/ml). A significant difference, however, was noted in 
LREC454 cultured in the presence of P-PNA4 (1.6 - 5 µM) alone (Figure 5-18) and 
LREC454 cultured in the presence of P-PNA4 (1.6 - 5 µM) in combination with CTX 
(2 µg/ml; Figure 5-19). Additionally, minimum inhibitory concentrations (to CTX) of 
LREC90 were not reduced in the presence of P-PNA4 (Figure 5-14; Figure 5-15).  
These data would strongly indicate specific anti-blaCTX-M-15 activity of P-PNA4 and 
P-PMO1. 
5.3.4.  Cefotaxime potentiating effect of peptide-conjugated antisense oligomers 
in field isolates expressing blaCTX-M-15  
Peptide conjugated PNA4, as previously noted, exhibited some inherent inhibitory 
effects when cultures were treated in the absence of cefotaxime. To determine that the 
combined effect of the antibiotic and P-PNA4 was greater than the effects of the sum of 
its constituent parts, i.e. to establish that there was a CTX potentiating effect, two 
methods were employed:  
i) A concentration of cefotaxime was established that yielded a similar inhibition profile 
(an equivalent amount of time taken to achieve logarithmic growth phase), as P-PNA4 
(3 µM) alone, in E. coli strain LREC525. A doubling of the CTX concentration enabled 
a visual estimation of the additive or synergistic nature of the P-PNA4/CTX 
combination.  
A starter culture was grown until an appropriate cell density (O.D. 600 nm = 0.1-0.2) was 
reached, diluted to yield 50,000 CFU/ml, and split into equal aliquots. One aliquot was 
cultured in the presence of the concentration of cefotaxime required to yield an 
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equivalent growth inhibitory effect as P-PNA4 (3 µM). Another aliquot was cultured in 
the presence of P-PNA4, a third aliquot was cultured in the presence of double the 
concentration of cefotaxime, and the final aliquot in the presence of cefotaxime and 
P-PNA4. The effect of the P-PNA4-cefotaxime combination was visibly greater than 
the effect of the double cefotaxime dose aliquot suggesting a CTX potentiating effect. 
ii) The fractional inhibitory concentration index (FICI) was evaluated for cefotaxime 
and P-PNA4. Maximum tested concentrations of P-PNA4 and P-PMO1 administered in 
the absence of CTX were insufficient to completely inhibit the growth of field isolates, 
and so a conservative estimation of an inhibitory concentration based on a visual 
extrapolation from dose-response growth curves was used to calculate an estimated 
fractional inhibitory concentration index value. In all cases a strong synergistic 
relationship was indicated (FICI < 0.05). 
5.3.5.  Comparative evaluation of the effects of clavulanic acid, sulbactam and 
tazobactam with P-PNA4 and P-PMO1 in increasing sensitivity to CTX in field 
isolates 
For comparison with the efficacy of antisense oligomers, field isolates were treated with 
a combination of CTX and the β-lactamase inhibitors clavulanic acid, sulbactam and 
tazobactam. There was no concentration of clavulanic acid tested (269 µM – 1.9 mM) 
that was found to completely inhibit growth of LREC454 cultures co-treated with CTX 
(48 µg/ml). In contrast, CTX (2 µg/ml) was sufficient to inhibit growth of LREC454 
cultures co-treated with P-PNA4 (3.2 µM), and CTX at a concentration of 24 µg/ml was 
found to be inhibitory when co-administered with P-PMO1 (30 µM). 
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The MIC (to CTX) of LREC525 was reduced in the presence of tazobactam (3.1 µM) 
from 260 µg/ml to 48 µg/ml. In the presence of sulbactam (4.3 µM) the MIC (to CTX) 
of LREC525 was also reduced from 260 µg/ml to 48 µg/ml. 
This compared with an equivalent MIC (to CTX) reduction (from 260 µg/ml to 
48 µg/ml) in the presence of P-PNA4 (3.2 µM). A co-treatment of P-PMO1 (30 µM) 
and CTX (96 µg/ml) was observed to be inhibitory in LREC525 cultures under the same 
conditions. 
These data suggest that the efficacy of P-PNA4 was comparable to tazobactam and 
sulbactam, and superior to clavulanic acid in partially restoring CTX sensitivity in a 
strain expressing blaCTX-M-15. The efficacy of P-PMO1 in increasing CTX sensitivity in 
a strain expressing blaCTX-M-15 was observed to be lower than that of either tazobactam 
or sulbactam, but greater than clavulanic acid. 
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Chapter 6.   
Exposure to cephalosporins stimulates an increase of β-lactamase activity in 
E. coli strains AS19/pJBRCTX516 and LREC460 
6.1.  Introduction 
In comparison with the observed effects of anti-blaCTX-M antisense agents in a cell-free 
translation/transcription coupled system, results obtained from inhibition of 
cefotaximase activity studies in whole cells appeared to show a markedly lower effect 
size than expected. At relatively low concentrations of PNA/PMO (500-1000 nM) near 
complete inhibition of blaCTX-M-15 was observed in such a cell-free system. However, 
when attempting to inhibit the activity of blaCTX-M-15 in whole, biologically active cells a 
much lower efficiency was observed. This was hypothesised to relate to a number of 
factors including, but not limited to: the inherent difficulties of delivering the antisense 
agents into the bacterial cell, efflux mechanisms responsible for pumping agents out of 
the cell, a high level of constitutive expression or an inducible β-lactamase upregulation 
mechanism. The apparent difficulties in achieving complete inhibition of the 
cefotaximase activity, contrasted with high levels of expression inhibition reported by 
other studies targeting different genes in the same species with the same or equivalent 
synthetic antisense agents. This may suggest blaCTX-M-15 is either a constitutively 
strongly expressed gene, or a differentially expressed inducible gene, under the control 
of one or more regulation mechanisms.   
Regulatory mechanisms that induce increased expression in other β-lactamases such as 
AmpC β-lactamases are known to exist [66]. Jacoby et al. showed that genes ampG and 
ampD essential for β-lactamase induction were also required for peptidoglycan 
recycling, suggesting a mechanism of cell-wall integrity monitoring, in which 
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β-lactamase induction was related to the levels of muropeptides (resulting from 
enzymatic digestion of glycan strands [180]) in the cytoplasm [181]. Lindberg et al. 
found that AmpC β-lactamase is inducible in the presence of the regulatory gene ampR 
[182]. The cytoplasmic protein, AmpD, and the membrane-bound protein AmpE have 
been linked to the detection of the activity of β-lactam antibiotics and the relaying of 
this signal to AmpR [183]. In the gram-negative pathogen Vibrio parahaemolyticus, a 
receptor which directly recognised β-lactam antibiotics was identified which controlled 
β-lactamase expression – mutants lacking the receptor were found to not produce 
β-lactamase and were re-sensitised to β-lactam antibiotics [184].  
To investigate evidence of increased levels of blaCTX-M expression in the presence of 3rd 
generation cephalosporins, 3 different methods were employed: 
1. Supernatant extracts from AS19/pJBRCTX516 obtained from cultures incubated 
in the presence of increasing concentrations of CTX were incubated with 
nitrocefin and the rate of degradation by β-lactamase monitored by 
spectrophotometry. 
2. AS19/pJBRCTX516 cultures were exposed to varying concentrations of CTX 
and samples taken at regular intervals. Remaining CTX was quantified from 
each sample by HPLC. 
3. AS19/pJBRCTX516 and LREC460 cultures were incubated with varying 
concentrations of the 3rd generation cephalosporin ceftriaxone (CRO) for 30 and 
45 minutes to differentially induce β-lactamase activity. Cells were disrupted 
and supernatant samples from each culture were transferred to a CTX solution. 
CTX degradation was quantified by an HPLC time-course assay. 
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6.2.  Results 
6.2.1.  Quantification of CTX induced β-lactamase expression upregulation by 
colourimetric nitrocefin based assay 
E. coli strain AS19/pJBRCTX516 was cultured from frozen glycerol stocks in MHB 
supplemented with CTX (final concentration of 2 µg/ml) and KAN (final concentration 
of 40 µg/ml) until early log phase (O.D. 600 nm = 0.1) was reached. The culture was 
diluted 1:500 and split into five equal (7.5 ml) aliquots. Each aliquot was cultured in the 
presence of final CTX concentrations of 0, 2, 16, 32 and 64 µg/ml and cultured at 
37° C. Aliquots (2 ml) were removed at time intervals 0, 1 and 2 hours and growth 
measured by spectrophotometry (O.D. 600 nm) to normalise results. Bacterial cells were 
separated by centrifugation and the supernatant removed. Aliquots (20 µl) of each 
supernatant were added to wells in a 96-well microtiter plate, pre-prepared with 
nitrocefin solution (final concentration of 200 µM), and β-lactamase activity monitored 
by spectrophotometry (O.D. 492 nm). The results indicated a more rapid reaction occurred 
with supernatant aliquots obtained from cultures exposed to higher CTX concentrations 
(Figure 6-1). The samples taken at the time of initial CTX exposure revealed no 
significant differences in the rate of nitrocefin reaction (Figure 6-1a). After 1 and 2 
hours of CTX pre-exposure, the subsequent nitrocefin colour change reaction proceeded 
more rapidly and in a dose dependant manner with supernatant aliquots obtained from 
cultures exposed to higher CTX concentrations (Figure 6-1b-c). The nitrocefin colour 
change reaction had been previously shown to have direct proportional relationship with 
β-lactamase quantity, and as such was a suitable marker for the quantification of 
β-lactamase present in solution. 
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Figure 6-1. Nitrocefin assay to measure the effects of CTX (0 - 64 µg/ml) on inducing 
β-lactamase activity in AS19/pJBRCTX516. 
Supernatant extracts from AS19/pJBRCTX516 incubated with CTX (0 - 64 µg/ml), a) 
nitrocefin reaction at the time of initial CTX exposure. b) Nitrocefin reaction after 1 
hour CTX incubation; c) nitrocefin reaction after 2 hours CTX incubation. Error bars 
indicate ± 1 standard deviation (n=2). Solid line: control, dashed line: CTX (2 µg/ml), 
dotted line: CTX (16 µg/ml), dash-dot line: CTX (32 µg/ml), dash-dot-dot line: CTX 
(64 µg/ml). 
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6.2.2.  Quantification of CTX degradation in AS19/pJBRCTX516 cultures 
exposed to differing levels of CTX concentrations  
E. coli strain AS19/pJBRCTX516 was cultured from frozen glycerol stocks until early 
log phase (O.D. 600 nm = 0.1 - 0.2) was reached. The culture was diluted 1:500 and split 
into 5 equal (20 ml) aliquots. Each aliquot was supplemented with CTX, or carrier 
medium, to achieve the following final concentrations: 0, 2, 16, 32 and 64 µg/ml and 
incubated at 37° C. At approximately 1 hour intervals culture growth was quantified by 
spectrophotometry (O.D. 600 nm) for each time interval, and aliquots (1 ml) were taken 
from each culture. HCl (1M, 85 µl) was added to halt enzymatic reactions of each 
aliquot by increasing acidity to pH 2.2. Remaining CTX in solution was quantified by 
HPLC for each time point in duplicate. The rate of CTX degradation increased 
proportionally with the increase in CTX exposure (Figure 6-2, Table 6-1). Culture 
growth was monitored by spectrophotometry for the purposes of normalising results, 
however, culture turbidity remained lower than the resolution of the spectrophotometer 
to accurately estimate CFU number – optical density readings for all samples remained 
below 0.002 (O.D. 600 nm) for the period of time that cefotaxime was still of quantifiable 
amounts in solution. β-Lactamase activity was regarded as having been produced from 
an approximately equivalent amount of cells. Maximum rates of CTX degradation were 
calculated from the linear section of the CTX degradation curve and are shown in Table 
6-1. 
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Figure 6-2. Effects of CTX exposure on β-lactamase activity in AS19/pJBRCTX516. 
AS19/pJBRCTX516 incubated with CTX (2 - 64 µg/ml), Error bars indicate ± 1 
standard deviation (n=2). Solid line: CTX (2 µg/ml), dashed line: CTX (16 µg/ml), 
dotted line: CTX (32 µg/ml), dash-dot line: CTX (64 µg/ml). 
 Table 6-1. Rates of CTX degradation in AS19/pJBRCTX516 exposed to different 
concentrations of CTX. 
CTX Concentration Maximum rate of CTX degradation (µg/ml/min) 
64 29.7 
32 10.7 
16 7.2 
2 3.4 
0 0 
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6.2.3.  Quantification of CTX degradation by supernatant extracts from E. coli 
cultures exposed to differing levels of ceftriaxone 
E. coli strain AS19/pJBRCTX516 and field isolate LREC460, both harbouring 
blaCTX-M-15, was cultured from frozen glycerol stocks until early log phase (O.D. 600 nm = 
0.1 - 0.2) was reached. The culture was diluted 1:500 and split into 5 equal (2 ml) 
aliquots. Each aliquot was supplemented with CRO (final concentrations 0 - 384 µg/ml) 
and incubated at 37° C for 30 minutes. Culture turbidity was measured (O. D. 600 nm) to 
normalise cell culture growth. Cell aggregates were disrupted by bead milling and 
separated by centrifugation. Supernatant aliquots (700 µl) were removed, added to 
700 µl CTX solution (800 µg/ml) and incubated at 37° C. 125 µl aliquots were removed 
at regular time intervals and added to pre-prepared HPLC vials containing 125 µl 
phosphate buffer/ HCl, pH2.2. The degradation of CTX over time (80 minutes) was 
quantified by HPLC. All studies were performed using independent cultures. 
AS19/pJBRCTX516 cultures were pre-exposed to CRO (0, 2, 32 and 64 µg/ml) for 30 
minutes. A dose dependant increase in the amount of CTX degradation was observed, 
with the exception of cultures exposed to CRO 0 and 2 µg/ml (Figure 6-3). The rate of 
CTX degradation for each concentration of ceftriaxone is shown in Figure 6-4. 
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Figure 6-3. Effects of exposure to ceftriaxone on the upregulation of cefotaximase 
activity in recombinant E. coli strain AS19/pJBRCTX516. 
E. coli cultures of strain AS19 harbouring the plasmid pJBRCTX516, were incubated 
with concentrations of CRO (2 - 64 µg/ml) for 30 minutes. Supernatants were collected, 
and incubated with CTX. A quantification of CTX degradation was established by 
HPLC in aliquots collected at regular intervals over 50 minutes. Solid line: CRO 
(0 µg/ml), dashed line: CRO (2 µg/ml), dotted line: CRO (32 µg/ml), dash-dot line: 
CRO (64 µg/ml), dash-dot-dot line: blank (HPLC control). Error bars indicate ± 1 
standard deviation (n=2). 
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Figure 6-4. Effects of pre-exposure to ceftriaxone (0 – 64 µg/ml) of E. coli strain 
AS19/pJBRCTX516 on the rate of cefotaxime degradation. 
Rate of degradation of CTX (µg/min/CFU) incubated with supernatant extracts from 
E. coli strain LREC460 was measured by HPLC.  AS19/pJBRCTX516 was incubated 
with CRO (0 - 64 µg/ml) for 30 minutes prior to the supernatant incubation with CTX. 
Error bars indicate ± 1 standard deviation (n=2).  
LREC460 cultures were exposed to CRO (0, 2, 64, 128 and 384 µg/ml) for 45 minutes. 
Supernatant aliquots (700 µl) were removed, added to 700 µl CTX solution (800 µg/ml) 
and incubated at 37° C. 125 µl aliquots were removed at regular time intervals and 
added to pre-prepared HPLC vials containing 125 µl phosphate buffer/ HCl, pH2.2. The 
degradation of CTX over time (110 minutes) was quantified by HPLC. A dose 
dependant increase in the amount of CTX degradation was observed, with the exception 
of cultures exposed to 0 and 2 µg/ml CRO (Figure 6-5). The rate of CTX degradation 
for each concentration of ceftriaxone is shown in Figure 6-6. 
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Figure 6-5. Effect of exposure of E. coli strain LREC460 to ceftriaxone (0 – 384 µg/ml) 
on cefotaximase activity. 
LREC460 incubated with CRO (0 - 384 µg/ml) for 45 minutes prior to the supernatant 
incubation with CTX. Error bars indicate ± 1 standard deviation (n=4). Solid line: CRO 
(0 µg/ml), dashed line: CRO (2 µg/ml), dotted line: CRO (64 µg/ml), dash-dot line: 
CRO (128 µg/ml), dash-dot-dot line: CRO (384 µg/ml). HPLC blank not shown (no 
hydrolysis over the time course was observed). 
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Figure 6-6. Effect of exposure of E. coli strain LREC460 to ceftriaxone (0 – 384 µg/ml) 
on the rate of cefotaxime degradation. 
LREC460 was incubated with CRO (0 - 384 µg/ml) for 45 minutes prior to the 
supernatant incubation with CTX. Error bars indicate ± 1 standard deviation (n=4).  
6.3.  Discussion 
The current study demonstrated, by three different techniques, increased CTX 
degradation induced by the exposure to the 3rd generation cephalosporins, cefotaxime 
and ceftriaxone in field isolate LREC460 and lab strain AS19 transformed with 
recombinant plasmid pJBRCTX516. Cultures not exposed to β-lactams were shown to 
express β-lactamase, indicating a level of constitutive expression. A proportional, 
dose-dependent upregulation of β-lactamase was indicated by the quantification of the 
markers of β-lactamase CTX-M activity: nitrocefin degradation and cefotaxime 
degradation. This induced upregulation of blaCTX-M-15 was observed in both field isolate 
LREC460 and in AS19 transformed with recombinant plasmid pJBRCTX516, which 
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may suggest that the regulatory mechanism was not plasmid-borne. Further studies 
would be required to elucidate the nature of this inducible upregulation. 
Further information relating to the nature of such a regulatory mechanism could be 
obtained by investigation of blaCTX-M-15 transcripts with such methods as quantitative 
PCR, RNA-seq or micro-arrays in cultures exposed to a range of antibiotic conditions. 
Transcript data obtained, and combined with data obtained from β-lactamase protein 
quantification assays would potentially add to the understanding of this phenomenon.  
The likelihood of the presence of a regulation mechanism controlling differential 
expression of blaCTX-M-15 also presents a possibility of one or more attractive additional 
or alternative translational inhibition targets to increase sensitivity to CTX in resistant 
bacteria.  
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Chapter 7.   
Molecular 3D tetrahedral nanostructure vectors for targeted intracellular 
delivery of synthetic antisense/antigene agents in bacteria  
7.1.  Introduction 
As previously discussed, one of the greatest obstacles to the inhibition of bacterial gene 
expression via synthetic antisense oligomers is the efficient intracellular delivery of 
inhibitory agents. The bacterial cell wall complex presents a major obstacle to delivery 
of antisense oligomers into field and clinical isolates [119, 136] which necessitates an 
efficient delivery strategy.  Currently, a commonly used and effective delivery method 
is conjugation of a synthetic antisense molecule to a cell-penetrating peptide. However, 
the use of cell-penetrating peptides has certain significant associated problems such as 
their inherent toxicity to bacterial and mammalian cells. Additionally, the synthesis of 
the peptides and conjugation to antisense agents is presently an expensive and time 
consuming procedure, making it unlikely to be able to transition into a viable 
therapeutic option unless bulk production methods were able to significantly reduce 
costs. Resistance to cell-penetrating peptides have also been observed to arise, for 
example linked to mutations in a gene coding for the active transporter SbmA [143]. 
Most cell-penetrating peptides have also been shown to lack discriminatory ability with 
no specificity to any cell type having been shown [145], hindering its application as a 
carrier for therapeutic molecules. This is potentially a significant hindrance to the 
implementation of CPPs as a delivery mechanism for therapeutic cargo molecules to 
treat bacterial infections – antisense oligomers bound to cell-penetrating peptides will 
be delivered into any cell type, including those of the host organism, reducing the 
bioavailability of therapeutic agents available to the target bacteria, and potentially 
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causing unwanted negative effects on host organisms own cells.  Previous studies have 
found a synergistic effect of certain antibiotics with cell-penetrating peptides  [147] and 
an increase in bacterial cell wall permeability [158]. These studies may suggest cell wall 
disruption is a likely mechanism of cell penetration and would be a disadvantageous 
characteristic for the development of target-specific therapeutic agents. 
The current study developed a potential alternative delivery vehicle for synthetic 
antisense oligomers; a novel delivery mechanism based on self-assembling 3D DNA 
tetrahedral structures. Setyawati et al. (2014) reported that a tetrahedral DNA structure 
was able to traverse the bacterial gram-negative cell wall and enter the cytoplasm [185]. 
The DNA tetrahedron designed and assembled by Setyawati et al. (2014) was based on 
the assembly methods described by Pei et al. (2010) and was designed to be 
self-assembling based on regions of complementarity between single-stranded DNA 
(ssDNA) [168]. This DNA tetrahedron consisted of four 55-base ssDNA strands, each 
strand incorporating unique regions of complementarity with other strands resulting in, 
by Watson-Crick base pairing, the folding of the strands to form a stable 3-dimensional 
equilateral tetrahedron. 
Adapting this approach to the design and construction of 3D structures based on 
ssDNA, the current study designed one DNA tetrahedron to incorporate PNA4 
(13-mer), and two tetrahedrons of differing sizes to incorporate PMO1 (25-mer) as part 
of their intrinsic structures. The delivery of the synthetic antisense component of the 
tetrahedron after translocation across the bacterial cell wall relied upon the DNA 
components of the structure being degraded either wholly or partially by endonucleases 
upon entering the bacterial cytoplasm, releasing the synthetic antisense agent from the 
DNA tetrahedron. Assembled tetrahedral vector sizes are defined by their constituent 
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total numbers of base-pairs – for example a tetrahedron assembled from three ssDNA 
oligomers and one 25 nucleotide PMO was identified as a 50 bp tetrahedron. 
7.1.1.  Design of ssDNA sequences to self-assemble into 3D tetrahedron 
nanoparticles carrying antisense oligomers 
7.1.1.1.  Design of a 50 bp tetrahedron nanoparticle to carry a single 25-mer 
PMO 
A DNA/PMO tetrahedron was designed to self-assemble from three 25-base ssDNA 
strands and unmodified PMO1 (Figure 7-1). After self-assembly, this was designed to 
result in a tetrahedron of a total size of 50 bp, with each edge being 8-9 bp in length, 
and PMO1 forming one face. Each DNA strand was designed with unique 
complementary regions to regions on the other strands and to PMO1 to facilitate the 
formation of the 3D structure. ssDNA strands were checked for unwanted hetero and 
homo dimerisation with Multiple Primer Analyzer (ThermoFisher Scientific). 
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Figure 7-1. Design of a 50 bp tetrahedron nanoparticle to carry a single 25-mer PMO.  
Single-stranded DNA strands, DNA1, DNA2 and DNA3 were designed with unique 
regions of complementarity with each other ssDNA strand and PMO1 to form a 3D 
tetrahedron. Paired regions of 100% complementarity are shown in grey. Tick marks 
represent approximate positions of individual DNA/PMO bases. 
7.1.1.2.  Design of a 108 bp tetrahedron nanoparticle to carry a single 25-mer 
PMO 
A DNA/PMO tetrahedron was designed to self-assemble from three 54 nt ssDNA 
oligonucleotides, one 29 nt ssDNA oligonucleotide and unmodified PMO1. After 
self-assembly, this was designed to form a tetrahedron of a total size of 108 bp, with 
each edge being 18 bp in length, and PMO1 forming a portion of two faces (Figure 7-2). 
ssDNA oligonucleotides were checked for unwanted hetero and homo dimerisation with 
Multiple Primer Analyzer (ThermoFisher Scientific). 
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Figure 7-2. 108 bp tetrahedron design to carry one 25-mer PMO (PMO1). 
ssDNA strands, DNA1, DNA2, DNA3 and DNA4 were designed with unique regions of 
complementarity with each other ssDNA strand and PMO1 to form a 3D tetrahedron. 
Paired regions of 100% complementarity are shown in grey: DNA1 region ‘a’ pairs with 
DNA2 region ‘c’, DNA1 region ‘b’ pairs with DNA3 region ‘a’, DNA1 region ‘c’ pairs 
with DNA4 region ‘c’, PMO1 region ‘a’ pairs with DNA2 region ‘d’, PMO1 region ‘b’ 
pairs with DNA4 region ‘b’, DNA2 region ‘a’ pairs with DNA4 region ‘a’, DNA2 
region ‘b’ pairs with DNA3 region ‘b’, DNA3 region ‘c’ pairs with DNA4 region ‘d’. 
Tick marks represent approximate positions of individual DNA/PMO1 bases. 
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7.1.1.3.  Design of a 108 bp tetrahedron nanoparticle to carry a single 13-mer 
PNA (PNA4) 
A DNA/PNA tetrahedron was designed to self-assemble from three 54 nt ssDNA 
oligonucleotides, one 41 nt ssDNA oligonucleotide and one 13-mer PNA (unmodified 
PNA4). After self-assembly, this was designed to result in a tetrahedron with a total size 
of 108 bp, each edge being 18 bp in length, and PNA4 carried by a region of 
complementarity with DNA3 (Figure 7-3). ssDNA strands were checked for unwanted 
hetero and homo dimerisation with Multiple Primer Analyzer (ThermoFisher 
Scientific). Of the three tetrahedron designs evaluated in the current study, this uniquely 
did not require the antisense oligomer to bend to form the 3D structure (Figure 7-3; 
Figure 7-4).  
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Figure 7-3. 108 bp tetrahedron design to carry one 13-mer PNA (PNA4). 
ssDNA strands, DNA1, DNA2, DNA3 and DNA4 were designed with unique regions of 
complementarity with each other ssDNA strand and PNA4 to form a 3D tetrahedron. 
Paired regions of 100% complementarity are shown in grey. PNA4 was complementary 
to region C of DNA3. Tick marks represent approximate positions of individual 
DNA/PNA bases. 
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Figure 7-4. 3D diagram representing assembled PNA4-carrying DNA tetrahedron. 
Regions of each strand of ssDNA are complementary to a unique region on another 
DNA strand. The strands fold to form a rigid 3D structure. Unmodified PNA4 is carried 
by complementarity with DNA3 over the region shown. 
7.1.2.  Tetrahedron designations 
Three tetrahedron designs carrying anti-blaCTX-M-15 oligomers were designed and 
constructed, as discussed, and are summarised in Table 7-1.  
 
Table 7-1. Antisense oligomer-carrying DNA tetrahedron designs. 
Designation Antisense oligomer cargo 
Antisense oligomer 
length (nt) 
Tetrahedron 
Size (bp) 
PMOP PMO1 25 50 
CPMOP PMO1 25 108 
SPNAP PNA4 13 108 
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7.2.  Results 
7.2.1.  Verification of assembly of tetrahedron by agarose gel electrophoresis 
Assembly of the tetrahedrons were verified by visualisation of DNA by agarose gel 
electrophoresis.  Component ssDNA strands, and combinations of strands annealed 
under the same conditions as described in the tetrahedron assembly protocol, were 
loaded in separate lanes, e.g. DNA1 + DNA2, DNA1 + DNA2 + DNA3, DNA1 + 
DNA2 + DNA3 + DNA4 + PNA4, and analysed for size by gel electrophoresis. The 
results suggested that the strands annealed to form progressively larger DNA complexes 
with the additional tetrahedron components; when visualised by gel electrophoresis, the 
reaction mixture comprising of all components necessary for tetrahedron formation 
yielded a single discreet band, in a position on the gel to indicate a larger DNA 
molecule than the component parts, and of approximately the expected size (Figure 
7-5). 
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Figure 7-5. Gel showing relative sizes of tetrahedron (SPNAP; 108 bp) component 
parts, partial assembly, and full assembly. 
Lane 1: Promega 100bp DNA ladder. Lane 2: DNA1. Lane 3: DNA2. Lane 4: DNA3. 
Lane 5: DNA4. Lane 6: DNA1 + DNA2. Lane 7: DNA1 + DNA2 + DNA3. Lane 8: 
DNA1 + DNA2 + DNA3 + DNA4 + PNA4 (complete tetrahedron (SPNAP) assembly). 
Lane 9: Promega 100 bp DNA ladder. 
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7.2.2.  Increase in sensitivity of E. coli strains to CTX when co-administered with 
50 bp PMO1-carrying tetrahedron PMOP 
E. coli strains AS19/pJBRCTX516 and field isolate LREC460 were challenged with 
CTX, 50 bp PMO1-carrying tetrahedron PMOP, and both in combination. No 
significant effects of PMOP were observed on LREC460 growth when treated in 
combination with CTX (not shown). Atypically permeable strain AS19, transformed 
with pJBRCTX516 was challenged with PMOP alone, CTX alone and PMOP and CTX 
in combination. No significant effects were observed in cultures incubated with PMOP 
or PMO1 alone (10-20 µM; Figure 7-6; Figure 7-7). Cultures incubated with CTX 
concentrations of 32 µg/ml and 64 µg/ml had a significant (p < 0.05) negative effect on 
growth - the lag phase was observed to be significantly longer in duration than that of 
the sample with no antibiotic – early log phase (O.D. 600 nm > 0.1) was reached in the 
culture with no antibiotic in 4.6 - 5.25 hours, when cultured in the presence of 32 µg/ml 
CTX this increased to 10.8 hours, when cultured in the presence of 64 µg/ml CTX this 
increased to 12.4 hours. This effect was further increased in cultures incubated in the 
presence of both CTX (64 µg/ml) and PMOP (10 µM; Figure 7-6), and the combination 
of CTX concentration of 32 µg/ml and PMOP of 20 µM was sufficient to completely 
inhibit growth (Figure 7-7). The inhibitory effect of CTX (32 µg/ml and 64 µg/ml) in 
the presence of PMOP was greater than that of PMO1.  
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Figure 7-6. Effects of CTX, PMO1 and PMOP on AS19/pJBRCTX516 growth. 
Growth curves showing effect on growth of atypically permeable E. coli strain AS19 
harbouring blaCTX-M-15-carrying plasmid pJBRCTX516 incubated with CTX, PMO1 and 
PMO1 carried by tetrahedron PMOP. Solid line: CTX (0 µg/ml), dashed line: CTX 
(0 µg/ml) + PMOP (10 µM), dotted line (partially obscured by thick solid line): CTX 
(0 µg/ml) + PMO1 (10 µM), thin solid line: CTX (64 µg/ml), thin dashed line: CTX (64 
µg/ml) + PMO1 (10 µM), thin dotted line: CTX (64 µg/ml) + PMOP (10 µM). Error 
bars indicate +/- 1 standard deviation (n=2). 
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Figure 7-7. Effects of CTX, PMO1 and PMOP on AS19/pJBRCTX516 growth. 
Growth curves showing effect on growth of atypically permeable E. coli strain 
harbouring blaCTX-M-15-carrying plasmid incubated with CTX, PMO1 and PMO1 carried 
by tetrahedron PMOP. Solid line: CTX (0 µg/ml), dashed line: CTX (0 µg/ml) + PMOP 
(20 µM), dotted line: CTX (0 µg/ml) + PMO1 (20 µM), thin solid line: CTX 
(32 µg/ml), thin dashed line: CTX (32 µg/ml) + PMO1 (20 µM), thin dotted line (no 
growth): CTX (32 µg/ml) + PMOP (20 µM). Error bars indicate +/- 1 standard deviation 
(n=3). 
7.2.3.  Increase in sensitivity of E. coli field isolate LREC461 to CTX when 
co-administered with 108 bp PMO-carrying tetrahedron CPMOP 
E. coli field isolate LREC461 carrying plasmid pEK204 which harboured blaCTX-M-3, 
was incubated in MHB supplemented with 108 bp DNA tetrahedron, CPMOP, carrying 
25-mer PMO1 (10 - 30 µM), and CTX (16 µg/ml). Growth was inhibited in a dose 
dependant manner (10 - 30 µM), completely inhibited at 30 µM (Figure 7-8). There 
were no observable inhibitory effects on growth when treated with CPMOP alone. 
Page 208 
 
Figure 7-8. Effects of the combination of CTX and CPMOP on the growth of field 
isolate LREC461. 
Growth curves showing effect on growth of field isolate LREC461 incubated with CTX 
and PMO1 carried by tetrahedron CPMOP. Solid line: CTX (16 µg/ml), dashed line: 
CTX (16 µg/ml) + CPMOP (10 µM), dotted line: CTX (16 µg/ml) + CPMOP (20 µM), 
dash-dot line (no growth): CTX (16 µg/ml) + CPMOP (30 µM). Error bars indicate +/- 
1 standard deviation (n=2). 
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7.2.4.  Increase in sensitivity of E. coli field isolate LREC461 to CTX when 
co-administered with 108 bp PNA-carrying tetrahedron SPNAP 
Field isolate LREC461 was challenged with a combination of CTX (16 µg/ml) and 
SPNAP (0 – 40 µM), and a synergistic (FICI < 0.5) dose dependant effect was 
observed, evidenced by the increasing the amount of time taken for cells to achieve 
logarithmic growth (Figure 7-9). 
 
Figure 7-9. Effects of CTX and SPNAP on growth of field isolate LREC461. 
Growth curves showing effect on growth of field isolate LREC461 incubated with CTX 
and PNA4 carried by tetrahedron SPNAP. Thick solid line: CTX (0 µg/ml), thin solid 
line: CTX (16 µg/ml), dashed line: CTX (16 µg/ml) + SPNAP (10 µM), dotted line: 
CTX (16 µg/ml) + SPNAP (20 µM), dash-dot line: CTX (16 µg/ml) + SPNAP (30 µM), 
dash-dot-dot line: CTX (16 µg/ml) + SPNAP (40 µM). Error bars indicate +/- 1 
standard deviation (n=2). 
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LREC461 was cultured in the absence of CTX, and in the presence of 108 bp 
PNA4-carrying tetrahedron, SPNAP (10 – 30 µM), no significant effects were observed 
(Figure 7-10). 
 
Figure 7-10. Effect of SPNAP on growth of field isolate LREC461 in the absence of 
CTX. 
Growth curves showing lack of effect on growth of field isolate LREC461 incubated 
with PNA4-carrying tetrahedron SPNAP. Solid line: no culture supplements, dashed 
line: SPNAP (10 µM), dotted line: SPNAP tetrahedron (20 µM), dash-dot line: SPNAP 
tetrahedron (30 µM). Error bars indicate +/- 1 standard deviation (n=2). 
A control DNA tetrahedron was assembled substituting a 13 nt ssDNA oligonucleotide 
for PNA4. The 13 nt ssDNA strand shared 100% sequence identity with PNA4 and the 
DNA tetrahedron was assembled using the components DNA1-DNA4 (Figure 7-3).  No 
significant negative effects on growth were observed when field isolate LREC461 was 
cultured in the presence of the DNA control tetrahedron (10 – 30 µM; Figure 7-11).  
Page 211 
 
Figure 7-11. Effect of DNA control tetrahedron on growth of field isolate LREC461. 
Growth curves showing effect on growth of field isolate LREC461 incubated with 
control DNA tetrahedron. Solid line: no culture supplements, dashed line: DNA control 
tetrahedron (10 µM), dotted line: DNA control tetrahedron (20 µM), dash-dot line: 
DNA control tetrahedron (30 µM). Error bars indicate ± 1 standard deviation (n=2).  
Small but significant negative effects on growth were observed when field isolate 
LREC461 was cultured in the presence of the DNA control tetrahedron (10 µM) and 
CTX (16 µg/ml) (Figure 7-12). An atypically high sensitivity to CTX (16 µg/ml) alone 
was observed in this instance, potentially as a result of a low bacterial cell count present 
in the culture. Attempts were made with each experiment to normalise the number of 
colony-forming units to 100,000 CFU/ml; colony counts after overnight incubation on 
LB agar revealed the amount present on this occasion to be 40,000 CFU/ml. 
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Figure 7-12. Effects of DNA control tetrahedron and SPNAP on LREC461 growth in 
the presence of CTX. 
Growth curves showing effect on growth of field isolate LREC461 incubated with 
control DNA tetrahedron and SPNAP. Solid line: CTX (16 µg/ml), dashed line: DNA 
control tetrahedron (10 µM) + CTX (16 µg/ml), dotted line (no growth): SPNAP 
(10 µM) + CTX (16 µg/ml). Error bars indicate ± 1 standard deviation (n=2). 
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7.3.  Discussion  
The current study demonstrated the potential application of three variations of a DNA 
tetrahedron to deliver antisense agents within a bacterial cell using complementary base 
pairing approach. The antisense oligomers available for initial evaluation of delivery 
vehicle efficacy were the unmodified anti-blaCTX-M PMO1 and PNA4 used throughout 
the current study (see Table 2-3 for sequences). The use of these antisense oligomers 
also provided direct comparison of blaCTX-M-15 expression inhibition by antisense 
oligomers carried by a DNA tetrahedron with the more conventional cell-penetrating 
peptide conjugate delivery strategy. 
A CTX potentiating effect was observed when AS19/pJBRCTX516 was incubated in 
the presence of CTX (32 µg/ml and 64 µg/ml) and 50 bp DNA/PMO1 tetrahedron, 
PMOP (10 µM and 20 µM). The effect size of the combination of CTX and tetrahedron 
was greater than that of the combination of CTX and PMO1 under the same conditions, 
suggesting that although AS19/pJBRCTX516 exhibited an atypically permeable 
phenotype, PMO1 carried in a tetrahedron structure achieved a greater level of cell wall 
penetration and cytoplasmic accumulation, resulting in a higher level of blaCTX-M-15 
expression inhibition and CTX re-sensitisation. A small inhibitory effect was observed 
(not shown) under similar conditions in isolates with typically permeable cell walls.  
Potentiation of CTX, in a dose dependent manner, was observed when field isolate 
LREC461, harbouring blaCTX-M-3, was incubated in the presence of CTX and the 108 bp 
tetrahedron, CPOMP, carrying PMO1. A dose dependent effect of greater size was 
observed when field isolate LREC461 was incubated in the presence of the combination 
of CTX and SPNAP; LREC461 was significantly more sensitive to CTX in the presence 
of SPNAP than CPMOP. 
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A control DNA tetrahedron was constructed, substituting ssDNA, of the same sequence, 
for the antisense oligomer. There were no observable effects in field isolates incubated 
in the presence of a DNA control tetrahedron in the absence of CTX. In the presence of 
CTX and DNA control tetrahedron combination, a small increase in CTX sensitivity 
was observed, possibly due to opportunistic co-translocation of CTX with the control 
DNA tetrahedron. Control data suggests no inherent antimicrobial properties of the 
structure and may indicate that membrane perturbation was not the primary mechanism 
of cell penetration.  
The observed re-sensitisation of field isolates to previously sub-lethal concentrations of 
CTX suggest that this DNA tetrahedron design penetrates a bacterial cell wall and 
delivers its cargo, which is able to specifically bind to its target and inhibit protein 
expression. Tetrahedron CPMOP had no observable inhibitory effects on cell growth 
when cells were treated in the absence of antibiotics. No significant inhibitory effects 
were observed when field isolate LREC461 was treated with PNA4-carrying 
tetrahedron SPNAP in the absence of CTX. This was not expected as PNA4 had been 
previously observed to exhibit dose-dependent inhibitory effects. Further studies are 
required to verify and elucidate this initial observation. 
The CTX-sensitising effects of both CPMOP and SPNAP were smaller than the 
equivalent peptide-conjugated antisense oligomers, potentially suggesting a less 
efficient penetration ability of the tetrahedron. However, the cell-penetrating peptide 
portion of the CPP-antisense oligomer conjugate, (KFF)3K, has been previously shown 
to have a synergistic effect with certain antibiotics [147, 158], and some potential 
inherent toxicity (this study). In addition, E. coli cell permeabilisation has been shown 
to be reduced in the presence of MgCl2 [158]. As the current study annealed the 
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tetrahedron components in an MgCl2-rich (50 mM) buffer, further studies are required 
to determine any significant increased cell penetrating efficacy of antisense agent-
carrying tetrahedral structures either annealed in the absence of MgCl2, or of 
tetrahedrons purified after assembly. 
Further studies are required to determine the range of bacterial strains susceptible to 
antisense oligomer mediated protein expression inhibition carried by DNA tetrahedrons. 
The mechanism of cellular uptake of DNA tetrahedrons in bacteria is presently unclear, 
although the lack of effect on cell growth of isolates challenged with a tetrahedron alone 
may suggest that the mechanism of penetration does not involve the disruption of the 
cell wall. A range of influx mutants could be generated and employed to investigate an 
active transport mechanism.  
The size of the tetrahedron would appear to have a large effect on penetration efficacy – 
a marked increase in the inhibitory ability of the PMO was observed when increasing 
the length of each edge from 8 to 18 bp. This would suggest further optimisation 
potential. Both size and shape of 3D DNA structures would appear to be of great 
importance in their ability to enter a bacterial cell. It may be advantageous to design and 
construct a range of DNA 3D structures of differing dimensions and shape, 
incorporating quantifiable and observable markers, to determine the optimal structure 
for use as a synthetic antisense oligomer delivery vehicle.  
In addition, the design of the DNA tetrahedron allows for the incorporation of multiple 
antisense molecules, potentially up to three 15-mer PNAs could be incorporated into a 
single 108 bp tetrahedron without significant reduction of structural integrity. Each 
PNA could potentially target a different gene transcript, allowing for inhibition of the 
expression of multiple genes with a single therapeutic molecule. 
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Studies to investigate the discriminatory potential of tetrahedral delivery vehicles would 
also be advantageous – cell-penetrating peptides commonly lack specificity for any cell 
types. A 108 bp 25-mer PMO-carrying tetrahedron was designed and constructed to 
carry an anti-dystrophin PMO, and found to have no observable effects in murine cell 
lines (L. Popplewell, pers. comm.). Although more data is required, this could suggest a 
degree of specificity to bacterial cells. This lack of observable effect in murine cells, 
combined with the lack of effect observed with control tetrahedrons in E. coli field 
isolates could implicate a non-membrane disruptive mechanism of cell penetration. A 
delivery vector that was specific to bacterial cells and did not have inherent negative 
effects on cell growth would be highly desirable characteristics for a targeted vector.  
With a demonstrated ability to both penetrate a bacterial cell wall and deliver an active 
synthetic antisense oligomer, this approach has a large range of optimisation options, 
and a variety of potential applications. The low cost, simplicity and speed of assembly 
would appear to make this a potentially viable alternative antisense oligomer delivery 
vehicle. 
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Chapter 8.   
Discussion, future work and conclusions 
8.1.  Discussion 
The application of antisense oligomers for the targeted inhibition of the expression of 
specific genes that confer resistance to extended-spectrum β-lactam antibiotics is an 
attractive strategy for the restoration of antimicrobial sensitivity.  PMO and PNA 
chemistries have both been successfully employed previously to inhibit bacterial protein 
expression in a targeted, sequence-specific manner [186]. A wide range of bacterial 
gene transcripts have been targeted and inhibited by synthetic antisense oligomers. For 
example, a 17-mer PNA was reported by Lecosnier et al. in 2011 to inhibit 
anti-insulin-like growth factor 1 receptor (IGF-1R) by 70-80% [118]. Geller et al. found 
that an 11-mer PMO significantly inhibited the viability E. coli through targeted 
inhibition of an essential gene (acpP) for phospholipid biosynthesis [127]. 
The current study designed and evaluated PMO and PNA antisense/antigene oligomers 
for effective reduction of a range of CTX-M group 1 β-lactamases. Anti-blaCTX-M 
antisense oligomers, three 13-mer PNAs and one 25-mer PMO, were designed and 
synthesised to target mRNA Shine-Dalgarno and start codon regions, having previously 
been shown to be the regions most susceptible for protein expression inhibition. 
β-Lactamase activity inhibition was demonstrated by the quantification cefotaxime 
degradation in a variety of systems including: a cell free transcription/translation assay 
using recombinant plasmids (pJBRCTX499 and pJBRCTX516) with a high amplitude 
promoter harbouring a CTX-M-15 gene, in a cell wall compromised mutant E. coli 
strain (AS19/pJBRCTX516) also containing this recombinant plasmid, and in a panel of 
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field isolates whose group 1 CTX-M plasmids had been previously sequenced (Table 
2-1).  
Bacterial cell wall penetration and delivery of antisense oligomers into field and clinical 
isolates with intact cell walls was accomplished by the use of the cell-penetrating 
peptide (KFF)3K as a carrier molecule, and by the development of a novel delivery 
vector.  
8.1.1.  Inhibition of β-lactamase expression in a cell-free 
translation/transcription coupled system 
In cell-free studies using constructed plasmid pJBRCTX516, harbouring a single copy 
of blaCTX-M-15, as the DNA template, PMO1 was observed to inhibit the expression of 
β-lactamase in a dose-dependent (50 - 1000 nM) manner. Neither a 25 nt scrambled 
control PMO, nor a 25 nt control PMO targeting an unrelated human (dystrophin) 
mRNA, was observed to have any inhibitory effects on β-lactamase expression. The 
control PMOs shared no sequence identity with any bacterial gene or transcript 
sequence. These data suggested high sequence specific inhibitory properties of 
anti-blaCTX-M PMO1. 
The inhibition of β-lactamase expression was also observed in a translation/transcription 
coupled system when pJBRCTX516 was incubated in the presence of PNAs 1, 3 and 4. 
Maximum observed β-lactamase activity inhibition amounts were: PNA1 (1000 nM)  – 
96%, PNA3 (1000 nM)  – 84% and PNA4 (1000 nM)  – 89% (Figure 8-1). As 
previously discussed herein, PMO1 and PNA4 were selected as the antisense oligomers 
of maximum interest for subsequent studies (Chapter 5). 
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8.1.2.  Increase in sensitivity of cell wall compromised mutant strain 
AS19/pJBRCTX516 to CTX when co-administered with PMO1   
In live cells, the β-lactamase expression inhibition properties of PMO1 were first 
evaluated using the atypically permeable cell-wall mutant E. coli strain AS19 
transformed with pJBRCTX516 harbouring blaCTX-M-15.  Specific anti-blaCTX-M-15 
activity was demonstrated by the combination of an observation of a cefotaxime 
potentiating effect of PMO1, a lack of effect on growth of control PMOs, and of an 
observation of no effect on growth when cultures were incubated in the presence of 
PMO1 and in the absence of cefotaxime. When cultured in the presence of both 
cefotaxime and PMO1, increased antibiotic sensitivity was observed in a dose-
dependent manner (5 – 40 nM). The typical minimum inhibitory concentration of 
cefotaxime for this transformant was 80 µg/ml. In the presence of PMO1 (40 µM), the 
minimum inhibitory concentration was reduced to 4 µg/ml. These data demonstrated the 
lack of any inherent toxicity of PMO1 at the concentrations used, and the specific 
activity of PMO1 against blaCTX-M-15.  
8.1.3.  Increase in sensitivity of cell wall compromised mutant strain 
AS19/pJBRCTX516 to CTX when co-administered with PNA4   
A dose-dependent effect of increasing the CTX sensitivity of AS19/pJBRCTX516 was 
observed when cultured in the presence of PNA4. This effect was greater than that of 
PMO1, with a PNA concentration of 20 µM required to reduce the MIC (to CTX) of 
AS19/pJBRCTX516 from 80 µg/ml to 4 µg/ml. However, a significant (p < 0.0001) 
negative effect on growth was observed when AS19/pJBRCTX516 was cultured in the 
presence of PNA4 alone (> 10 µM) suggesting either inherent toxicity of PNA4 or the 
effect of off-target sequence similarity.  
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As previously noted, a smaller antisense molecule with fewer bases naturally leads to a 
greater risk of a lack of specificity, with more sequences likely to share partial sequence 
identity. This risk is increased when the target area is extra-genic, as is the case with 
PNA4, where regions are likely to be conserved. A BLAST search revealed that the 
region targeted by PNA4 shared 11 and 12 consecutive bases of the total 13, of genes 
coding for condesin subunit F, and NADH:ubiquinone oxidoreductase respectively. 
Both of these genes play essential roles in E. coli, and this is a likely explanation of the 
observed negative effect on growth when field isolates were challenged with PNA4 
alone. The negative effects of putative off-target sequence identity were insufficient to 
inhibit growth in any field isolate tested up to 40 µM, and the effects of cefotaxime and 
PNA4 were shown to be strongly synergistic suggesting that β-lactamase was the 
primary and preferential target of PNA4. The negative effects of growth of cultures 
incubated in the presence of PNA4 alone at concentrations of 5 µM and lower, were not 
significantly (p = 0.2524) different from control cultures grown in the absence of PNA4. 
8.1.4.  Increase in sensitivity of field and clinical isolates to CTX when 
co-administered with peptide conjugated PMO1 and PNA4   
No effect on cefotaxime sensitivity was observed when field isolate LREC461 carrying 
resistance plasmid pEK204 harbouring blaCTX-M-3 was cultured in the presence of the 
PMO1 (5 – 20 µM) or PNA4 (5 – 40 µM). This was not unexpected as previous studies 
have shown that E. coli with an intact cell wall do not efficiently take up PMOs [119]. 
To overcome this barrier, anti-blaCTX-M PMO1 and PNA4 were covalently bound to the 
cell-penetrating peptide, (KFF)3K, which has been shown to be effective in promoting 
uptake across the bacterial cell wall and delivering a cargo molecule into the cytoplasm 
[121, 158]. 
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A panel of field isolates and clinical E. coli strains, each harbouring a β-lactamase-
producing gene from CTX-M-group 1 was challenged with a combination of peptide-
conjugated antisense agent and cefotaxime. All isolates tested showed an increased 
sensitivity to CTX when treated with P-PMO1 or P-PNA4 ranging from a reduction in 
the MIC (to CTX) of blaCTX-M-3-harbouring E. coli strain LREC461 from 35 µg/ml to 
16 µg/ml (P-PMO1, 30 µM), to E. coli strain LREC454 harbouring blaCTX-M-15 from 
110 µg/ml to 2 µg/ml (P-PNA4, 3.2 µM; Table 5-3).  
The CTX re-sensitising effectiveness of P-PNA4 ranged from 9 to 56-fold greater than 
that of P-PMO1. There were no significant effects of P-PNA4 alone at concentrations of 
less than 5 µM although at higher concentrations (> 10 µM), in the absence of 
cefotaxime, P-PNA4 significantly inhibited the growth of field isolates. The reason for 
the greater effect of P-PNA4 over P-PMO1 remains unclear, although the higher 
binding strength of PNAs enables a smaller molecule, potentially facilitating more 
efficient cell penetration. It would be reasonable to suggest that a smaller molecule is 
able to penetrate the bacterial cell wall more efficiently than a larger molecule, and 
further studies would be useful to clarify if this is indeed the case. The data obtained 
from cell-free studies in a translation/transcription coupled system, thus removing the 
cell wall penetration obstacles, demonstrated that PMO1 inhibited β-lactamase 
expression more efficiently than any PNA tested. This may suggest that size, and thus 
penetration efficiency in live cells, is a significant contributory factor to the efficacy of 
bacterial gene expression inhibition with antisense oligomers. The ability of PNAs to 
form complexes with double-stranded DNA has been previously described and 
demonstrated [117], potentially also contributing to the overall larger observed effect of 
P-PNA4 over P-PMO1. Further studies would be needed to elucidate this situation 
further. 
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Control studies using P-PMO1 and P-PNA4 in the presence and absence of CTX in 
strain LREC90 harbouring blaCTX-M-14, to which anti-blaCTX-M-15 P-PMO1 and P-PNA4 
had only partial sequence complementarity, revealed no synergistic relationship with 
CTX. In addition, when strains harbouring blaCTX-M-15 were challenged with P-PMO1 
and P-PNA4 alone, a comparable effect size to that shown in LREC90 was observed. 
Previously sub-lethal concentrations of CTX were sufficient to completely inhibit 
growth of these group 1 strains when in the presence of P-PMO1 or P-PNA4 at 
concentrations observed to have small or insignificant effects alone. 
8.2.  β-Lactam induced upregulation of β-lactamase activity in AS19/pJBRCTX516 
and field isolates 
Studies in a cell-free environment demonstrated the abilities of antisense oligomers to 
completely inhibit the expression of blaCTX-M-15 (100% at a PMO1 concentration of 1000 
nM) under certain conditions. It was therefore unexpected that a restoration of CTX 
sensitivity to a comparable level to that of the CTX sensitive host parental strain (AS19; 
1- 2 µg/ml) was not observed in E. coli strain AS19/pJBRCTX516 when treated with 
relatively high concentrations of PMO1 (40 µM) or PNA4 (20 µM).  
The current study provided experimental evidence to suggest that in conditions of 
increasing concentrations of CTX, in both field isolates and AS19/pJBRCTX516 there 
is a proportional upregulation of β-lactamase activity. This would appear to present an 
obstacle to be overcome in the goal of the restoration of sensitivity to 3rd generation 
cephalosporin antibiotics in bacteria with a phenotype of reduced susceptibility. The 
differential expression mechanism is presently unclear and requires further study. 
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8.3.  Molecular bacterial intracellular delivery vectors for targeted synthetic 
antisense/antigene agents 
The current study designed and developed a self-assembling 3D tetrahedral novel vector 
for the transportation of antisense oligomers across the cell wall of E .coli field isolate 
LREC461. This vector had the advantages of being quick, inexpensive and simple to 
assemble, and had no observable inherent toxic properties in the field isolates tested. A 
dose-dependent effect (10 – 30 µM) of increasing CTX sensitivity was observed, and 
there was no effect on growth when field isolates were treated with a control 
tetrahedron. The data presented in the current study (the combined effects of CTX and 
SPNAP on culture growth of field isolate LREC461, and the lack of any significant 
effects of SPNAP alone) suggest that the tetrahedral vector was successful in delivering 
its cargo to the bacterial cytoplasm. Further studies, such as the labelling of the 
tetrahedron with a quantifiable reporter molecule, are required to verify this. 
The use of the tetrahedral DNA vector as a carrier for the antisense oligomers PMO1 
and PNA4 provided a comparison of efficacy with the same antisense oligomers 
conjugated to the cell-penetrating peptide (KFF)3K. The smaller effect of the PNA or 
PMO carried by the tetrahedron compared with the same PNA or PMO carried by a 
cell-penetrating peptide, suggest that further optimisation of the tetrahedron is required. 
However, the cell-penetrating peptide, (KFF)3K, has been shown to have some inherent 
bacterial toxicity, and also have a synergistic effect with certain antibiotics [147]. The 
contribution of the peptide portion of the P-PMO1 and P-PNA4 conjugates to the 
overall negative effects on bacterial growth in the current study make a direct 
comparison between antisense oligomers carried by a tetrahedron (which in the absence 
of CTX had no observable effects on growth) and those carried by (KFF)3K difficult, 
and further studies would be required to separate the effect sizes of the component parts. 
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8.4.  Future Work 
8.4.1.  Optimisation of anti-blaCTX-M-15 synthetic antisense sequences 
There would appear to be scope for optimisation and enhancements of the effects of the 
anti-blaCTX-M PMO and PNAs by alterations to the mRNA target area and lengths of 
antisense oligomers. Due to operational constraints, it was not possible to design and 
synthesise a series of tiled PNAs and PMOs to span a larger region of blaCTX-M mRNA. 
As previous studies had indicated that the most effective areas to target for efficient 
protein inhibition were the start codon region and the SD region, three PNAs and one 
PMO were targeted to that region. The results from the current study demonstrated a 
greater effect size of PNA over PMO in inhibiting the expression of β-lactamase in field 
isolates and the atypically permeable strain AS19, although as they differed in both 
length and target region they were not directly comparable. 
In cell-free studies, the β-lactamase inhibitory effect of the three PNAs varied from 84% 
inhibition (PNA3, 1000 nM) to 96% inhibition (PNA1; 1000 nM; Figure 8-1). This 
suggests that small changes in the PNA sequence and hence the region result in a large 
effect on the ultimate effect of the inhibitory agents. 
 
 
Figure 8-1. β-Lactamase activity inhibition by PNA1 (1000 nM), PNA3 (1000 nM) and 
PNA4 (1000 nM) in a cell-free translation/transcription coupled system. 
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It is possible that a refinement of the PNA target region design and size would yield 
greater inhibitory efficiency. Further PNA designs targeting the start codon and 
extending downstream would also be likely to yield greater specificity and reduce 
off-target hybridisation. 
8.4.2.  Potential complementary/additional genetic targets in addition to blaCTX-M 
for translational inhibition by antisense oligomers to increase sensitivity to CTX in 
resistant E. coli strains 
Having demonstrated the β-lactam induced upregulation of β-lactamase, the potential 
exists to enhance and complement the effect of re-sensitising E. coli strains to CTX by 
inhibiting the expression of other related genes. The mechanism by which blaCTX-M is 
upregulated in the presence of 3rd generation cephalosporins is currently unclear, 
however, a similar mechanism to the previously described ampicillin peptide dependent 
repressor release system may be a potential candidate for investigation [181]. The gene 
for a muro-peptide permease (ampG) or, potentially, the regulatory gene ampR [182] 
may thus be an attractive potential target for additional inhibition by antisense 
oligomers, which could potentially complement and enhance the effects of blaCTX-M 
inhibition.  
β-Lactam antibiotics, inhibiting the formation of cross-links between components of the 
peptidoglycan layer, and thus inhibiting the formation of the cell wall, have a 
bactericidal effect on dividing cells only. In the presence of a β-lactam antibiotic, upon 
detection of an inhibition of cell wall synthesis, the SOS response is induced [187, 188], 
extending the static non-dividing phase and arresting the growth phase of the cell cycle 
as part of its defensive mechanism. An antisense inhibition strategy targeting genes 
responsible for the detection of cell-wall damage, such as muropeptide transporters for 
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example, co-administered with a β-lactamase antisense inhibition agent could 
potentially greatly increase the effect of a β-lactamase inhibitor/β-lactam antibiotic 
combination. 
A receptor identified as directly recognising β-lactam antibiotics and inducing the 
expression of β-lactamase in Vibrio parahaemolyticus [184] may suggest the possibility 
of a related receptor in other species, which could also prove an attractive target for 
expression inhibition with a goal of restoring antibiotic sensitivity. 
8.4.3.  Further development of self-assembling DNA based delivery vehicles for 
synthetic antisense agents 
Initial studies with a DNA tetrahedron as a carrier for antisense agents were successful 
in increasing sensitivity of field isolates to CTX in field isolates, and there is potential 
for further development. As previously noted, E. coli cell permeabilisation has been 
shown to be reduced in the presence of MgCl2 [158], which is a component of the 
tetrahedron annealing buffer (50 mM). An alternative annealing buffer or a tetrahedron 
purification step may yield higher cell penetration efficacy. 
 The tetrahedron observed to be most efficacious in increasing CTX sensitivity in field 
isolate LREC461, was the 13-mer PNA-carrying 108 bp tetrahedron SPNAP. This 
tetrahedron could potentially incorporate an additional PNA into its design whilst still 
maintaining structural integrity and rigidity (Figure 8-2). This structure could 
incorporate either two PNAs of the same design to increase its overall PNA 
concentration, or two different PNAs with separate targets. In the case of restoring 
β-lactam sensitivity, for example, this tetrahedron design could incorporate one PNA to 
target and inhibit the expression of β-lactamase and another to inhibit the expression of 
a muro-peptide transporter. This approach could potentially result in a single therapeutic 
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agent with dual complementary targets to achieve an enhanced effect on the inhibition 
of the expression of β-lactamase. 
 
 
 
 
Figure 8-2. Illustrative structural design diagram of DNA tetrahedron to carry two 
13-mer PNA antisense oligomers. 
Proposed design of tetrahedron incorporating two PNA oligomers to target two 
genes/transcripts simultaneously. Complementary base-pairing regions are shown in 
grey (refer to Table 8-1). Tick marks represent approximate positions of individual 
DNA/PNA bases. 
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Table 8-1. Regions of complementarity between regions of proposed 2-PNA DNA 
tetrahedron before self-assembly. 
This table provides a key to the regions of complementarity shown in  
Figure 8-2. 
  Regions of complementarity 
  DNA2 DNA3 DNA4 PNA1 PNA2 
DN
A1
 
a  a    
b c     
c     All 
d b     
e   b   
DN
A2
 
a   c   
d  e    
DN
A3
 b   a   
c    All  
d   d   
 
Further optimisation of the tetrahedral antisense oligomer vehicle could include studies 
into relative penetration efficiencies of varying sizes and shapes. The current study 
constructed two size variations of an equilateral tetrahedron. Further investigation 
would be required to ascertain the optimum size and shape for maximum penetration 
efficiency. 
The penetration mechanism of the tetrahedron is currently unclear, and it is not yet 
known if it is discriminatory, again, further studies are required to elucidate this. Initial 
studies with mammalian cells suggested that a 108 bp PMO-carrying tetrahedron was 
unable to cross the cell membrane. This may suggest bacterial discriminatory potential, 
and could implicate a specific bacterial receptor-mediated uptake mechanism. Further 
studies are required. 
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8.5.  Conclusions 
The current study designed and developed synthetic antisense oligomers to inhibit the 
expression of β-lactamase and restore sensitivity in E. coli strains with a phenotype of 
reduced-susceptibility. Sensitivity was increased in field and clinical isolates, and these 
are the first studies to show a re-sensitisation to third generation cephalosporins of these 
strains. 
The data obtained from inhibition studies of blaCTX-M in field isolates, and the potential 
for further optimisation and enhancement, demonstrated the potential for therapeutic use 
of P-PMOs and P-PNAs in re-sensitising resistant bacteria to CTX.  
The development of a tetrahedral nucleic acid nanoparticle vector for the delivery of 
PNAs and PMOs further increases the potential of antisense biotechnology for 
diagnostic, research and therapeutic applications.  
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Appendix A 
 
  
Figure A-1. Growth curves showing effects of P-PMO1 (30 µM) and CTX (24 µg/ml) 
on field isolate LREC454 harbouring blaCTX-M-15. 
LREC454 incubated with CTX (24 µg/ml) and P-PMO1 (30 µM). Solid line: control, 
dashed line: CTX (24 µg/ml), dotted line: CTX (24 µg/ml) + P-PMO1 (30 µM). Error 
bars indicate ± 1 standard deviation (n=2). 
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Figure A-2. Growth curves showing effects of P-PNA4 (3.2 µM) and CTX (2 µg/ml) on 
field isolate LREC454 harbouring blaCTX-M-15. 
LREC454 incubated with CTX (2 µg/ml) and P-PNA4 (3.2 µM). Solid line: control, 
dashed line: CTX (2 µg/ml), dotted line: P-PNA4 (3.2 µM), dash-dot line: CTX 
(2 µg/ml) + P-PNA4 (3.2 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure A-3. Growth curves showing effects of P-PNA4 (3.2 µM) and CTX (24 µg/ml) 
on field isolate LREC460 harbouring blaCTX-M-15. 
LREC460 incubated with CTX (24 µg/ml) and P-PNA4 (3.2 µM). Solid line: control, 
dashed line: CTX (24 µg/ml), dotted line: P-PNA4 (3.2 µM), dash-dot line: CTX 
(24 µg/ml) + P-PNA4 (3.2 µM). Error bars indicate ± 1 standard deviation (n=3). 
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Figure A-4. Growth curves showing effect of P-PMO1 (40 µM) and CTX (32 µg/ml) on 
field isolate LREC460 harbouring blaCTX-M-15. 
LREC460 incubated with CTX (32 µg/ml) and P-PMO1 (40 µM). Solid line: control, 
dashed line: CTX (32 µg/ml), dotted line: CTX (32 µg/ml) + P-PMO1 (40 µM). Error 
bars indicate ± 1 standard deviation (n=3). 
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Figure A-5. Growth curves showing effects of P-PMO1 (30 µM) and CTX (16 µg/ml) 
on field isolate LREC461 harbouring blaCTX-M-3. 
LREC461 incubated with CTX (16 µg/ml) and P-PMO1 (30 µM). Solid line: control, 
dashed line: CTX (16 µg/ml), dotted line: CTX (16 µg/ml) + P-PMO1 (30 µM). Error 
bars indicate ± 1 standard deviation (n=3). 
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Figure A-6. Growth curves showing effects of P-PNA4 (5 µM) and CTX (8 µg/ml) on 
field isolate LREC461 harbouring blaCTX-M-3. 
LREC461 incubated with CTX (8 µg/ml) and P-PNA4 (5 µM). Solid line: control, 
dotted line: CTX (8 µg/ml), dashed line: P-PNA4 (5 µM), dash-dot line: CTX (8 µg/ml) 
+ P-PNA4 (5 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure A-7. Growth curves showing effects of P-PMO1 (30 µM) and CTX (10 µg/ml) 
on field isolate B3804 harbouring blaCTX-M-1. 
B3804 incubated with CTX (10 µg/ml) and/or P-PMO1 (30 µM). Solid line: control, 
dashed line: CTX (10 µg/ml), dotted line: P-PMO1 (30 µM), dash-dot line: CTX 
(10 µg/ml) + P-PMO1 (30 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure A-8. Growth curves showing effects of P-PNA4 (3.2 µM) and CTX (2 µg/ml) on 
field isolate B3804 harbouring blaCTX-M-1. 
B3804 incubated with CTX (2 µg/ml) and/or P-PNA4 (3.2 µM). Solid line: control, 
dashed line: CTX (2 µg/ml), dotted line: P-PNA4 (3.2 µM), dash-dot line: CTX 
(2 µg/ml) + P-PNA4 (3.2 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure A-9. Growth curves showing effects of P-PNA4 (3.2 µM) and CTX (48 µg/ml) 
on field isolate LREC525 harbouring blaCTX-M-15. 
LREC525 incubated with CTX (48 µg/ml) and P-PNA4 (3.2 µM). Solid line: control, 
dotted line: CTX (48 µg/ml), dashed line: P-PNA4 (3.2 µM), dash-dot line: CTX 
(48 µg/ml) + P-PNA4 (3.2 µM). Error bars indicate ± 1 standard deviation (n=2).
Page 262 
 
Figure A-10. Growth curves showing effects of P-PMO1 (30 µM) and CTX (96 µg/ml) 
on field isolate LREC525 harbouring blaCTX-M-15. 
LREC525 incubated with CTX (96 µg/ml) and/or P-PMO1 (30 µM). Solid line: control, 
dashed line: CTX (96 µg/ml), dotted line: P-PMO1 (30 µM), dash-dot line: CTX 
(96 µg/ml) + P-PMO1 (30 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure A-11. Growth curves showing effects of P-PNA4 (3.2 µM) and CTX (12 µg/ml) 
on field isolate BZ693/P harbouring blaCTX-M-3/33. 
BZ693/P incubated with CTX (12 µg/ml) and P-PNA4 (3.2 µM). Solid line: control, 
dotted line: CTX (12 µg/ml), dashed line: P-PNA4 (3.2 µM), dash-dot line: CTX (12 
µg/ml) + P-PNA4 (3.2 µM). Error bars indicate ± 1 standard deviation (n=2). 
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Figure A-12. Growth curves showing effects of P-PMO1 (30 µM) and CTX (15 µg/ml) 
on field isolate BZ693/P harbouring blaCTX-M-3/33. 
BZ693/P incubated with CTX (15 µg/ml) and P-PMO1 (30 µM). Solid line: control, 
dotted line: CTX (15 µg/ml), dashed line: CTX (15 µg/ml) + P-PMO1 (30 µM). Error 
bars indicate ± 1 standard deviation (n=2). 
